Adtalem Global Education (ATGE) 10-K 6 Aug 24 2024 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2024	Jul. 31, 2024	Dec. 31, 2023
Document Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	001-13988
Entity Registrant Name	Adtalem Global Education Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-3150143
Entity Address, Address Line One	500 West Monroe Street
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60661
City Area Code	312
Local Phone Number	651-1400
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	true
Document Financial Statement Restatement Recovery Analysis [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 2,277,779,425
Entity Common Stock, Shares Outstanding		37,689,832
Current Fiscal Year End Date	--06-30
Document Fiscal Year Focus	2024
Entity Central Index Key	0000730464
Document Fiscal Period Focus	FY
Amendment Flag	false
Auditor Name	PricewaterhouseCoopers LLP
Auditor Firm ID	238
Auditor Location	Chicago, Illinois
New York Stock Exchange
Document Information [Line Items]
Title of 12(b) Security	Common stock, $0.01 par value per share
Trading Symbol	ATGE
Security Exchange Name	NYSE
NYSE Chicago
Document Information [Line Items]
Title of 12(b) Security	Common stock, $0.01 par value per share
Trading Symbol	ATGE
Security Exchange Name	CHX

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Current assets:
Cash and cash equivalents	$ 219,306	$ 272,194
Restricted cash	1,896	2,881
Accounts and financing receivables, net	126,833	102,749
Prepaid expenses and other current assets	70,050	102,473
Total current assets	418,085	480,297
Noncurrent assets:
Property and equipment, net	248,524	244,649
Operating lease assets	176,755	174,677
Deferred income taxes	49,088	56,694
Intangible assets, net	776,694	812,338
Goodwill	961,262	961,262
Other assets, net	103,184	80,624
Assets held for sale	7,825	0
Total noncurrent assets	2,323,332	2,330,244
Total assets	2,741,417	2,810,541
Current liabilities:
Accounts payable	102,626	81,812
Accrued payroll and benefits	71,373	52,041
Accrued liabilities	96,957	105,806
Deferred revenue	185,272	153,871
Current operating lease liabilities	31,429	37,673
Total current liabilities	487,657	431,203
Noncurrent liabilities:
Long-term debt	648,712	695,077
Long-term operating lease liabilities	167,712	163,441
Deferred income taxes	29,526	26,068
Other liabilities	38,675	37,416
Total noncurrent liabilities	884,625	922,002
Total liabilities	1,372,282	1,353,205
Commitments and contingencies
Shareholders' equity:
Common stock, $0.01 par value per share, 200,000 shares authorized; 37,681 and 42,310 shares outstanding as of June 30, 2024 and June 30, 2023, respectively	832	822
Additional paid-in capital	611,949	568,761
Retained earnings	2,540,509	2,403,750
Accumulated other comprehensive loss	(2,227)	(2,227)
Treasury stock, at cost, 45,513 and 39,922 shares as of June 30, 2024 and June 30, 2023, respectively	(1,781,928)	(1,513,770)
Total shareholders' equity	1,369,135	1,457,336
Total liabilities and shareholders' equity	$ 2,741,417	$ 2,810,541

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands	Jun. 30, 2024	Jun. 30, 2023
Statement of Financial Position [Abstract]
Common Stock, Par Value	$ 0.01	$ 0.01
Common Stock, Shares Authorized	200,000	200,000
Common Stock, Shares Outstanding	37,681	42,310
Treasury Stock, Shares	45,513	39,922

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Revenue	$ 1,584,652	$ 1,450,826	$ 1,381,842
Operating cost and expense:
Cost of educational services	698,548	648,486	659,776
Student services and administrative expense	632,965	586,009	566,494
Restructuring expense	1,870	18,817	25,628
Business acquisition and integration expense	34,215	42,661	53,198
Gain on sale of assets	0	(13,317)	0
Total operating cost and expense	1,367,598	1,282,656	1,305,096
Operating income	217,054	168,170	76,746
Other income (expense):
Interest expense	(63,659)	(63,100)	(129,348)
Other income, net	10,542	6,965	1,108
Income (loss) from continuing operations before income taxes	163,937	112,035	(51,494)
(Provision for) benefit from income taxes	(26,224)	(10,283)	15,539
Income (loss) from continuing operations	137,713	101,752	(35,955)
Discontinued operations:
Loss from discontinued operations before income taxes	(762)	(8,464)	(986)
(Loss) gain on disposal of discontinued operations before income taxes	0	(3,576)	473,483
(Provision for) benefit from income taxes	(174)	3,646	(125,551)
(Loss) income from discontinued operations	(936)	(8,394)	346,946
Net income	$ 136,777	$ 93,358	$ 310,991
Basic:
Continuing operations (In dollars per share)	$ 3.49	$ 2.27	$ (0.74)
Discontinued operations (In dollars per share)	(0.02)	(0.19)	7.17
Total basic earnings per share (In dollar per share)	3.47	2.08	6.43
Diluted:
Continuing operations (In dollars per share)	3.42	2.23	(0.74)
Discontinued operations (In dollars per share)	(0.02)	(0.18)	7.17
Total diluted earnings per share (In dollars per share)	$ 3.39	$ 2.05	$ 6.43
Weighted-average shares outstanding:
Basic shares (In shares)	39,413	44,781	48,388
Diluted shares (In shares)	40,307	45,600	48,388

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Other comprehensive income (loss), net of tax:
Net income and comprehensive income before reclassification	$ 136,777	$ 93,358	$ 310,991
Reclassification adjustment for realized loss on foreign currency translation adjustments	0	0	296
Reclassification adjustment for loss on interest rate swap	0	0	6,695
Comprehensive income	$ 136,777	$ 93,358	$ 317,982

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Operating activities:
Net income	$ 136,777	$ 93,358	$ 310,991
Loss (income) from discontinued operations	936	8,394	(346,946)
Income (loss) from continuing operations	137,713	101,752	(35,955)
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation	25,947	14,299	22,611
Amortization and impairments to operating lease assets	32,641	48,470	44,748
Depreciation	39,676	41,376	44,574
Amortization of acquired intangible assets	35,644	61,239	97,274
Amortization and write-off of debt discount and issuance costs	5,663	9,129	42,654
Provision for bad debts	53,175	32,999	27,141
Deferred income taxes	11,073	(5,087)	(544)
Loss on disposals, accelerated depreciation, and impairments to property and equipment	466	3,999	3,501
Gain on extinguishment of debt	0	(71)	(2,072)
(Gain) loss on investments	(1,365)	3,689	3,271
Gain on sale of assets	0	(13,317)	0
Unrealized loss on assets held for sale	647	0	0
Changes in assets and liabilities:
Accounts and financing receivables	(76,355)	(56,309)	(41,391)
Prepaid expenses and other current assets	(8,781)	9,324	(2,827)
Cloud computing implementation assets	(27,154)	(13,873)	0
Accounts payable	18,330	24,744	(15,724)
Accrued payroll and benefits	19,422	(15,683)	(12,118)
Accrued liabilities	27,422	241	(16,305)
Deferred revenue	40,622	5,807	70,355
Operating lease liabilities	(36,692)	(59,188)	(49,147)
Other assets and liabilities	(9,727)	1,150	(16,044)
Net cash provided by operating activities-continuing operations	288,367	194,690	164,002
Net cash provided by (used in) operating activities-discontinued operations	7,408	(2,776)	(153,401)
Net cash provided by operating activities	295,775	191,914	10,601
Investing activities:
Capital expenditures	(48,893)	(26,014)	(31,054)
Proceeds from sales of marketable securities	1,732	7,635	3,447
Purchases of marketable securities	(689)	(1,508)	(3,624)
Proceeds from note receivable related to property sold	0	46,800	0
Payment for purchase of business, net of cash and restricted cash acquired	0	0	(1,488,054)
Net cash (used in) provided by investing activities-continuing operations	(47,850)	26,913	(1,509,285)
Net cash used in investing activities-discontinued operations	0	0	(3,287)
Proceeds from sale of business, net of cash transferred	0	0	960,768
Payment for working capital adjustment for sale of business	0	(3,174)	0
Net cash (used in) provided by investing activities	(47,850)	23,739	(551,804)
Financing activities:
Proceeds from exercise of stock options	17,089	2,625	8,879
Employee taxes paid on withholding shares	(7,731)	(4,592)	(2,834)
Proceeds from stock issued under Colleague Stock Purchase Plan	810	608	535
Repurchases of common stock for treasury	(261,966)	(123,133)	(120,000)
Payment on equity forward contract	0	(13,162)	(30,000)
Proceeds from issuance of long-term debt	1,896	0	850,000
Repayments of long-term debt	(51,896)	(150,861)	(1,079,713)
Payment of debt discount and issuance costs	0	0	(49,553)
Payment for purchase of redeemable noncontrolling interest of subsidiary	0	0	(1,790)
Net cash used in financing activities	(301,798)	(288,515)	(424,476)
Net decrease in cash, cash equivalents and restricted cash	(53,873)	(72,862)	(965,679)
Cash, cash equivalents and restricted cash at beginning of period	275,075	347,937	1,313,616
Cash, cash equivalents and restricted cash at end of period	221,202	275,075	347,937
Supplemental cash flow disclosure:
Interest paid	57,842	53,126	107,093
Income taxes paid, net	31,475	12,312	94,355
Non-cash investing and financing activities:
Accrued capital expenditures	8,718	5,125	4,321
Accrued liability for repurchases of common stock	0	2,995	0
Accrued excise tax on share repurchases	3,338	1,126	0
Settlement of financing liability with assets	0	38,606	0
DeVry University
Investing activities:
Proceeds from note receivable related to property sold	$ 0	$ 0	$ 10,000

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock, Common	Total
Balance at the beginning of period at Jun. 30, 2021	$ 811	$ 519,826	$ 1,999,405	$ (9,218)	$ (1,217,307)	$ 1,293,517
Balance at the beginning of period (in shares) at Jun. 30, 2021	81,099,000				31,846,000
Net income			310,991			310,991
Reclassification adjustment for realized gain (loss) on foreign currency translation adjustments				296		296
Reclassification adjustment for loss on interest rate swap				6,695		6,695
Stock-based compensation		23,247				23,247
Net activity from stock-based compensation awards	$ 7	8,872			$ (2,834)	6,045
Net activity from stock-based compensation awards (in shares)	697,000				82,000
Proceeds from stock issued under Colleague Stock Purchase Plan		(97)			$ 692	$ 595
Proceeds from stock issued under Colleague Stock Purchase Plan (in shares)					(19,000)	(18,328)
Repurchases of common stock for treasury					$ (120,000)	$ (120,000)
Repurchases of common stock for treasury (in shares)					4,710,000
Equity forward contract		(30,000)				(30,000)
Balance at the end of period at Jun. 30, 2022	$ 818	521,848	2,310,396	(2,227)	$ (1,339,449)	1,491,386
Balance at the end of period (in shares) at Jun. 30, 2022	81,796,000				36,619,000
Net income			93,358			93,358
Reclassification adjustment for realized gain (loss) on foreign currency translation adjustments						0
Reclassification adjustment for loss on interest rate swap						0
Stock-based compensation		14,299				14,299
Net activity from stock-based compensation awards	$ 4	2,621			$ (4,592)	(1,967)
Net activity from stock-based compensation awards (in shares)	436,000				115,000
Proceeds from stock issued under Colleague Stock Purchase Plan		(7)	(4)		$ 687	$ 676
Proceeds from stock issued under Colleague Stock Purchase Plan (in shares)					(19,000)	(18,463)
Settlement of equity forward contract		30,000			$ (43,162)	$ (13,162)
Repurchases of common stock for treasury					$ (127,254)	(127,254)
Repurchases of common stock for treasury (in shares)					3,207,000
Balance at the end of period at Jun. 30, 2023	$ 822	568,761	2,403,750	(2,227)	$ (1,513,770)	$ 1,457,336
Balance at the end of period (in shares) at Jun. 30, 2023	82,232,000				39,922,000	42,310,000
Net income			136,777			$ 136,777
Reclassification adjustment for realized gain (loss) on foreign currency translation adjustments						0
Reclassification adjustment for loss on interest rate swap						0
Stock-based compensation		25,947				25,947
Net activity from stock-based compensation awards	$ 10	17,078			$ (7,731)	9,357
Net activity from stock-based compensation awards (in shares)	962,000				165,000
Proceeds from stock issued under Colleague Stock Purchase Plan		163	(18)		$ 756	$ 901
Proceeds from stock issued under Colleague Stock Purchase Plan (in shares)					(20,000)	(19,666)
Repurchases of common stock for treasury					$ (261,183)	$ (261,183)
Repurchases of common stock for treasury (in shares)					5,446,000
Balance at the end of period at Jun. 30, 2024	$ 832	$ 611,949	$ 2,540,509	$ (2,227)	$ (1,781,928)	$ 1,369,135
Balance at the end of period (in shares) at Jun. 30, 2024	83,194,000				45,513,000	37,681,000

Nature of Operations

Nature of Operations	12 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	1. Nature of Operations In this Annual Report on Form 10-K, Adtalem Global Education Inc., together with its subsidiaries, is collectively referred to as “Adtalem,” “we,” “our,” “us,” or similar references. Adtalem is a leading healthcare educator in the U.S. Our schools consist of Chamberlain University (“Chamberlain”), Walden University (“Walden”), American University of the Caribbean School of Medicine (“AUC”), Ross University School of Medicine (“RUSM”), and Ross University School of Veterinary Medicine (“RUSVM”). AUC, RUSM, and RUSVM are collectively referred to as the “medical and veterinary schools.” See Note 22 “Segment Information” for information on our reportable segments. Beginning in the second quarter of fiscal year 2022, Adtalem eliminated its Financial Services segment when the Association of Certified Anti-Money Laundering Specialists (“ACAMS”), Becker Professional Education (“Becker”), OnCourse Learning (“OCL”), and EduPristine were classified as discontinued operations. In accordance with U.S. generally accepted accounting principles (“GAAP”), we have classified the ACAMS, Becker, OCL, and EduPristine entities as “Discontinued Operations” in all periods presented as applicable. As a result, all financial results, disclosures, and discussions of continuing operations in this Annual Report on Form 10-K exclude ACAMS, Becker, OCL, and EduPristine operations, unless otherwise noted. On March 10, 2022, we completed the sale of ACAMS, Becker, and OCL and on June 17, 2022, we completed the sale of EduPristine. In addition, we continue to incur costs associated with ongoing litigation and settlements related to the DeVry University divestiture, which was completed during fiscal year 2019, and are classified as expense within discontinued operations. See Note 4 “Discontinued Operations” for additional information.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies For each accounting topic that is addressed in its own note, the description of the accounting policy may be found in the related note. Other significant accounting policies are described below. Principles of Consolidation The Consolidated Financial Statements include the accounts of Adtalem and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. We have prepared the Consolidated Financial Statements in accordance with GAAP. Unless otherwise noted, amounts presented within the Notes to Consolidated Financial Statements refer to our continuing operations. Unless indicated, or the context requires otherwise, references to years refer to Adtalem’s fiscal years. Certain items presented in tables may not sum due to rounding. Business acquisition and integration expense was $34.2 million, $42.7 million, and $53.2 million in fiscal year 2024, 2023, and 2022, respectively. These are transaction costs associated with acquiring Walden and costs associated with integrating Walden into Adtalem. In addition, during fiscal year 2023, we initiated transformation initiatives to accelerate growth and organizational agility. Certain costs relating to this transformation are included in business acquisition and integration expense in the Consolidated Statements of Income. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents Cash and cash equivalents consist of highly liquid investments with original maturities of three months or less. The carrying value of cash and cash equivalents approximate fair value. We maintain cash and cash equivalent balances that exceed federally insured limits. We have not experienced any losses on our cash and cash equivalents. Restricted Cash Restricted cash represents amounts received from federal and state governments under various student aid grant and loan programs and such restricted funds are held in separate bank accounts. Once the financial aid authorization and disbursement process for the student has been completed, the funds are transferred to unrestricted accounts, and these funds then become available for use in Adtalem’s operations. This authorization and disbursement process that precedes the transfer of funds generally occurs within the period of the academic term for which such funds were authorized. Restricted cash also includes an imprest cash balance used for Adtalem’s self-insured employee medical benefits program. Property and Equipment Property and equipment is recorded at cost less accumulated depreciation. Cost includes additions and those improvements that enhance performance, increase the capacity, or lengthen the useful lives of the assets. Purchases of computer software, including external costs and certain internal costs (including payroll and payroll-related costs of employees) directly associated with developing computer software applications for internal use, are capitalized. Assets under construction are reflected in construction in progress until they are placed into service for their intended use. Depreciation is recognized on a straight-line basis over the estimated useful lives of the related assets. Leasehold improvements are amortized on a straight-line basis over the shorter of the useful life of the asset or lease term. Repairs and maintenance costs are expensed as incurred. Upon sale or retirement of an asset, the accounts are relieved of the cost and the related accumulated depreciation, with any resulting gain or loss included in income. See Note 11 “Property and Equipment, Net” for additional information, including useful lives by asset category. Goodwill and Intangible Assets Goodwill and indefinite-lived intangible assets are not amortized, but are tested for impairment annually and when an event occurs or circumstances change such that it is more likely than not that an impairment may exist. Our annual testing date is May 31. We have the option to assess goodwill for impairment by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If it is determined that the reporting unit fair value is more likely than not less than its carrying value, or if we do not elect the option to perform an initial qualitative assessment, we perform a quantitative assessment of the reporting unit’s fair value. If the carrying value of a reporting unit containing the goodwill exceeds the fair value of that reporting unit, an impairment loss is recognized equal to the difference between the carrying value of the reporting unit and its fair value, not to exceed the carrying value of goodwill. We also have the option to perform a qualitative assessment to test indefinite-lived intangible assets for impairment by determining whether it is more likely than not that the indefinite-lived intangible assets are impaired. If it is determined that the indefinite-lived intangible asset is more likely than not impaired, or if we do not elect the option to perform an initial qualitative assessment, we perform a quantitative assessment of the indefinite-lived intangible assets. If the carrying value of the indefinite-lived intangible assets exceeds its fair value, an impairment loss is recognized to the extent the carrying value exceeds fair value. For intangible assets with finite lives, we evaluate for potential impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If the carrying value is no longer recoverable based upon the undiscounted future cash flows of the asset or asset group, the amount of the impairment is the difference between the carrying amount and the fair value of the asset or asset group. Intangible assets with finite lives are amortized over their expected economic lives, ranging from three All intangible assets and certain goodwill are being amortized for tax reporting purposes over statutory lives. Determining the fair value of a reporting unit or an intangible asset involves the use of significant estimates and assumptions. Management bases its fair value estimates on assumptions it believes to be reasonable at the time, but such assumptions are subject to inherent uncertainty. Actual results may differ from those estimates, which could lead to future impairments of goodwill or intangible assets. See Note 13 “Goodwill and Intangible Assets” for additional information on our goodwill and intangible assets impairment analysis. Capitalized Curriculum Development Certain costs incurred to create course and educational material for a program offering are capitalized as curriculum development assets within other assets, net on the Consolidated Balance Sheets. Costs are capitalized for new programs or products, or the content being developed enhances, updates, or improves current programs, curriculum, or products, so long as the cost incurred extends the useful life of the existing curriculum and course content. Costs that are capitalized include payroll and payroll-related costs for employees who spend time producing content and external vendor costs related to the project. Adtalem begins capitalizing costs during the content development phase, which includes time to develop course materials based on the requirements defined in the planning phase. Curriculum development assets are amortized on a straight-line basis over the estimated useful life, which is generally three Cloud Computing Arrangements For cloud computing arrangements that are a service contract, we capitalize certain implementation costs incurred, including external costs and certain internal costs (including payroll and payroll-related costs of employees), during the development stage of implementing the cloud computing hosting arrangement. Capitalized costs related to cloud computing arrangements are included within prepaid expenses and other current assets and other assets, net on the Consolidated Balance Sheets. We expense costs as incurred during the preliminary planning and post-implementation stages. Capitalized implementation costs are amortized on a straight-line basis over the contractual term of the cloud computing arrangement, which includes renewal options that are reasonably certain to be exercised, which is generally five years. Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If the carrying value is no longer recoverable based upon the undiscounted future cash flows of the asset or asset group, the amount of the impairment is the difference between the carrying amount and the fair value of the asset or asset group. Events that may trigger an impairment analysis could include a decision by management to exit a market or a line of business or to consolidate operating locations. Treasury Stock Shares that are repurchased by Adtalem under its share repurchase programs are recorded as treasury stock at cost and result in a reduction in shareholders’ equity. See Note 16 “Share Repurchases” for additional information. From time to time, shares of our common stock are delivered back to Adtalem under a swap arrangement resulting from employees’ exercise of stock options pursuant to the terms of the Adtalem’s stock-based incentive plans (see Note 18 “Stock-Based Compensation”). In addition, shares of our common stock are delivered back to Adtalem for payment of withholding taxes from employees for vesting of stock-based compensation awards. These shares are recorded as treasury stock at cost and result in a reduction in shareholders’ equity. Treasury shares are reissued at market value, less a 10% discount, to the Adtalem Colleague Stock Purchase Plan in exchange for employee payroll deductions. The 10% discount is considered compensatory and recorded as an expense in the Consolidated Statements of Income. When treasury shares are reissued, Adtalem uses an average cost method to reduce the treasury stock balance. Gains on the difference between the average cost and the reissuance price, less the amount recorded as expense, are credited to additional paid-in capital. Losses on the difference are charged to additional paid-in capital to the extent that previous net gains from reissuance are included therein, otherwise such losses are charged to retained earnings. Earnings per Share Basic earnings per share (“EPS”) is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted EPS is computed by dividing net income by diluted weighted-average number of shares outstanding during the period. Diluted EPS considers the impact of potentially dilutive shares, except in periods in which there is a loss from continuing operations, because the inclusion of the potential common shares would have an antidilutive effect. Dilutive shares are computed using the treasury stock method and reflect the additional shares that would be outstanding if dilutive stock-based grants were exercised or vested during the period. Income Taxes Adtalem accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences of temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Adtalem also recognizes future tax benefits associated with tax loss and credit carryforwards as deferred tax assets. Adtalem’s deferred tax assets are reduced by a valuation allowance, when in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Adtalem measures deferred tax assets and liabilities using enacted tax rates in effect for the year in which Adtalem expects to recover or settle the temporary differences. The effect of a change in tax rates on deferred taxes is recognized in the period that the change is enacted. Adtalem reduces its net tax assets for the estimated additional tax and interest that may result from tax authorities disputing uncertain tax positions Adtalem has taken. Restructuring Charges Restructuring charges include costs for severance and related benefits for workforce reductions, impairments on operating lease assets, losses on disposals of property and equipment related to campus and administrative office consolidations, and contract termination costs (see Note 6 “Restructuring Expense”). When estimating the costs of exiting lease space, estimates are made which could differ materially from actual results and result in additional restructuring charges or reversals in future periods. Advertising Costs Advertising costs are expensed when incurred and totaled $227.9 million, $219.4 million, and $190.7 million for the years ended June 30, 2024, 2023, and 2022, respectively. Advertising costs are included in student services and administrative expense in the Consolidated Statements of Income. Foreign Currency Translation The financial position and results of operations of the AUC, RUSM, and RUSVM Caribbean operations are measured using the U.S. dollar as the functional currency. As such, there is no translation gain or loss associated with these operations. EduPristine’s operations and Becker’s and ACAMS’s international operations were measured using the local currency as the functional currency. Assets and liabilities of these entities are translated to U.S. dollars using exchange rates in effect at the balance sheet dates. Income and expense items are translated at monthly average exchange rates. The resulting translation adjustments are recorded as foreign currency translation adjustments in the Consolidated Statements of Comprehensive Income. Translation adjustments for foreign subsidiaries whose functional currencies were previously their respective currencies are suspended in accumulated other comprehensive loss on the Consolidated Balance Sheets. Transaction gains or losses during each of the fiscal years presented were not material. Recent Accounting Standards In March 2022, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2022-02: “Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures.” The guidance was issued as improvements to Accounting Standards Codification (“ASC”) 326. The vintage disclosure changes are relevant to Adtalem and require an entity to disclose current-period gross write-offs by year of origination for financing receivables. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The amendments should be applied prospectively. We adopted this guidance on July 1, 2023. The amendments impacted our disclosures and did not otherwise impact Adtalem’s Consolidated Financial Statements. In November 2023, the FASB issued ASU No. 2023-07: “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” The guidance was issued to improve disclosures about reportable segments and addresses requests from investors for additional, more detailed information about a reportable segment’s expenses by requiring entities to provide disclosures of significant segment expenses and other segment items. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The amendments should be applied retrospectively. Early adoption of the amendments is permitted, including adoption in an interim period. The amendments will impact our segment disclosures but will not otherwise impact Adtalem’s Consolidated Financial Statements. In December 2023, the FASB issued ASU No. 2023-09: “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” The guidance was issued to enhance the transparency and decision usefulness of income tax disclosures by requiring entities to provide additional information in the rate reconciliation and additional disclosures about income taxes paid. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2024. The amendments should be applied prospectively and retrospective application is permitted. Early adoption of the amendments is permitted. The amendments will impact our income tax disclosures but will not otherwise impact Adtalem’s Consolidated Financial Statements. We reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on our Consolidated Financial Statements. Revision to Previously Issued Financial Statements During the fourth quarter of fiscal year 2024, Adtalem identified an error in the presentation of capitalized cloud computing implementation costs in its previously issued financial statements. In accordance with Accounting Standards Codification (“ASC”) 350-40 “Intangibles, Goodwill and Other, Internal-Use Software,” capitalized cloud computing implementation costs should be presented in the same line item in the Consolidated Balance Sheets as a prepayment of the fees for the associated hosting arrangement, and the cash flows from capitalized implementation costs should be presented in the same manner as cash flows for the fees associated with the hosting arrangement. Adtalem previously presented capitalized cloud implementation costs in property and equipment, net rather than as prepaid expenses and other current assets and other assets, net on the Consolidated Balance Sheets. Adtalem previously presented the cash flows from capitalized implementation costs as capital expenditures within investing activities rather than within cash flows from operating activities in the Consolidated Statements of Cash Flows. Adtalem assessed the materiality of this error individually and in the aggregate with other previously identified errors to prior periods’ Consolidated Financial Statements in accordance with SEC Staff Accounting Bulletin (“SAB”) No. 99 “Materiality” and SAB 108 “Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements” codified in ASC 250 “Accounting Changes and Error Corrections.” Adtalem concluded that the errors were not material to prior periods and therefore, amendments of previously filed reports are not required. However, Adtalem determined it was appropriate to revise its previously issued financial statements. In accordance with ASC 250, Adtalem corrected prior periods presented herein by revising the financial statement line item amounts previously disclosed in SEC filings in order to achieve comparability in the Consolidated Financial Statements. The Consolidated Balance Sheets as of June 30, 2023 and the Consolidated Statements of Cash Flows for the year ended June 30, 2023 have been revised in this Annual Report on Form 10-K, and the impact of this revision of Adtalem’s previously reported annual Consolidated Financial Statements are detailed below. In connection with this revision, Adtalem also corrected other immaterial errors in the prior periods, including certain errors that had previously been adjusted for in the period identified. We have also revised impacted amounts within the accompanying Notes to Consolidated Financial Statements. The following table summarizes the effect of the revision on the affected line items within the Consolidated Balance Sheets (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2023 ​ ​ As Reported ​ Adjustment ​ As Revised Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 273,689 ​ $ (1,495) ​ $ 272,194 Restricted cash ​ ​ 1,386 ​ ​ 1,495 ​ ​ 2,881 Prepaid expenses and other current assets ​ ​ 100,715 ​ ​ 1,758 ​ ​ 102,473 Total current assets ​ ​ 478,539 ​ ​ 1,758 ​ ​ 480,297 Noncurrent assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Property and equipment, net ​ ​ 258,522 ​ ​ (13,873) ​ ​ 244,649 Other assets, net ​ ​ 68,509 ​ ​ 12,115 ​ ​ 80,624 Total noncurrent assets ​ ​ 2,332,002 ​ ​ (1,758) ​ ​ 2,330,244 The following table summarizes the effect of the revision on the affected line items within the Consolidated Statements of Cash Flows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2023 ​ ​ As Reported ​ Adjustment ​ As Revised Operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustments to reconcile net income to net cash provided by operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation ​ $ 41,575 ​ $ (199) ​ $ 41,376 Changes in assets and liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cloud computing implementation assets ​ ​ — ​ ​ (13,873) ​ ​ (13,873) Accounts payable ​ ​ 21,666 ​ ​ 3,078 ​ ​ 24,744 Net cash provided by operating activities-continuing operations ​ ​ 205,684 ​ ​ (10,994) ​ ​ 194,690 Net cash provided by operating activities ​ ​ 202,908 ​ ​ (10,994) ​ ​ 191,914 Investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures ​ ​ (37,008) ​ ​ 10,994 ​ ​ (26,014) Net cash provided by investing activities-continuing operations ​ ​ 15,919 ​ ​ 10,994 ​ ​ 26,913 Net cash provided by investing activities ​ ​ 12,745 ​ ​ 10,994 ​ ​ 23,739 Non-cash investing and financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued capital expenditures ​ ​ 8,203 ​ ​ (3,078) ​ ​ 5,125 ​

Acquisitions

Acquisitions	12 Months Ended
	Jun. 30, 2024
Acquisitions [Abstract]
Acquisitions	3. Acquisitions Walden University On August 12, 2021, Adtalem completed the acquisition of 100% of the equity interest of Walden for $1,488.1 million, net of cash and restricted cash of $83.4 million. Adtalem funded the purchase with the $800.0 million in Notes (as defined in Note 14 “Debt”), the $850.0 million Term Loan B (as defined in Note 14 “Debt”), and available cash on hand. Walden offers more than 100 online certificate, bachelor’s, master’s, and doctoral degrees. The acquisition furthers Adtalem’s growth strategy as a leading healthcare educator in the U.S. The operations of Walden are included in Adtalem’s Walden reportable segment (see Note 22 “Segment Information”). The results of Walden’s operations have been included in the Consolidated Financial Statements of Adtalem since the date of acquisition. For fiscal year 2022, this included revenue of $485.4 million and net loss of $3.9 million from the operations of Walden. In addition, we incurred acquisition-related costs of $22.3 million in fiscal year 2022, which were included in business acquisition and integration expense in the Consolidated Statements of Income. The following table summarizes the fair values of the assets acquired and liabilities assumed at the date of acquisition (in thousands): ​ ​ ​ ​ ​ ​ ​ August 12, ​ ​ 2021 Assets acquired: ​ ​ ​ Cash and cash equivalents ​ $ 65,010 Restricted cash ​ ​ 18,389 Accounts and financing receivables ​ ​ 22,091 Prepaid expenses and other current assets ​ ​ 8,819 Property and equipment ​ 25,882 Operating lease assets ​ ​ 6,096 Deferred income taxes ​ ​ 59 Intangible assets ​ 833,351 Goodwill ​ 651,052 Other assets, net ​ 21,316 Total assets acquired ​ 1,652,065 Liabilities assumed: ​ ​ Accounts payable ​ 31,971 Accrued payroll and benefits ​ 25,639 Accrued liabilities ​ 1,620 Deferred revenue ​ ​ 10,958 Current operating lease liabilities ​ ​ 1,983 Long-term operating lease liabilities ​ ​ 4,343 Other liabilities ​ ​ 4,098 Total liabilities assumed ​ 80,612 Net assets acquired ​ $ 1,571,453 ​ The fair value of the assets acquired includes accounts receivable of $22.1 million. The gross amount due under contracts is $37.9 million, of which $15.8 million was expected to be uncollectible. Goodwill, which represents the excess of the purchase price over the fair value of the net assets acquired, was all assigned to the Walden reporting unit and reportable segment. The entire goodwill amount is tax deductible. Factors that contributed to a purchase price resulting in the recognition of goodwill includes Walden’s strategic fit into Adtalem’s healthcare educator strategy, the reputation of the Walden brand as a leader in online education industry, and potential future growth opportunity. Of the $833.4 million of acquired intangible assets, $495.8 million was assigned to Title IV eligibility and accreditations and $119.6 million was assigned to trade names, each of which has been determined not to be subject to amortization. The values and estimated useful lives of other intangible assets acquired were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ August 12, 2021 ​ ​ Value ​ Estimated ​ ​ Assigned ​ Useful Life Student relationships ​ $ 161,900 ​ 3 years Curriculum $ 56,091 5 years ​ The Title IV eligibility and accreditations intangible asset was valued using the with and without method of the income approach. The student relationships intangible asset was valued using the multi-period excess earnings method. The trade name intangible asset was valued using the relief-from-royalty method. The curriculum intangible asset was valued using the cost to replace method. Significant judgments and assumptions were used in these valuations. We applied judgment which involved the use of significant assumptions with respect to the discount rate and recovery period for the Title IV eligibility and accreditations intangible asset and royalty rate and discount rate for the trade name intangible asset. We also applied judgment which involved the use of assumptions, including the discount rate and EBITDA margin for the student relationships intangible asset and labor rates and hours and obsolescence rate for the curriculum intangible asset. The following unaudited pro forma financial information summarizes our results of operations as though the acquisition occurred on July 1, 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2022 Revenue ​ $ 1,451,081 Net income ​ $ 385,110 ​ The unaudited pro forma financial information includes adjustments to reflect the additional amortization that would have been charged assuming the fair value adjustments to intangible assets had been applied from July 1, 2020, with the consequential tax effects. The unaudited pro forma financial information also includes adjustments to reflect the additional interest expense on the debt we issued to fund the acquisition (see Note 14 “Debt” for additional information). As the ticking fees are representative of the historical interest expense incurred by Adtalem on the Term Loan B from the period of February 12, 2021 to August 12, 2021 and the unaudited pro forma financial information for fiscal year 2021 has been adjusted to include interest expense assuming the Term Loan B had been entered into as of July 1, 2020, we have made a further adjustment to remove the ticking fees recognized in the unaudited pro forma financial information for fiscal year 2022 (see Note 14 “Debt” for additional information on ticking fees). Had the Term Loan B been drawn upon on July 1, 2020, none of the ticking fees would have been incurred and, accordingly, the inclusion of such amounts would be duplicative to the interest expense incurred by Adtalem on a pro forma basis. The acquisition transaction costs we incurred in connection with the Walden acquisition are reflected in the unaudited pro forma financial information results for fiscal year 2021. This unaudited pro forma financial information is for informational purposes only. It does not reflect the integration of the business or any synergies that may result from the acquisition. As such, it is not indicative of the results of operations that would have been achieved had the acquisition been consummated on July 1, 2020. In addition, the unaudited pro forma financial information amounts are not indicative of future operating results.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Jun. 30, 2024
Discontinued Operations And Disposal Groups [Abstract]
Discontinued Operations	4. Discontinued Operations On December 11, 2018, Adtalem completed the sale of DeVry University to Cogswell Education, LLC (“Cogswell”) for de minimis consideration. As the sale represented a strategic shift that had a major effect on Adtalem’s operations and financial results, DeVry University is presented in Adtalem’s Consolidated Financial Statements as a discontinued operation. The purchase agreement includes an earn-out entitling Adtalem to payments of up to $20.0 million over a ten-year period payable based on DeVry University’s financial results. Adtalem received $5.5 million, $4.1 million, and $2.9 million during fiscal year 2024, 2023, and 2022, respectively, related to the earn-out. We have received a total of $12.5 million related to the earn-out thus far. In connection with the closing of the sale, Adtalem loaned to DeVry University $10.0 million under the terms of the promissory note, dated as of December 11, 2018 (the “DeVry Note”). The DeVry Note bore interest at a rate of 4% per annum, payable annually in arrears, and had a maturity date of January 1, 2022. We received the loan repayment of $10.0 million during the third quarter of fiscal year 2022. On March 10, 2022, Adtalem completed the sale of ACAMS, Becker, and OCL to Wendel Group and Colibri Group (“Purchaser”), pursuant to the Equity Purchase Agreement (“Purchase Agreement”) dated January 24, 2022. Pursuant to the terms and subject to the conditions set forth in the Purchase Agreement, Adtalem sold the issued and outstanding shares of ACAMS, Becker, and OCL to the Purchaser for $962.7 million, net of cash of $21.5 million, subject to certain post-closing adjustments. In addition, on June 17, 2022, Adtalem completed the sale of EduPristine for de minimis consideration, which resulted in a transfer of $1.9 million in cash. We recorded a loss of $3.6 million in fiscal year 2023 for post-closing working capital adjustments to the initial sales prices for ACAMS, Becker, and OCL and a tax return to provision adjustment, which is included in (loss) gain on disposal of discontinued operations before income taxes in the Consolidated Statements of Income. These divestitures are the culmination of a long-term strategy to sharpen the focus of our portfolio and enhance our ability to address the growing and unmet demand for healthcare professionals in the U.S. As these sales represented a strategic shift that had a major effect on Adtalem’s operations and financial results, these businesses previously included in our former Financial Services segment are presented in Adtalem’s Consolidated Financial Statements as discontinued operations. The following is a summary of income statement information reported as discontinued operations, which includes expense from ongoing litigation costs and settlements related to the DeVry University and Carrington College divestitures, ACAMS, Becker, OCL, and EduPristine operations through the date of each respective sale, the gain on disposal of these entities, a loss from post-closing working capital adjustments to the initial sales prices and a tax return to provision adjustment, and the earn-outs we received (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Revenue ​ $ — ​ $ — ​ $ 153,762 Operating cost and expense: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cost of educational services ​ — ​ — ​ 26,996 Student services and administrative expense ​ 762 ​ 8,464 ​ 126,252 Restructuring expense ​ — ​ — ​ 1,500 Total operating cost and expense ​ 762 ​ 8,464 ​ 154,748 Loss from discontinued operations before income taxes ​ (762) ​ (8,464) ​ (986) (Loss) gain on disposal of discontinued operations before income taxes ​ ​ — ​ ​ (3,576) ​ ​ 473,483 (Provision for) benefit from income taxes ​ (174) ​ 3,646 ​ (125,551) (Loss) income from discontinued operations ​ $ (936) ​ $ (8,394) ​ $ 346,946 ​

Revenue

Revenue	12 Months Ended
	Jun. 30, 2024
Revenue from Contract with Customer [Abstract]
Revenue	5. Revenue Revenue is recognized when control of the promised goods or services is transferred to our customers (students), in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. The following tables disaggregate revenue by source (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2024 ​ ​ Chamberlain ​ Walden Medical and Veterinary ​ Consolidated Tuition and fees $ 633,522 $ 595,332 $ 342,389 $ 1,571,243 Other ​ ​ — ​ ​ — ​ ​ 13,409 ​ ​ 13,409 Total $ 633,522 $ 595,332 $ 355,798 $ 1,584,652 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2023 ​ ​ Chamberlain ​ Walden Medical and Veterinary ​ Consolidated Tuition and fees ​ $ 571,034 $ 533,725 $ 334,323 $ 1,439,082 Other ​ ​ — ​ ​ — ​ ​ 11,744 ​ ​ 11,744 Total $ 571,034 $ 533,725 $ 346,067 $ 1,450,826 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2022 ​ ​ Chamberlain ​ Walden Medical and Veterinary ​ Consolidated Tuition and fees ​ $ 557,536 $ 485,393 $ 328,382 $ 1,371,311 Other ​ ​ — ​ ​ — ​ ​ 10,531 ​ ​ 10,531 Total $ 557,536 $ 485,393 $ 338,913 $ 1,381,842 ​ In addition, see Note 22 “Segment Information” for a disaggregation of revenue by geographical region. Performance Obligations and Revenue Recognition Tuition and fees Other Arrangements for payment are agreed to prior to registration of the student’s first academic term. The majority of U.S. students obtain Title IV or other financial aid resulting in institutions receiving a significant amount of the transaction price at the beginning of the academic term. Students not utilizing Title IV or other financial aid funding may pay after the academic term is complete. Transaction Price Revenue, or transaction price, is measured as the amount of consideration expected to be received in exchange for transferring goods or services. Students may receive discounts, scholarships, or refunds, which gives rise to variable consideration. The amounts of discounts or scholarships are generally applied to individual student accounts when such amounts are awarded. Therefore, the transaction price is immediately reduced directly by these discounts or scholarships from the amount of the standard tuition rate charged. Scholarships and discounts that are only applied to future tuition charged are considered a separate performance obligation if they represent a material right in accordance with ASC 606. In those instances, we defer the value of the related performance obligation associated with the future scholarship or discount based on estimates of future redemption based on our historical experience of student persistence toward completion of study. The contract liability associated with these material rights is presented as deferred revenue within current liabilities and other liabilities within noncurrent liabilities on the Consolidated Balance Sheets based on the amounts expected to be redeemed in the next 12 months. The contract liability amount associated with these material rights within current liabilities is $24.1 million and $10.6 million as of June 30, 2024 and 2023, respectively, and the amount within noncurrent liabilities is $19.6 million and $10.4 million as of June 30, 2024 and 2023, respectively. The noncurrent contract liability associated with these material rights is expected to be earned over approximately the next four fiscal years. Upon withdrawal, a student may be eligible to receive a refund, or partial refund, the amount of which is dependent on the timing of the withdrawal during the academic term. If a student withdraws prior to completing an academic term, federal and state regulations and accreditation criteria permit Adtalem to retain a set percentage of the total tuition received from such student, which varies with, but generally equals or exceeds, the percentage of the academic term completed by such student. Payment amounts received by Adtalem in excess of such set percentages of tuition are refunded to the student or the appropriate funding source. For contracts with similar characteristics and historical data on refunds, the expected value method is applied in determining the variable consideration related to refunds. Estimates of Adtalem’s expected refunds are determined at the outset of each academic term, based upon actual refunds in previous academic terms. Reserves related to refunds are presented as refund liabilities within accrued liabilities on the Consolidated Balance Sheets. All refunds are netted against revenue during the applicable academic term. Management reassesses collectability on a student-by-student basis throughout the period revenue is recognized. This reassessment is based upon new information and changes in facts and circumstances relevant to a student’s ability to pay. Management also reassesses collectability when a student withdraws from the institution and has unpaid tuition charges. Such unpaid charges do not meet the threshold of reasonably collectible and are recognized as revenue on a cash basis. Contract Balances Students are billed at the beginning of each academic term and payment is due at that time. Adtalem’s performance obligation is to provide educational services in the form of instruction during the academic term and to provide for any scholarships or discounts that are deemed a material right under ASC 606. As instruction is provided or the deferred value of material rights are redeemed, deferred revenue is reduced. A significant portion of student payments are from Title IV financial aid and other programs and are generally received during the first month of the respective academic term. For students utilizing Adtalem’s credit extension programs (see Note 10 “Accounts and Financing Receivables”), payments are generally received after the academic term, and the corresponding performance obligation, is complete. When payments are received, accounts and financing receivables is reduced. Deferred revenue within current liabilities is $185.3 million and $153.9 million as of June 30, 2024 and 2023, respectively, and deferred revenue within noncurrent liabilities is $19.6 million and $10.4 million as of June 30, 2024 and 2023, respectively. Revenue of $153.9 million and $149.8 million was recognized during fiscal year 2024 and 2023, respectively, that was included in the deferred revenue balance at the beginning of fiscal year 2024 and 2023, respectively. The difference between the opening and closing balances of deferred revenue includes decreases from revenue recognized during the period, increases from charges related to the start of academic terms beginning during the period, increases from payments received related to academic terms commencing after the end of the period, and increases from recognizing additional performance obligations for material rights during the period.

Restructuring Expense

Restructuring Expense	12 Months Ended
	Jun. 30, 2024
Restructuring and Related Activities [Abstract]
Restructuring Expense	6. Restructuring Expense During fiscal year 2024, Adtalem recorded restructuring expense primarily driven by prior real estate consolidations at Adtalem’s home office. We continue to incur restructuring charges or reversals related to exited leased space from previous restructuring activities. During fiscal year 2023, Adtalem recorded restructuring expense primarily driven by real estate consolidations at Walden, Medical and Veterinary, and Adtalem’s home office resulting in impairments on operating lease assets and property and equipment. During fiscal year 2022, Adtalem recorded restructuring expense primarily driven by workforce reductions and contract terminations related to synergy actions with regards to the Walden acquisition and Medical and Veterinary and Adtalem’s home office real estate consolidations. When estimating costs of exiting lease space, estimates are made which could differ materially from actual results and may result in additional restructuring charges or reversals in future periods. Termination benefit charges represent severance pay and benefits for employees impacted by workforce reductions. Adtalem’s home office is classified as “Home Office” in Note 22 “Segment Information.” Restructuring expense by segment were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2024 ​ ​ Real Estate and Other ​ Termination Benefits ​ Total Walden ​ $ (776) $ — $ (776) Medical and Veterinary ​ ​ 402 ​ 40 ​ 442 Home Office ​ ​ 2,204 ​ — ​ 2,204 Total ​ $ 1,830 ​ $ 40 ​ $ 1,870 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2023 ​ ​ Real Estate and Other ​ Termination Benefits ​ Total Chamberlain ​ $ 818 $ — $ 818 Walden ​ ​ 3,191 ​ 54 ​ 3,245 Medical and Veterinary ​ ​ 7,071 ​ 616 ​ 7,687 Home Office ​ ​ 6,117 ​ 950 ​ 7,067 Total ​ $ 17,197 ​ $ 1,620 ​ $ 18,817 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2022 ​ ​ Real Estate and Other ​ Termination Benefits ​ Total Chamberlain ​ $ 835 $ 2,003 $ 2,838 Walden ​ ​ — ​ 4,053 ​ 4,053 Medical and Veterinary ​ ​ 7,675 ​ 2,116 ​ 9,791 Home Office ​ ​ 5,977 ​ 2,969 ​ 8,946 Total ​ $ 14,487 ​ $ 11,141 ​ $ 25,628 ​ The following table summarizes the separation and restructuring plan activity for fiscal years 2023 and 2024, for which cash payments are required (in thousands): ​ ​ ​ ​ ​ Liability balance as of June 30, 2022 ​ $ 813 Increase in liability (separation and other charges) ​ 1,620 Reduction in liability (payments and adjustments) ​ (1,692) Liability balance as of June 30, 2023 ​ 741 Increase in liability (separation and other charges) ​ 40 Reduction in liability (payments and adjustments) ​ (781) Liability balance as of June 30, 2024 ​ $ — ​ These liability balances are recorded as accrued liabilities on the Consolidated Balance Sheets.

Other Income, Net

Other Income, Net	12 Months Ended
	Jun. 30, 2024
Other Income and Expenses [Abstract]
Other Income, Net	7. Other Income, Net Other income, net consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Interest and dividend income ​ $ 9,177 ​ $ 10,654 ​ $ 4,379 Investment gain (loss) ​ 1,365 ​ (3,689) ​ (3,271) Other income, net ​ $ 10,542 ​ $ 6,965 ​ $ 1,108 ​ Investment gain (loss) includes trading gains and losses related to the rabbi trust used to fund nonqualified deferred compensation plan obligations (see Note 19 “Employee Benefit Plans” for additional information). In addition, investment gain (loss) includes an impairment of $5.0 million in fiscal year 2023 on an equity investment with no readily determinable fair value (see Note 20 “Fair Value Measurements” for additional information).

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	8. Income Taxes Income from continuing operations before income taxes, classified by source of income, was as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Domestic ​ $ 89,752 ​ $ 51,422 ​ $ (112,151) Foreign ​ 74,185 ​ 60,613 ​ 60,657 Total ​ $ 163,937 ​ $ 112,035 ​ $ (51,494) ​ The components of the provision for (benefit from) income taxes were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ 2024 ​ 2023 ​ 2022 Current tax provision (benefit): ​ ​ ​ ​ ​ ​ ​ ​ U.S. federal ​ $ 11,243 ​ $ 13,761 ​ $ (6,767) State and local ​ 3,489 ​ 824 ​ 4,154 Foreign ​ 419 ​ 614 ​ 725 Total current ​ 15,151 ​ 15,199 ​ (1,888) Deferred tax provision (benefit): ​ ​ ​ ​ ​ ​ ​ ​ ​ U.S. federal ​ 4,870 ​ (1,099) ​ (6,425) State and local ​ 2,745 ​ (4,347) ​ (6,597) Foreign ​ 3,458 ​ 530 ​ (629) Total deferred ​ 11,073 ​ (4,916) ​ (13,651) Provision for (benefit from) income taxes ​ $ 26,224 ​ $ 10,283 ​ $ (15,539) ​ The effective tax rate differs from the statutory tax rates as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ ​ 2023 ​ ​ 2022 Income tax at statutory rate ​ $ 34,427 ​ 21.0 % ​ $ 23,527 ​ 21.0 % ​ $ (10,814) ​ 21.0 % Lower rates on foreign operations ​ (11,419) (7.0) % ​ (11,668) (10.4) % ​ (12,879) 25.0 % State income taxes ​ 4,557 2.8 % ​ 2,719 2.4 % ​ (661) 1.3 % Loss on investment in subsidiary ​ — — % ​ — — % ​ (1,669) 3.2 % Deferred tax benefit from acquisitions and divestitures ​ — — % ​ — — % ​ (1,153) 2.2 % Research and development tax credits ​ ​ (1,589) ​ (1.0) % ​ ​ (1,862) ​ (1.7) % ​ ​ — — % Change in valuation allowance ​ ​ (621) ​ (0.4) % ​ ​ (9,769) ​ (8.7) % ​ ​ 5,406 (10.5) % Reduction in state loss carryforwards ​ ​ — ​ — % ​ ​ 2,340 ​ 2.1 % ​ ​ (5,882) 11.4 % Permanent non-deductible items ​ 2,293 1.4 % ​ 1,630 1.5 % ​ 2,788 (5.4) % Foreign tax provisions under GILTI ​ ​ 4,908 ​ 3.0 % ​ 3,569 ​ 3.2 % ​ 8,581 ​ (16.7) % Change in unrecognized tax benefits ​ ​ (6,849) ​ (4.2) % ​ 791 ​ 0.7 % ​ 56 ​ (0.1) % Other ​ 517 0.3 % ​ (994) (0.9) % ​ 688 (1.3) % Provision for (benefit from) income taxes ​ $ 26,224 16.0 % ​ $ 10,283 9.2 % ​ $ (15,539) 30.2 % ​ Deferred income tax assets and liabilities result primarily from temporary differences in the recognition of various expenses for tax and financial statement purposes, and from the recognition of the tax benefits of net operating loss carryforwards. The components of the deferred income tax assets and liabilities were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2024 ​ 2023 Employee benefits ​ $ 15,866 ​ $ 11,719 Stock-based compensation ​ 7,664 ​ 7,310 Receivable reserve ​ 9,028 ​ 6,246 Capitalized research and experimental costs ​ 9,322 ​ 8,075 Operating lease liabilities ​ ​ 42,526 ​ ​ 41,235 Other reserves ​ 12,439 ​ 6,246 Loss and credit carryforwards, net ​ 15,426 ​ 19,259 Less: valuation allowance ​ — ​ (621) Gross deferred tax assets ​ 112,271 ​ 99,469 Depreciation ​ (8,298) ​ (5,643) Deferred taxes on unremitted foreign earnings ​ ​ (210) ​ ​ (428) Amortization of intangible assets ​ (50,035) ​ (31,294) Operating lease assets ​ ​ (34,166) ​ ​ (31,478) Gross deferred tax liability ​ (92,709) ​ (68,843) Net deferred tax asset ​ $ 19,562 ​ $ 30,626 ​ As of June 30, 2024, Adtalem had $164.4 million of gross, post apportioned state net operating loss carryforwards, and $13.0 million of gross foreign net operating loss carryforwards in St. Maarten. As of June 30, 2023, Adtalem had $190.8 million of gross, post apportioned state net operating loss carryforwards, and $17.3 million of foreign net operating loss carryforwards in St. Maarten and other jurisdictions. Adtalem has the following tax net operating loss (tax effected), interest (tax effected), and credit carryforwards as of June 30, 2024 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ Years of Expiration ​ ​ 2024 ​ Beginning ​ Ending U.S. interest expense carryforwards ​ $ 506 no expiration U.S. credit carryforwards ​ ​ 672 ​ 2027 ​ 2030 State net operating loss carryforwards ​ 9,053 2025 2043 State interest expense carryforwards ​ ​ 592 ​ no expiration State credit carryforwards ​ ​ 130 ​ no expiration Foreign net operating loss carryforwards ​ 4,473 2030 2033 Total loss and credit carryforwards, net ​ $ 15,426 ​ ​ ​ ​ Two of Adtalem’s businesses benefit from local tax incentives: RUSM, which operates in Barbados and RUSVM, which operates in St. Kitts. RUSM and RUSVM each have agreements with their respective domestic governments that exempt them from local income taxation. RUSM has an exemption in Barbados until 2039. RUSVM has an exemption in St. Kitts until 2037. Adtalem does not assert that the accumulated undistributed earnings of its foreign subsidiaries are indefinitely reinvested in foreign jurisdictions. Adtalem has accrued immaterial applicable state income and foreign withholding taxes on such undistributed earnings. Adtalem reviews the realizability of its deferred tax assets and related valuation allowances on a quarterly basis, or whenever events or changes in circumstances indicate that a review is required. In determining the requirement for a valuation allowance, the historical and projected financial results of the legal entity or consolidated group recording the net deferred tax asset are considered, along with any other positive or negative evidence. A valuation allowance is established when, based on the weight of available evidence, it is more likely than not that all or a portion of a deferred tax asset will not be realized. Based on our review of all available positive and negative evidence, it is more likely than not that we will recognize all deferred tax assets and, therefore, we do not have a valuation allowance on our deferred tax assets as of June 30, 2024. The valuation allowance on our deferred tax assets was $0.6 million as of June 30, 2023 and mainly related to foreign net operating loss carryforwards. The valuation allowance decreased by $0.6 million in fiscal year 2024 compared to fiscal year 2023 and decreased by $9.8 million in fiscal year 2023 compared to fiscal year 2022. Insufficient projected taxable income in certain jurisdictions may give rise to the need for a valuation allowance. We will continue to evaluate the need for valuation allowances and, as circumstances change, the valuation allowance may change. The changes in our valuation allowances were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Balance at beginning of period ​ $ 621 ​ $ 10,390 ​ $ 4,985 Charged to costs and expenses ​ — ​ (2,677) ​ 5,522 Deductions ​ (621) ​ (7,092) ​ (117) Balance at end of period ​ $ — ​ $ 621 ​ $ 10,390 ​ Our effective tax rates from continuing operations were 16.0%, 9.2%, and 30.2% in fiscal year 2024, 2023, and 2022, respectively. In fiscal year 2024, our effective tax rate increase was primarily due to an increase in the percentage of earnings from operations in higher taxed jurisdictions and a limitation of tax benefits on certain executive compensation. The rate increase was partially offset due to the lapsing of statues of limitations for unrecognized tax benefits in fiscal year 2024. In addition, in fiscal year 2023, we released a valuation allowance on certain deferred tax assets based on our reassessment of the amount of state net operating loss carryforwards that are more likely than not to be realized. The income tax expenses in fiscal years 2024 and 2023 and the income tax benefit in fiscal year 2022 reflect the U.S. federal tax rate of 21% adjusted for taxes related to global intangible low-taxed income (“GILTI”), limitation of tax benefits on certain executive compensation, the rate of tax applied by state and local jurisdictions, the rate of tax applied to earnings outside the U.S., tax incentives, tax credits related to research and development expenditures, changes in valuation allowance, liabilities for uncertain tax positions, and tax benefits on stock-based compensation. As of June 30, 2024 and 2023, the total amount of gross unrecognized tax benefits for uncertain tax positions was $6.7 million and $13.1 million, respectively, which if recognized, would impact the effective tax rate. We expect that our unrecognized tax benefits will decrease during the next 12 months due to the settlement of various audits and the lapsing of statutes of limitation. We estimate this decrease to be immaterial. Adtalem classifies interest and penalties on tax uncertainties as a component of the provision for income taxes. The total amount of interest and penalties accrued as of June 30, 2024 and 2023 was $1.2 million and $1.6 million, respectively. Interest and penalties expense recognized during the years ended June 30, 2024, 2023, and 2022 were a net decrease of $0.4 million, a net increase of $0.7 million, and a net increase of $0.3 million, respectively. The changes in our unrecognized tax benefits were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Balance at beginning of period ​ $ 13,128 ​ $ 11,645 ​ $ 9,836 Increases from positions taken during prior periods ​ 953 ​ 1,299 ​ 1,074 Decreases from positions taken during prior periods ​ (1,248) ​ — ​ (1,737) Increases from positions taken during the current period ​ 554 ​ 665 ​ 2,845 Reductions due to lapse of statute ​ (6,664) ​ (481) ​ (373) Balance at end of period ​ $ 6,723 ​ $ 13,128 ​ $ 11,645 ​ Adtalem files tax returns in the U.S. federal jurisdiction and in various state and foreign jurisdictions based on existing tax laws and incentives. Adtalem remains generally subject to examination in the U.S. for years beginning on or after July 1, 2020; in various states for years beginning on or after July 1, 2019; and in our significant foreign jurisdictions for years beginning on or after July 1, 2017.

Earnings per Share

Earnings per Share	12 Months Ended
	Jun. 30, 2024
Earnings per Share
Earnings per Share	9. Earnings per Share The following table sets forth the computations of basic and diluted earnings per share and antidilutive shares (in thousands, except per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Numerator: ​ ​ ​ ​ ​ ​ ​ ​ ​ Net income (loss): ​ ​ ​ ​ ​ ​ Continuing operations ​ $ 137,713 ​ $ 101,752 ​ $ (35,955) Discontinued operations ​ ​ (936) ​ ​ (8,394) ​ ​ 346,946 Net income ​ $ 136,777 ​ $ 93,358 ​ $ 310,991 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Denominator: ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-average basic shares outstanding ​ ​ 39,413 ​ 44,781 ​ 48,388 Effect of dilutive stock awards ​ ​ 894 ​ 743 ​ — Effect of ASR ​ ​ — ​ 76 ​ — Weighted-average diluted shares outstanding ​ ​ 40,307 ​ 45,600 ​ 48,388 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Earnings (loss) per share: ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic: ​ ​ ​ ​ ​ ​ ​ ​ ​ Continuing operations ​ $ 3.49 ​ $ 2.27 ​ $ (0.74) Discontinued operations ​ $ (0.02) ​ $ (0.19) ​ $ 7.17 Total basic earnings per share ​ $ 3.47 ​ $ 2.08 ​ $ 6.43 Diluted: ​ ​ ​ ​ ​ ​ ​ ​ ​ Continuing operations ​ $ 3.42 ​ $ 2.23 ​ $ (0.74) Discontinued operations ​ $ (0.02) ​ $ (0.18) ​ $ 7.17 Total diluted earnings per share ​ $ 3.39 ​ $ 2.05 ​ $ 6.43 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-average antidilutive shares ​ ​ 115 ​ ​ 403 ​ ​ 1,869 ​ As a result of incurring a net loss from continuing operations in fiscal year 2022, potential common stock of 416 thousand shares were excluded from diluted loss per share because the effect would have been antidilutive. As further described in Note 16 “Share Repurchases,” on March 14, 2022, we entered into an accelerated share repurchase (“ASR”) agreement to repurchase $150.0 million of common stock. For purposes of calculating earnings per share, Adtalem reflected the ASR agreement as a repurchase of Adtalem common stock and as a forward contract indexed to its own common stock. Based on the volume-weighted average price of Adtalem’s common stock per the terms of the ASR agreement, common stock of 76 thousand shares were contingently issuable by Adtalem under the ASR agreement and were included in the diluted earnings per share calculation for fiscal year 2023 because the effect would have been dilutive. As of October 14, 2022, the ASR agreement is no longer outstanding. Diluted earnings per share was computed using the treasury stock method for stock awards. Certain shares related to stock awards were excluded from the computation of earnings per share because the effect would have been antidilutive.

Accounts and Financing Receivab

Accounts and Financing Receivables	12 Months Ended
	Jun. 30, 2024
Receivables [Abstract]
Accounts and Financing Receivables	10. Accounts and Financing Receivables Our accounts receivables relate to student balances occurring in the normal course of business. Accounts receivables have a term of less than one year and are included in accounts and financing receivables, net on our Consolidated Balance Sheets. Our financing receivables relate to credit extension programs where the student is provided payment terms in excess of one year with their respective school and are included in accounts and financing receivables, net and other assets, net on our Consolidated Balance Sheets. The classification of our accounts and financing receivable balances was as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2024 ​ ​ ​ Gross ​ ​ Allowance ​ ​ Net Accounts receivables, current ​ $ 159,406 ​ $ (35,336) ​ $ 124,070 Financing receivables, current ​ ​ 5,239 ​ ​ (2,476) ​ ​ 2,763 Accounts and financing receivables, current ​ $ 164,645 ​ $ (37,812) ​ $ 126,833 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Financing receivables, current ​ $ 5,239 ​ $ (2,476) ​ $ 2,763 Financing receivables, noncurrent ​ ​ 36,214 ​ ​ (10,082) ​ ​ 26,132 Total financing receivables ​ $ 41,453 ​ $ (12,558) ​ $ 28,895 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2023 ​ ​ ​ Gross ​ ​ Allowance ​ ​ Net Accounts receivables, current ​ $ 129,318 ​ $ (29,190) ​ $ 100,128 Financing receivables, current ​ ​ 4,757 ​ ​ (2,136) ​ ​ 2,621 Accounts and financing receivables, current ​ $ 134,075 ​ $ (31,326) ​ $ 102,749 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Financing receivables, current ​ $ 4,757 ​ $ (2,136) ​ $ 2,621 Financing receivables, noncurrent ​ ​ 36,368 ​ ​ (9,332) ​ ​ 27,036 Total financing receivables ​ $ 41,125 ​ $ (11,468) ​ $ 29,657 ​ Our financing receivables relate to credit extension programs available to students at Chamberlain, AUC, RUSM, and RUSVM. These credit extension programs are designed to assist students who are unable to completely cover educational costs consisting of tuition, fees, and books, and are available only after all other student financial assistance has been applied toward those purposes. In addition, AUC, RUSM, and RUSVM allow students to finance their living expenses. Repayment plans for financing agreements are developed to address the financial circumstances of the particular student. Interest charges at rates from 3.0% to 12.0% per annum accrue each month on the unpaid balance once a student withdraws or graduates from a program. Most students are required to begin repaying their loans while they are still in school with a minimum payment level designed to demonstrate their capability to repay, which reduces the possibility of over borrowing. Payments may increase upon completing or departing school. After a student leaves school, the student typically will have a monthly installment repayment plan. Credit Quality The primary credit quality indicator for our financing receivables is delinquency. Balances are considered delinquent when contractual payments on the loan become past due. We write-off financing receivable balances when they are at least 181 days past due. Payments are applied first to outstanding interest and then to the unpaid principal balance. The credit quality analysis of financing receivables as of June 30, 2024 was as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortized Cost Basis by Origination Year ​ ​ ​ ​ ​ Prior ​ 2020 ​ 2021 ​ 2022 ​ 2023 ​ 2024 ​ Total 1-30 days past due $ 552 ​ $ — $ 214 $ 111 $ 1,188 $ 1,146 $ 3,211 31-60 days past due ​ ​ 213 ​ ​ 90 ​ ​ 65 ​ ​ 37 ​ ​ 567 ​ ​ 1,488 ​ ​ 2,460 61-90 days past due ​ ​ 174 ​ ​ — ​ ​ 5 ​ ​ 110 ​ ​ 370 ​ ​ 257 ​ ​ 916 91-120 days past due ​ ​ — ​ ​ 11 ​ ​ 434 ​ ​ 20 ​ ​ 206 ​ ​ 791 ​ ​ 1,462 121-150 days past due ​ ​ 51 ​ ​ 88 ​ ​ 63 ​ ​ 314 ​ ​ 268 ​ ​ 91 ​ ​ 875 Greater than 150 days past due ​ ​ 2,556 ​ ​ 466 ​ ​ 1,366 ​ ​ 1,300 ​ ​ 1,920 ​ ​ 987 ​ ​ 8,595 Total past due ​ ​ 3,546 ​ ​ 655 ​ ​ 2,147 ​ ​ 1,892 ​ ​ 4,519 ​ ​ 4,760 ​ ​ 17,519 Current ​ ​ 6,014 ​ ​ 748 ​ ​ 3,944 ​ ​ 1,897 ​ ​ 4,549 ​ ​ 6,782 ​ ​ 23,934 Financing receivables, gross ​ $ 9,560 ​ $ 1,403 ​ $ 6,091 ​ $ 3,789 ​ $ 9,068 ​ $ 11,542 ​ $ 41,453 Gross write-offs ​ $ 1,145 ​ $ 279 ​ $ 509 ​ $ 597 ​ $ 729 ​ $ 2 ​ $ 3,261 The credit quality analysis of financing receivables as of June 30, 2023 was as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortized Cost Basis by Origination Year ​ ​ ​ ​ ​ Prior ​ 2019 ​ 2020 ​ 2021 ​ 2022 ​ 2023 ​ Total 1-30 days past due $ 186 ​ $ 79 $ 115 $ 137 $ 735 $ 1,944 $ 3,196 31-60 days past due ​ ​ 61 ​ ​ 34 ​ ​ — ​ ​ 359 ​ ​ 573 ​ ​ 1,103 ​ ​ 2,130 61-90 days past due ​ ​ 97 ​ ​ 39 ​ ​ 110 ​ ​ 65 ​ ​ 559 ​ ​ 368 ​ ​ 1,238 91-120 days past due ​ ​ 2 ​ ​ 17 ​ ​ 2 ​ ​ 13 ​ ​ 77 ​ ​ 200 ​ ​ 311 121-150 days past due ​ ​ 62 ​ ​ 37 ​ ​ 26 ​ ​ 45 ​ ​ 147 ​ ​ 129 ​ ​ 446 Greater than 150 days past due ​ ​ 2,641 ​ ​ 734 ​ ​ 708 ​ ​ 2,071 ​ ​ 1,457 ​ ​ 381 ​ ​ 7,992 Total past due ​ ​ 3,049 ​ ​ 940 ​ ​ 961 ​ ​ 2,690 ​ ​ 3,548 ​ ​ 4,125 ​ ​ 15,313 Current ​ ​ 6,199 ​ ​ 1,112 ​ ​ 820 ​ ​ 5,350 ​ ​ 2,608 ​ ​ 9,723 ​ ​ 25,812 Financing receivables, gross ​ $ 9,248 ​ $ 2,052 ​ $ 1,781 ​ $ 8,040 ​ $ 6,156 ​ $ 13,848 ​ $ 41,125 ​ Allowance for Credit Losses The allowance for credit losses represents an estimate of the lifetime expected credit losses inherent in our accounts and financing receivable balances as of each balance sheet date. In evaluating the collectability of our accounts and financing receivable balances, we utilize historical events, current conditions, and reasonable and supportable forecasts about the future. For our accounts receivables, we primarily use historical loss rates based on an aging schedule and a student’s status to determine the allowance for credit losses. As these accounts receivables are short-term in nature, management believes a student’s status provides the best credit loss estimate, while also factoring in delinquency. Students still attending classes, recently graduated, or current on payments are more likely to pay than those who are inactive due to being on a leave of absence, withdrawing from school, or not current on payments. For our financing receivables, we primarily use historical loss rates based on an aging schedule. As these financing receivables are based on long-term financing agreements offered by Adtalem, management believes that delinquency provides the best credit loss estimate. As the financing receivable balances become further past due, it is less likely we will receive payment, causing our estimate of credit losses to increase. The following tables provide a roll-forward of the allowance for credit losses (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accounts ​ Financing ​ Total June 30, 2021 $ 11,559 ​ $ 16,832 $ 28,391 Write-offs ​ ​ (15,980) ​ ​ (5,287) ​ ​ (21,267) Recoveries ​ ​ 11,488 ​ ​ 35 ​ ​ 11,523 Provision for credit losses ​ ​ 23,830 ​ ​ 3,311 ​ ​ 27,141 June 30, 2022 ​ ​ 30,897 ​ ​ 14,891 ​ ​ 45,788 Write-offs ​ ​ (43,273) ​ ​ (7,653) ​ ​ (50,926) Recoveries ​ ​ 12,207 ​ ​ 590 ​ ​ 12,797 Provision for credit losses ​ ​ 29,359 ​ ​ 3,640 ​ ​ 32,999 June 30, 2023 ​ ​ 29,190 ​ ​ 11,468 ​ ​ 40,658 Write-offs ​ ​ (54,897) ​ ​ (3,261) ​ ​ (58,158) Recoveries ​ ​ 10,806 ​ ​ 1,413 ​ ​ 12,219 Provision for credit losses ​ ​ 50,237 ​ ​ 2,938 ​ ​ 53,175 June 30, 2024 ​ $ 35,336 ​ $ 12,558 ​ $ 47,894 ​ Other Financing Receivables In connection with the sale of DeVry University, Adtalem loaned $10.0 million to DeVry University under the terms of the DeVry Note. The DeVry Note bore interest at a rate of 4% per annum, payable annually in arrears, and had a maturity date of January 1, 2022. We received the loan payment of $10.0 million during the third quarter of fiscal year 2022. On July 31, 2019, Adtalem sold its Chicago, Illinois, campus facility to DePaul College Prep Foundation (“DePaul College Prep”). In connection with the sale, Adtalem held a mortgage from DePaul College Prep for $46.8 million. The mortgage was due on July 31, 2024 as a balloon payment and bore interest at a rate of 4% per annum, payable monthly. The carrying value of the DePaul College Prep loan receivable was included in other assets, net on the Consolidated Balance Sheets and was determined by discounting the future cash flows using an average of current rates for similar arrangements, which was estimated at 7% per annum. On February 23, 2023, DePaul College Prep paid the mortgage in full, which resulted in derecognition of the note receivable from the Consolidated Balance Sheets.

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Jun. 30, 2024
Property, Plant And Equipment [Abstract]
Property and Equipment, Net	11. Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ Useful Life ​ 2024 ​ 2023 Land - $ 31,776 ​ $ 35,956 Buildings and improvements ​ 10 - 31 years ​ ​ 200,274 ​ ​ 206,349 Leasehold improvements ​ Shorter of asset useful life or lease term ​ ​ 114,019 ​ ​ 99,777 Furniture and equipment ​ 3 - 8 years ​ ​ 103,961 ​ ​ 125,594 Software ​ 3 - 5 years ​ ​ 113,219 ​ ​ 92,212 Construction in progress ​ - ​ ​ 11,554 ​ ​ 23,390 Property and equipment, gross ​ ​ ​ ​ 574,803 ​ ​ 583,278 Accumulated depreciation ​ ​ ​ (326,279) ​ (338,629) Property and equipment, net ​ ​ ​ $ 248,524 ​ $ 244,649 ​ Depreciation expense was $39.7 million, $41.4 million, and $44.6 million for the years ended June 30, 2024, 2023, and 2022, respectively. During the second quarter of fiscal year 2024, management committed to a plan to sell a building owned by Adtalem located in Naperville, Illinois, and the building met criteria to be classified as assets held for sale. As a result, the building’s carrying value of $8.4 million was adjusted to its estimated fair value less cost to sell of $7.8 million, and the resulting $0.6 million charge was recognized within student services and administrative expense in the Consolidated Statements of Income for the year ended June 30, 2024. In addition, the building is presented as assets held for sale on the Consolidated Balance Sheets as of June 30, 2024. On July 31, 2019, Adtalem sold its Chicago, Illinois, campus facility to DePaul College Prep for $52.0 million. Adtalem received $5.2 million of cash at the time of closing and held a mortgage, secured by the property, from DePaul College Prep for $46.8 million. The mortgage was due on July 31, 2024 as a balloon payment and bore interest at a rate of 4% per annum, payable monthly. The buyer had an option to make prepayments. Due to Adtalem’s involvement with financing the sale, the transaction did not qualify as a sale for accounting purposes. Adtalem continued to maintain the assets associated with the sale on the Consolidated Balance Sheets. We recorded a note receivable of $40.3 million and a financing payable of $45.5 million at the time of the sale, which were classified as other assets, net and other liabilities, respectively, on the Consolidated Balance Sheets. See Note 10 “Accounts and Financing Receivables” for a discussion on the discounting of the note receivable. On February 23, 2023, DePaul College Prep paid the mortgage in full. The $46.8 million received during fiscal year 2023 is classified as an investing activity in the Consolidated Statements of Cash Flows. Upon receiving full repayment of the mortgage, Adtalem no longer is involved in the financing of the sale and therefore derecognized the note receivable, the financing payable, and the assets associated with the campus facility, which resulted in recognizing a gain on sale of assets of $13.3 million in fiscal year 2023. This gain was recorded at Adtalem’s home office, which is classified as “Home Office” in Note 22 “Segment Information.”

Leases

Leases	12 Months Ended
	Jun. 30, 2024
Lessee Disclosure [Abstract]
Leases	12. Leases We determine if a contract contains a lease at inception. We have entered into operating leases for academic sites, housing facilities, and office space which expire at various dates through November 2039, most of which include options to terminate for a fee or extend the leases for an additional five-year period. The lease term includes the noncancelable period of the lease, as well as any periods for which we are reasonably certain to exercise extension options. We elected to account for lease and non-lease components (e.g., common-area maintenance costs) as a single lease component for all operating leases. Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. We have not entered into any financing leases. Operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets represent our right to use an underlying asset during the lease term. Operating lease assets and liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. Operating lease assets are adjusted for any prepaid or accrued lease payments, lease incentives, initial direct costs, and impairments. Our incremental borrowing rate is utilized in determining the present value of the lease payments based upon the information available at the commencement date. Our incremental borrowing rate is determined using a secured borrowing rate for the same As of June 30, 2024, we had entered into three additional operating leases that have not yet commenced. The first lease is expected to commence during the first quarter of fiscal year 2025, has a 10-year lease term, and will result in an additional operating lease asset and operating lease liability liability liability The components of lease cost were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Operating lease cost ​ $ 44,365 ​ $ 48,181 ​ $ 55,257 Sublease income ​ (9,107) ​ (13,329) ​ (13,920) Total lease cost ​ $ 35,258 ​ $ 34,852 ​ $ 41,337 ​ Maturities of lease liabilities as of June 30, 2024 were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ Operating Fiscal Year ​ Leases 2025 ​ $ 44,419 2026 ​ ​ 44,406 2027 ​ ​ 43,012 2028 ​ ​ 36,054 2029 ​ ​ 26,313 Thereafter ​ ​ 89,337 Total lease payments ​ 283,541 Less: tenant improvement allowance not yet received ​ ​ (8,631) Less: imputed interest ​ ​ (75,769) Present value of lease liabilities ​ $ 199,141 ​ Lease term and discount rate were as follows: ​ ​ ​ ​ ​ ​ ​ June 30, 2024 Weighted-average remaining operating lease term (years) ​ ​ 6.8 Weighted-average operating lease discount rate ​ ​ 7.4% ​ Supplemental of cash flow information related to leases were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Cash paid for amounts in the measurement of operating lease liabilities (net of sublease receipts) ​ $ 41,063 ​ $ 58,198 ​ $ 52,540 Operating lease assets obtained in exchange for operating lease liabilities ​ $ 34,719 ​ $ 32,476 ​ $ 49,136 ​ Adtalem maintains agreements to sublease either a portion or the full leased spac e at four of its operating lease locations. Most of these subleases are a result of Adtalem retaining leases associated with restructured lease activities at DeVry University and Carrington College prior to their divestitures during fiscal year 2019. All sublease expirations with DeVry University and Carrington College coincide with Adtalem’s original head lease expiration dates. At that time, Adtalem will be relieved of its obligations. In addition, Adtalem has entered into subleases with non-affiliated entities for vacated or partially vacated space from restructuring activities. Adtalem’s sublease agreements expire at various dates through December 2025. We record sublease income as an offset against our lease expense recorded on the head lease. For leases which Adtalem vacated or partially vacated space, we recorded estimated restructuring charges in prior periods. Actual results may differ from these estimates, which could result in additional restructuring charges or reversals in future periods. Future minimum sublease income under these agreements as of June 30, 2024, were as follows (in thousands): ​ ​ ​ ​ ​ Fiscal Year ​ Amount 2025 ​ $ 5,255 2026 ​ 2,038 Total sublease rental income ​ $ 7,293 ​

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	13. Goodwill and Intangible Assets Goodwill balances by reporting unit were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2024 ​ 2023 Chamberlain ​ $ 4,716 ​ $ 4,716 Walden ​ ​ 651,052 ​ ​ 651,052 AUC ​ 68,321 ​ 68,321 RUSM ​ 180,089 ​ 180,089 RUSVM ​ 57,084 ​ 57,084 Total ​ $ 961,262 ​ $ 961,262 ​ Goodwill balances by reportable segment were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2024 ​ 2023 Chamberlain ​ $ 4,716 ​ $ 4,716 Walden ​ ​ 651,052 ​ ​ 651,052 Medical and Veterinary ​ ​ 305,494 ​ ​ 305,494 Total ​ $ 961,262 ​ $ 961,262 ​ Amortizable intangible assets consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2024 ​ June 30, 2023 ​ ​ ​ ​ Gross Carrying ​ Accumulated ​ Gross Carrying ​ Accumulated ​ Weighted-Average ​ ​ Amount ​ Amortization ​ Amount ​ Amortization ​ Amortization Period Student relationships ​ $ 161,900 ​ $ (161,900) $ 161,900 ​ $ (137,476) 3 Years Curriculum ​ 56,091 ​ (32,257) 56,091 ​ (21,037) 5 Years Total ​ $ 217,991 ​ $ (194,157) $ 217,991 ​ $ (158,513) ​ ​ Indefinite-lived intangible assets consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2024 ​ 2023 Walden trade name ​ $ 119,560 ​ $ 119,560 AUC trade name ​ ​ 17,100 ​ ​ 17,100 RUSM trade name ​ ​ 3,500 ​ ​ 3,500 RUSVM trade name ​ ​ 1,600 ​ ​ 1,600 Chamberlain Title IV eligibility and accreditations ​ 1,200 ​ 1,200 Walden Title IV eligibility and accreditations ​ ​ 495,800 ​ ​ 495,800 AUC Title IV eligibility and accreditations ​ 100,000 ​ 100,000 RUSM Title IV eligibility and accreditations ​ 11,600 ​ 11,600 RUSVM Title IV eligibility and accreditations ​ 2,500 ​ 2,500 Total ​ $ 752,860 ​ $ 752,860 ​ Indefinite-lived intangible asset balances by reportable segment were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2024 ​ 2023 Chamberlain ​ $ 1,200 ​ $ 1,200 Walden ​ ​ 615,360 ​ ​ 615,360 Medical and Veterinary ​ ​ 136,300 ​ ​ 136,300 Total ​ $ 752,860 ​ $ 752,860 ​ Amortization expense for amortized intangible assets was $35.6 million, $61.2 million, and $97.3 million for the years ended June 30, 2024, 2023, and 2022, respectively. Future intangible asset amortization expense, by reporting unit, is expected to be as follows (in thousands): ​ ​ ​ ​ ​ Fiscal Year ​ Walden 2025 ​ $ 11,220 2026 ​ 11,220 2027 ​ 1,394 Total ​ $ 23,834 ​ Curriculum is amortized on a straight-line basis. Student relationships is amortized based on the estimated retention of the students and considers the revenue and cash flow associated with these existing students. Indefinite-lived intangible assets related to trade names and Title IV eligibility and accreditations are not amortized, as there are no legal, regulatory, contractual, economic, or other factors that limit the useful life of these intangible assets to the reporting entity. Goodwill and indefinite-lived intangible assets are not amortized, but are tested for impairment annually and when an event occurs or circumstances change such that it is more likely than not that an impairment may exist. There were no triggering events in fiscal year 2024 and our annual testing date is May 31. Adtalem has five reporting units that contain goodwill and indefinite-lived intangible assets. These reporting units constitute components for which discrete financial information is available and regularly reviewed by segment management. We have the option to assess goodwill for impairment by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If it is determined that the reporting unit fair value is more likely than not less than its carrying value, or if we do not elect the option to perform an initial qualitative assessment, we perform a quantitative assessment of the reporting unit’s fair value. If the carrying value of a reporting unit containing the goodwill exceeds the fair value of that reporting unit, an impairment loss is recognized equal to the difference between the carrying value of the reporting unit and its fair value, not to exceed the carrying value of goodwill. We also have the option to perform a qualitative assessment to test indefinite-lived intangible assets for impairment by determining whether it is more likely than not that the indefinite-lived intangible assets are impaired. If it is determined that the indefinite-lived intangible asset is more likely than not impaired, or if we do not elect the option to perform an initial qualitative assessment, we perform a quantitative assessment of the indefinite-lived intangible assets. If the carrying value of the indefinite-lived intangible assets exceeds its fair value, an impairment loss is recognized to the extent the carrying value exceeds fair value. As of May 31, 2024, we elected to perform a qualitative assessment for all reporting units, except AUC. We analyzed qualitative factors, including results of operations and business conditions of the four reporting units where a qualitative assessment was performed, significant changes in cash flows of the reporting unit level or individual indefinite-lived intangible asset level, if applicable, as well as how much previously calculated fair values exceeded carrying values to determine if it is more likely than not that the goodwill or indefinite-lived intangible assets were impaired. Based on the qualitative assessment of the four reporting units, it was determined that it was more likely than not that the fair values of the reporting units or individual indefinite-lived intangible assets exceeded the respective carrying values. As of May 31, 2024, we did not elect to perform a qualitative assessment for the AUC trade name and AUC Title IV eligibility and accreditation indefinite-lived intangible assets, and therefore performed a quantitative assessment of the respective fair values. In determining fair value of the AUC trade name indefinite-lived intangible asset, we used the relief-from-royalty method. The significant assumptions used in this valuation approach are the risk-adjusted discount rate of 12.5%, forecasted revenue, a terminal revenue growth rate of 3.0%, and a royalty rate of 5.5%. In determining fair value of the AUC Title IV eligibility and accreditation indefinite-lived intangible asset, we used the with and without method in a discounted cash flow model. The significant assumptions used in this valuation approach are the risk-adjusted discount rate of 12.5%, forecasted revenue with and without the accreditations in place, and forecasted earnings before interest, taxes, depreciation, and amortization (“EBITDA”) with and without the accreditations in place. Based on these quantitative assessments, it was determined that the fair values of these indefinite-lived intangible assets in the AUC reporting unit exceeded their carrying values and therefore no impairment was identified. As of May 31, 2024, we did not elect to perform a qualitative assessment for our AUC reporting unit and therefore performed a quantitative assessment of the reporting unit’s fair value. In determining fair value of the AUC reporting unit, we used the discounted cash flow model and the market multiple valuation approach. The significant assumptions used in the discounted cash flow model are the risk-adjusted discount rate of 12.5%, forecasted revenue and EBITDA, and a terminal growth rate of 3.0%. The significant assumptions used in the market multiple valuation approach include earnings multiples for comparable companies. Based on this quantitative assessment, it was determined that the fair value of the AUC reporting unit exceeded its carrying value and therefore no goodwill impairment was identified. Determining the fair value of a reporting unit or an intangible asset involves the use of significant estimates and assumptions. Management bases its fair value estimates on assumptions it believes to be reasonable at the time, but such assumptions are subject to inherent uncertainty. Actual results may differ from those estimates. If economic conditions deteriorate, interest rates rise, or operating performance of our reporting units do not meet expectations such that we revise our long-term forecasts, we may recognize impairments of goodwill and other intangible assets in future periods.

Debt

Debt	12 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Debt	14. Debt Long-term debt consisted of the following senior secured credit facilities (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2024 ​ 2023 Senior Secured Notes due 2028 ​ $ 404,950 ​ $ 404,950 Term Loan B ​ 253,333 ​ 303,333 Total principal ​ 658,283 ​ 708,283 Unamortized debt discount and issuance costs ​ (9,571) ​ (13,206) Long-term debt ​ $ 648,712 ​ $ 695,077 ​ Scheduled future maturities of long-term debt were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ Maturity Fiscal Year ​ Payments 2025 ​ $ — 2026 ​ — 2027 ​ — 2028 ​ 404,950 2029 ​ 253,333 Total ​ $ 658,283 ​ Senior Secured Notes due 2028 On March 1, 2021, Adtalem issued $800.0 million aggregate principal amount of 5.50% Senior Secured Notes due 2028 (the “Notes”), which mature on March 1, 2028, pursuant to an indenture, dated as of March 1, 2021 (the “Indenture”), by and between Adtalem and U.S. Bank National Association, as trustee and notes collateral agent. The Notes were sold within the U.S. only to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the U.S. to non-U.S. persons in reliance on Regulation S under the Securities Act. The Notes were issued at 100.0% of their par value. The Notes bear interest at a rate of 5.50% per year, payable semi-annually in arrears on March 1 and September 1 of each year, commencing on September 1, 2021, to holders of record on the preceding February 15 and August 15, as the case may be. The Notes are guaranteed by certain of Adtalem’s subsidiaries that are borrowers or guarantors under its senior secured credit facilities and certain of its other senior indebtedness, subject to certain exceptions (the “Guarantors”). As of August 12, 2021, the Notes were secured, subject to permitted liens and certain other exceptions, by first priority liens on the same collateral that secures the obligations under Adtalem’s senior secured credit facilities. At any time prior to March 1, 2024, we could have redeemed all or a part of the Notes at a redemption price equal to 100% of the principal amount of the Notes being redeemed plus a make-whole premium set forth in the Indenture and accrued and unpaid interest, if any, to, but not including, the redemption date. We may redeem the Notes, in whole or in part, at any time on or after March 1, 2024 at redemption prices equal to 102.75%, 101.375%, and 100% of the principal amount of the Notes redeemed if the redemption occurs during the twelve-month periods beginning on March 1 of the years 2024, 2025, and 2026 and thereafter, respectively, in each case plus accrued and unpaid interest, if any, thereon to, but not including, the applicable redemption date. In addition, at any time prior to March 1, 2024, Adtalem could have redeemed up to 40% of the aggregate principal amount of the Notes at a redemption price equal to 105.5% of the aggregate principal amount of the Notes redeemed, plus accrued and unpaid interest, if any, to, but not including, the redemption date, with the net cash proceeds from one or more qualifying equity offerings. On April 11, 2022, we repaid $373.3 million of Notes at a price equal to 100% of the principal amount of the Notes. During June 2022, we repurchased on the open market an additional $20.8 million of Notes at a price equal to approximately 90% of the principal amount of the Notes, resulting in a gain on extinguishment of debt of $2.1 million recorded within interest expense in the Consolidated Statements of Income for the year ended June 30, 2022. This debt was subsequently retired. During the first quarter of fiscal year 2023, we repurchased on the open market an additional $0.9 million of Notes at a price equal to approximately 92% of the principal amount of the Notes, resulting in a gain on extinguishment of debt of $0.1 million recorded within interest expense in the Consolidated Statements of Income for the year ended June 30, 2023. This debt was subsequently retired. The principal balance of the Notes is $405.0 million as of June 30, 2024. Accrued interest on the Notes of $7.4 Credit Agreement On August 12, 2021, in connection with the Walden acquisition, Adtalem entered into its new credit agreement (the “Credit Agreement”) that provides for (1) a $850.0 million senior secured term loan (“Term Loan B”) with a maturity date of August 12, 2028 and (2) a $400.0 million senior secured revolving loan facility (“Revolver”) with a maturity date of August 12, 2026. We refer to the Term Loan B and Revolver collectively as the “Credit Facility.” The Revolver has availability for letters of credit and currencies other than U.S. dollars of up to $400.0 million. On June 27, 2023, Adtalem entered into Amendment No. 1 to Credit Agreement, identifying the Secured Overnight Financing Rate (“SOFR”) as the benchmark rate to replace LIBOR for eurocurrency rate loans within the Credit Agreement effective the first quarter of fiscal year 2024. Term Loan B Prior to January 26, 2024, borrowings under the Term Loan B bore interest at Adtalem’s option at a rate per annum equal to SOFR, subject to a SOFR floor of 0.75%, plus an applicable margin ranging from 4.00% to 4.50% for eurocurrency term loan borrowings or 3.00% to 3.50% for alternative base rate (“ABR”) borrowings depending on Adtalem’s net first lien leverage ratio for such period. On January 26, 2024, we repriced our Term Loan B loan resulting in a 0.50% reduction in our margin interest rate. As of January 26, 2024, borrowings under the Term Loan B bear interest at Adtalem’s option at a rate per annum equal to SOFR, subject to a SOFR floor of 0.75%, plus an applicable margin ranging from 3.50% to 4.00% for eurocurrency term loan borrowings or 2.50% to 3.00% for ABR borrowings depending on Adtalem’s net first lien leverage ratio for such period. As of June 30, 2024, the interest rate for borrowings under the Term Loan B facility was 8.84%, which approximated the effective interest rate. The Term Loan B originally required quarterly installment payments of $2.125 million beginning on March 31, 2022. On March 11, 2022, we made a prepayment of $396.7 million on the Term Loan B. With that prepayment, we are no longer required to make quarterly installment payments. We made additional Term Loan B prepayments of $100.0 million, $50.0 million, and $50.0 million on September 22, 2022, November 22, 2022, and January 26, 2024, respectively. The principal balance of the Notes is $253.3 million as of June 30, 2024. Revolver Borrowings under the Revolver bear interest at a rate per annum equal to SOFR, subject to a SOFR floor of 0.75%, plus an applicable margin ranging from 3.75% to 4.25% for SOFR borrowings or 2.75% to 3.25% for ABR borrowings depending on Adtalem’s net first lien leverage ratio for such period. There were no borrowings under the Revolver during the year ended June 30, 2024, 2023, and 2022. The Credit Agreement requires payment of a commitment fee equal to 0.25% as of June 30, 2024, of the unused portion of the Revolver. The commitment fee expense is recorded within interest expense in the Consolidated Statements of Income. The amount unused under the Revolver was $242.1 million as of June 30, 2024. Prior Credit Agreement On April 13, 2018, Adtalem entered into a credit agreement (the “Prior Credit Agreement”) that provided for (1) a $300.0 million senior secured term loan (“Prior Term Loan B”), which was set to mature on April 13, 2025 and (2) a $300.0 million revolving facility (“Prior Revolver”), which was set to mature on April 13, 2023. We refer to the Prior Term Loan B and Prior Revolver collectively as the “Prior Credit Facility.” Prior Term Loan B For eurocurrency rate loans, Prior Term Loan B interest was equal to LIBOR or a LIBOR-equivalent rate plus 3%. For base rate loans, Prior Term Loan B interest was equal to the base rate plus 2%. The Prior Term Loan B required quarterly installment payments of $750,000, with the balance due at maturity on April 13, 2025. On March 24, 2020, we executed a pay-fixed, receive-variable interest rate swap agreement (the “Swap”) with a multinational financial institution to mitigate risks associated with the variable interest rate on our Prior Term Loan B debt. We paid interest at a fixed rate of 0.946% and received variable interest of one-month LIBOR (subject to a minimum of 0.00%), on a notional amount equal to the amount outstanding under the Prior Term Loan B. The effective date of the Swap was March 31, 2020 and settlements with the counterparty occurred on a monthly basis. The Swap was set to terminate on February 28, 2025. During the operating term of the Swap, the annual interest rate on the amount of the Prior Term Loan B was fixed at 3.946% (including the impact of the 3% interest rate margin on LIBOR loans) for the applicable interest rate period. The Swap was designated as a cash flow hedge and as such, changes in its fair value were recognized in accumulated other comprehensive loss on the Consolidated Balance Sheets and were reclassified into the Consolidated Statements of Income within interest expense in the periods in which the hedged transactions affected earnings. On July 29, 2021, prior to refinancing our Credit Agreement (as discussed above), we settled and terminated the Swap for $4.5 million, which resulted in a charge to interest expense for the year ended June 30, 2022. Prior Revolver Prior Revolver interest was equal to LIBOR or a LIBOR-equivalent rate for eurocurrency rate loans or a base rate, plus an applicable margin based on Adtalem’s consolidated leverage ratio, as defined in the Prior Credit Agreement. The applicable margin ranged from 1.75% to 2.75% for eurocurrency rate loans and from 0.75% to 1.75% for base rate loans. Debt Discount and Issuance Costs The Term Loan B was issued at a price of 99% of its principal amount, resulting in an original issue discount of 1%. The debt discount and issuance costs related to the Notes and Term Loan B are presented as a direct deduction from the face amount of the debt, while the debt issuance costs related to the Revolver are classified as other assets, net on the Consolidated Balance Sheets. The debt discount and issuance costs are amortized as interest expense over seven years for the Notes and Term Loan B and over five years for the Revolver. The remaining $6.0 million of unamortized debt issuance costs related to the Prior Credit Facility and the $10.3 million of debt issuances costs associated with an unused bridge facility, which was in place should the permanent financing not have been obtained, were expensed in interest expense in the Consolidated Statements of Income for the year ended June 30, 2022. In addition, based on the $396.7 million prepayment on the Term Loan B and $394.1 million prepayment on the Notes during fiscal year 2022, we expensed $12.5 million and $6.8 million, respectively, in interest expense in the Consolidated Statements of Income for the year ended June 30, 2022, which was the proportionate amount of the remaining unamortized debt discount and issuance costs related to the Term Loan B and Notes as of the prepayment dates. In addition, based on the $150.0 million and $50.0 million prepayments on the Term Loan B during fiscal year 2023 and 2024, respectively, we expensed $4.3 million and $1.1 million in interest expense in the Consolidated Statements of Income for the years ended June 30, 2023 and 2024, respectively, which was the proportionate amount of the remaining unamortized debt discount and issuance costs related to the Term Loan B as of the prepayment dates. The following table summarizes the unamortized debt discount and issuance costs activity for fiscal year 2024 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Notes ​ Term Loan B ​ Revolver ​ Total Unamortized debt discount and issuance costs as of June 30, 2023 ​ $ 5,592 ​ $ 7,614 ​ $ 6,355 ​ $ 19,561 Amortization of debt discount and issuance costs ​ (1,146) ​ (1,376) ​ (2,028) ​ (4,550) Debt discount and issuance costs write-off ​ ​ — ​ ​ (1,113) ​ ​ — ​ ​ (1,113) Unamortized debt discount and issuance costs as of June 30, 2024 ​ $ 4,446 ​ $ 5,125 ​ $ 4,327 ​ $ 13,898 ​ Off-Balance Sheet Arrangements The U.S. Department of Education (“ED”) has recently allowed reductions in our letters of credit totaling $90.8 million. On January 31, 2024, ED allowed a $76.2 million letter of credit in favor of ED to expire without any requirement for Adtalem to renew it. On April 26, 2024, ED indicated that it would permit Adtalem to reduce its $84.0 million surety-backed letter of credit in favor of ED on behalf of Walden, which allows Walden to participate in Title IV programs, to $69.4 million, which took effect on June 24, 2024, and was extended through December 31, 2024. In addition, Adtalem had a letter of credit outstanding under its Revolver in the amount of $157.9 million as of June 30, 2024, in favor of ED, which allows Adtalem institutions to participate in Title IV programs. As of June 30, 2024, Adtalem had $227.3 million of letters of credit outstanding in favor of ED. Interest Expense Interest expense consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Notes interest expense ​ $ 22,272 ​ $ 22,301 ​ $ 39,371 Term Loan B interest expense ​ ​ 26,324 ​ ​ 26,831 ​ ​ 33,413 Term Loan B ticking fees ​ ​ — ​ ​ — ​ ​ 5,330 Prior Term Loan B interest expense ​ ​ — ​ ​ — ​ ​ 1,272 Term Loan B debt discount and issuance costs write-off ​ ​ 1,113 ​ ​ 4,282 ​ ​ 12,471 Notes issuance costs write-off ​ ​ — ​ ​ 15 ​ ​ 6,771 Gain on extinguishment of debt ​ ​ — ​ ​ (71) ​ ​ (2,072) Unused bridge fee ​ ​ — ​ ​ — ​ ​ 10,329 Prior Credit Facility issuance costs write-off ​ ​ — ​ ​ — ​ ​ 6,000 Swap settlement ​ ​ — ​ ​ — ​ ​ 4,525 Amortization of debt discount and issuance costs ​ ​ 4,550 ​ ​ 4,832 ​ ​ 7,083 Letters of credit fees ​ ​ 8,639 ​ ​ 3,847 ​ ​ 3,968 Other ​ ​ 761 ​ ​ 1,063 ​ ​ 887 Total ​ $ 63,659 ​ $ 63,100 ​ $ 129,348 ​ Covenants and Guarantees The Credit Agreement and Notes contain customary covenants, including restrictions on our restricted subsidiaries’ ability to merge and consolidate with other companies, incur indebtedness, grant liens or security interest on assets, make acquisitions, loans, advances or investments, or sell or otherwise transfer assets. Under the terms of the Credit Agreement, beginning on the fiscal quarter ending December 31, 2021 and through December 31, 2023, Adtalem was required to maintain a Total Net Leverage Ratio of equal to or less than 4.00 to 1.00, which changed to 3.25 to 1.00 for the fiscal quarter ending March 31, 2024 and thereafter. The Total Net Leverage Ratio under the Credit Agreement is defined as the ratio of (a) the aggregate principal amount of Consolidated Debt (as defined in the Credit Agreement) of Adtalem and its subsidiaries as of the last day of the most recently ended Test Period (as defined in the Credit Agreement) minus Obligations under the Credit Agreement are secured by a first-priority lien on substantially all of the assets of Adtalem and certain of its domestic wholly owned subsidiaries (the “Subsidiary Guarantors”), which Subsidiary Guarantors also guarantee the obligations of Adtalem under the Credit Agreement, subject to certain exceptions. The Credit Agreement contains customary affirmative and negative covenants customary for facilities of its type, which, among other things, generally limit (with certain exceptions): mergers, amalgamations, or consolidations; the incurrence of additional indebtedness (including guarantees); the incurrence of additional liens; the sale, assignment, lease, conveyance or transfer of assets; certain investments; dividends and stock redemptions or repurchases in excess of certain amounts; transactions with affiliates; engaging in materially different lines of business; payments and modifications of indebtedness or the governing documents of Adtalem or any Subsidiary Guarantor; and other activities customarily restricted in such agreements. The Credit Agreement contains customary events of default for facilities of this type. If an event of default under the Credit Agreement occurs and is continuing, the commitments thereunder may be terminated and the principal amount outstanding thereunder, together with all accrued and unpaid interest and other amounts owed thereunder, may be declared immediately due and payable. The Term Loan B requires mandatory prepayments equal to the net cash proceeds from an asset sale or disposition which is not reinvested in assets within one-year from the date of disposition if the asset sale or disposition is in excess of $20.0 million, among other mandatory prepayment terms (see the Credit Agreement, as filed under Form 8-K dated August 12, 2021, for additional information and term definitions). With the $396.7 million prepayment on March 11, 2022 on the Term Loan B, the $394.1 million prepayment on the Notes during the fourth quarter of fiscal year 2022, and the $100.0 million prepayment on September 22, 2022 on the Term Loan B, we satisfied the mandatory prepayment requirement resulting from the sale proceeds received from the sale of our previous Financial Services segment. No other mandatory prepayments have been required since the execution of the Credit Agreement. The Notes contain covenants that limit the ability of Adtalem and each of the Guarantors to incur or guarantee additional debt or issue disqualified stock or preferred stock; pay dividends and make other distributions on, or redeem or repurchase, capital stock; make certain investments; incur certain liens; enter into transactions with affiliates; consolidate, merge, sell or otherwise dispose of all or substantially all of its assets; create certain restrictions on the Guarantors to make dividends or other payments to Adtalem; designate restricted subsidiaries as unrestricted subsidiaries; and transfer or sell certain assets. These covenants are subject to a number of important exceptions and qualifications. The Indenture and the Notes also provide for certain customary events of default which, if any of them occurs, would permit or require the principal of and accrued interest on the Notes to become or be declared due and payable or would allow the trustee or the holders of at least 25% in principal amount of the then outstanding Notes to declare the principal of and accrued and unpaid interest, if any, on all the Notes to be due and payable by notice in writing to Adtalem and, upon such declaration, such principal and accrued and unpaid interest, if any, will be due and payable immediately. Adtalem was in compliance with the Credit Agreement debt covenants and the Notes covenants as of June 30, 2024.

Redeemable Noncontrolling Inter

Redeemable Noncontrolling Interest	12 Months Ended
	Jun. 30, 2024
Noncontrolling Interest [Abstract]
Redeemable Noncontrolling Interest	15. Redeemable Noncontrolling Interest Prior to the third quarter of fiscal year 2022, Adtalem maintained a 69% ownership interest in EduPristine with the remaining 31% owned by Kaizen Management Advisors (“Kaizen”), an India-based private equity firm. Beginning on March 26, 2020, Adtalem had the right to exercise a call option and purchase any remaining EduPristine stock from Kaizen. Likewise, Kaizen had the right to exercise a put option and sell up to 33% of its remaining ownership interest in EduPristine to Adtalem. Beginning on March 26, 2022, Kaizen had the right to exercise a put option and sell its remaining ownership interest in EduPristine to Adtalem. During fiscal year 2022, Adtalem purchased the remaining ownership interest in EduPristine from Kaizen for $1.8 million, resulting in Adtalem owning 100% of EduPristine. Subsequently, Adtalem sold EduPristine in its entirety on June 17, 2022 (see Note 4 “Discontinued Operations” for additional information). Since the put option was out of the control of Adtalem, authoritative guidance required the redeemable noncontrolling interest, which included the value of the put option, to be presented outside of the equity section of the Consolidated Balance Sheets.

Share Repurchases

Share Repurchases	12 Months Ended
	Jun. 30, 2024
Dividends And Share Repurchase Program [Abstract]
Share Repurchases	16. Share Repurchases Open Market Share Repurchase Programs On March 1, 2022, we announced that the Board authorized Adtalem’s thirteenth share repurchase program, which allowed Adtalem to repurchase up to $300.0 million of its common stock through February 25, 2025. On January 16, 2024, Adtalem completed its thirteenth share repurchase program. On January 19, 2024, we announced that the Board authorized Adtalem’s fourteenth share repurchase program, which allows Adtalem to repurchase up to $300.0 million of its common stock through January 16, 2027. Adtalem made share repurchases under its share repurchase programs as follows, which includes the market price of the shares, commissions, and excise tax (in thousands, except shares and per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Total number of share repurchases ​ ​ 5,446,113 ​ ​ 3,207,036 ​ ​ — Total cost of share repurchases ​ $ 261,183 ​ $ 127,254 ​ $ — Average price paid per share ​ $ 47.96 ​ $ 39.68 ​ $ — ​ As of June 30, 2024, $211.6 million of authorized share repurchases were remaining under the fourteenth share repurchase program. The timing and amount of any future repurchases will be determined based on an evaluation of market conditions and other factors. These repurchases may be made through open market purchases, accelerated share repurchases, privately negotiated transactions, or otherwise. Repurchases will be funded through available cash balances and ongoing business operating cash generation and may be suspended or discontinued at any time. Shares of stock repurchased under the programs are held as treasury shares. Repurchases under our share repurchase programs reduce the weighted-average number of shares of common stock outstanding for basic and diluted earnings per share calculations . ASR Agreement On March 14, 2022, we entered into an ASR agreement to repurchase $150.0 million of common stock. We received an initial delivery of 4,709,576 On March 14, 2022, we recorded the $150.0 million purchase price of the ASR as a reduction to shareholders’ equity, consisting of a $120.0 million increase in treasury stock and a $30.0 million reduction in additional paid-in capital, which represented an equity forward contract, on the Consolidated Balance Sheets. During the second quarter of fiscal year 2023, the $30.0 million initially recorded as a reduction in additional paid-in capital was reclassified to treasury stock and an additional $13.2 million was recorded in treasury stock, which represented our final cash settlement payment.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	12 Months Ended
	Jun. 30, 2024
Comprehensive Income, Net Of Tax [Abstract]
Accumulated Other Comprehensive Loss	17. Accumulated Other Comprehensive Loss The following table shows the changes in accumulated other comprehensive loss by component (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Foreign currency translation adjustments ​ ​ ​ ​ ​ ​ ​ ​ ​ Beginning balance ​ $ (2,227) ​ $ (2,227) ​ $ (2,523) Reclassification from other comprehensive income ​ ​ — ​ ​ — ​ ​ 296 Ending balance ​ $ (2,227) ​ $ (2,227) ​ $ (2,227) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest rate swap ​ ​ ​ ​ ​ ​ ​ ​ ​ Beginning balance, gross ​ $ — ​ $ — ​ $ (8,926) Beginning balance, tax effect ​ ​ — ​ ​ — ​ ​ 2,231 Beginning balance, net of tax ​ ​ — ​ ​ — ​ ​ (6,695) Reclassification from other comprehensive income ​ ​ — ​ ​ — ​ ​ 6,695 Ending balance ​ $ — ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total ending balance ​ $ (2,227) ​ $ (2,227) ​ $ (2,227) ​

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Jun. 30, 2024
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	18. Stock-Based Compensation Adtalem’s current stock-based incentive plan is its Fourth Amended and Restated Incentive Plan of 2013, which is administered by the Compensation Committee of the Board. Under the plan, directors, key executives, and managerial employees are eligible to receive stock options, restricted stock units (“RSUs”), performance-based restricted stock units (“PSUs”), and other forms of stock awards. As of June 30, 2024, 2,106,199 shares of common stock were available for future issuance under this plan. Stock-based compensation expense is recognized on a straight-line basis over the required service period. Adtalem accounts for stock-based compensation granted to retirement eligible employees that fully vests upon an employee’s retirement under the non-substantive vesting period approach. Under this approach, the entire stock-based compensation expense is recognized at the grant date for stock-based grants issued to retirement eligible employees. For non-retirement eligible employees, stock-based compensation expense is recognized over the requisite service period. We account for forfeitures of unvested awards in the period they occur. Adtalem issues new shares of common stock to satisfy stock option exercises, RSU vests, and PSU vests. Stock-based compensation expense, which is included in student services and administrative expense, and the related income tax benefit were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Stock-based compensation ​ $ 25,947 ​ $ 14,299 ​ $ 22,611 Income tax benefit ​ (8,594) ​ (3,938) ​ (3,658) Stock-based compensation, net of tax ​ $ 17,353 ​ $ 10,361 ​ $ 18,953 ​ There was no capitalized stock-based compensation cost as of each of June 30, 2024 and 2023. Stock Options Beginning in fiscal year 2023, the Compensation Committee of the Board determined to no longer grant stock options. Prior to fiscal year 2023, we granted stock options generally with a four-year graduated vesting from the grant date and expire ten years from the grant date. The following table summarizes stock option activity for the year ended June 30, 2024: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ ​ ​ Number of ​ ​ ​ Remaining ​ Aggregate ​ ​ Stock ​ Weighted-Average ​ Contractual Life ​ Intrinsic Value ​ ​ Options ​ Exercise Price ​ (in years) ​ (in thousands) Outstanding as of June 30, 2023 1,045,801 ​ $ 36.02 ​ ​ ​ ​ Exercised (494,314) ​ ​ 34.57 ​ ​ ​ ​ Expired (1,144) ​ ​ 28.32 ​ ​ ​ ​ Outstanding as of June 30, 2024 550,343 ​ 37.34 6.0 ​ $ 16,989 Exercisable as of June 30, 2024 410,668 ​ $ 38.07 5.7 ​ $ 12,376 ​ The fair value of stock options that vested during the years ended June 30, 2024, 2023, and 2022 was $1.9 million, $2.1 million, and $4.7 million, respectively. As of June 30, 2024, $0.4 million of unrecognized stock-based compensation expense related to unvested stock options is expected to be recognized over a remaining weighted-average period of 1.3 years. The total intrinsic value of stock options exercised for the years ended June 30, 2024, 2023, and 2022 was $10.0 million, $1.1 million, and $6.9 million, respectively. The tax benefit from options exercised for the years ended June 30, 2024, 2023, and 2022 was $2.5 million, $0.3 million, and $1.8 million, respectively. The fair value of Adtalem’s stock options was estimated using a binomial model. This model uses historical cancellation and exercise experience of Adtalem to determine the option value. It also considers the illiquid nature of employee options during the vesting period. The weighted-average estimated grant date fair value of options granted at market price under Adtalem’s stock-based incentive plans during the year ended June 30, 2022 was $14.72. No stock options were granted during fiscal years 2024 and 2023. The fair value of Adtalem’s stock option grants was estimated assuming the following weighted-average assumptions: ​ ​ ​ ​ ​ ​ ​ Fiscal Year ​ ​ ​ 2022 ​ Expected life (in years) 6.56 Expected volatility 39.99 % Risk-free interest rate 0.94 % Dividend yield 0.00 % ​ The expected life of the options RSUs Prior to fiscal year 2023, we granted RSUs generally with a four-year graduated vesting from the grant date. Beginning in fiscal year 2023, we grant RSUs generally with a three-year graduated vesting from the grant date. We also regularly grant RSUs to our Board members with a one-year cliff vest from the grant date. The fair value per share of RSUs is the closing market price of our common stock on the grant date. The following table summarizes RSU activity for the year ended June 30, 2024: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ Number of ​ Grant Date ​ ​ RSUs ​ Fair Value Unvested as of June 30, 2023 737,733 ​ $ 37.22 Granted 399,220 ​ 44.24 Vested (340,923) ​ 38.00 Forfeited (40,189) ​ 38.53 Unvested as of June 30, 2024 755,841 ​ $ 40.51 ​ The weighted-average grant date fair value per share of RSUs granted in the years ended June 30, 2024, 2023, and 2022 was $44.24, $39.90, and $35.57 respectively. The grant date fair value of RSUs that vested during the years ended June 30, 2024, 2023, and 2022 was $13.0 million, $9.4 million, and $7.9 million, respectively. As of June 30, 2024, $14.5 million of unrecognized stock-based compensation expense related to unvested RSUs is expected to be recognized over a remaining weighted-average period of 1.6 years. PSUs We issue PSUs generally with a three-year cliff vest from the grant date. The fair value per share of PSUs is the closing market price of our common stock on the grant date. We estimate the number of shares that will vest under our PSU awards when recognizing stock-based compensation expense for each reporting period. The final number of shares that vest under our PSUs is based on metrics approved by the Compensation Committee of the Board. The following table summarizes PSU activity for the year ended June 30, 2024: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ Number of ​ Grant Date ​ ​ PSUs ​ Fair Value Unvested as of June 30, 2023 490,300 ​ $ 35.17 Granted (1) 336,900 ​ 50.02 Vested (126,918) ​ 29.92 Forfeited (70,512) ​ 35.60 Unvested as of June 30, 2024 629,770 ​ $ 43.77 (1) ​ The weighted-average grant date fair value per share of PSUs granted in the years ended June 30, 2024, 2023, and 2022 was $50.02, $40.43, and $33.84, respectively. The grant date fair value of PSUs that vested during the years ended June 30, 2024, 2023, and 2022 was $4.1 million, $3.4 million, and $2.6 million, respectively. As of June 30, 2024, $15.5 million of unrecognized stock-based compensation expense related to unvested PSUs is expected to be recognized over a remaining weighted-average period of 1.6 years.

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Jun. 30, 2024
Retirement Benefits [Abstract]
Employee Benefit Plans	19. Employee Benefit Plans 401(k) Retirement Plan All U.S. employees who meet certain eligibility requirements can participate in Adtalem’s 401(k) Retirement Plan. Adtalem makes a matching employer contribution into the 401(k) Retirement Plan of 100% up to the first 6% of the participant’s eligible compensation. Expense for the matching employer contributions under the plan was $19.7 million, $17.9 million, and $18.4 million for the years ended June 30, 2024, 2023, and 2022, respectively. Colleague Stock Purchase Plan Under provisions of Adtalem’s current Colleague Stock Purchase Plan, any eligible employee may authorize Adtalem to withhold up to $25,000 of annual wages to purchase common stock of Adtalem. Adtalem implemented a new Colleague Stock Purchase Plan approved by stockholders at Adtalem’s annual meeting of stockholders held on November 6, 2019 which allows for the issuance of 500,000 shares. Currently, employees can purchase Adtalem’s common stock at 90% of the prevailing market price on the purchase date. Adtalem subsidizes the remaining 10% and pays all brokerage commissions and administrative fees associated with the plan. These expenses were insignificant for the years ended June 30, 2024, 2023, and 2022. Total shares issued under the plans were 19,666, 18,463, and 18,328 for the years ended June 30, 2024, 2023, and 2022, respectively. These plans are intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code. Currently, Adtalem is re-issuing treasury shares to satisfy colleague share purchases under this plan. Nonqualified Deferred Compensation Plan Adtalem has a nonqualified deferred compensation (“NDCP”) plan for highly compensated employees and its Board members. The plan allows participants to make tax-deferred contributions that cannot be made under the 401(k) Retirement Plan because of Internal Revenue Service limitations. The plan permits the deferral of up to 50% of a participant’s salary and up to 100% of a participant’s bonus or board fee. Adtalem currently matches up to 6% of the total eligible compensation of participants who make contributions under the plan. Amounts contributed and deferred under the plan are credited or charged with the performance of investment options offered under the plan as elected by the participants. The participant’s “investments” are in a hypothetical portfolio of investments which are tracked by an administrator. Total liabilities under the NDCP plan included in accrued liabilities on the Consolidated Balance Sheets as of June 30, 2024 and 2023 were $12.2 million and $12.6 million, respectively. The increase or decrease in the fair value of the liabilities under the NDCP plan is included in student services and administrative expense in the Consolidated Statements of Income. We have elected to fund our NDCP plan obligations through a rabbi trust. The rabbi trust is subject to creditor claims in the event of insolvency, but the assets held in the rabbi trust are not available for general corporate purposes. Amounts in the rabbi trust are placed in investments whose performance is generally consistent with the investments chosen by participants under their NDCP plan accounts, which are designated as trading securities and carried at fair value. The fair value of the investments in the rabbi trust included in prepaid expenses and other current assets on the Consolidated Balance Sheets as of June 30, 2024 and 2023 was $13.2 million and $12.5 million, respectively. We record trading gains and losses in other income, net in the Consolidated Statements of Income.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	20. Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. The guidance specifies a fair value hierarchy based upon the observability of inputs used in valuation techniques. Observable inputs (highest level) reflect market data obtained from independent sources, while unobservable inputs (lowest level) reflect internally developed market assumptions. The guidance establishes fair value measurement classifications under the following hierarchy: Level 1 – Level 2 – Observable inputs other than prices included in Level 1, such as quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs or significant value-drivers are observable in active markets. Level 3 – Model-derived valuations in which one or more significant inputs or significant value-drivers are unobservable. When available, Adtalem uses quoted market prices to determine fair value, and such measurements are classified within Level 1. In cases where market prices are not available, Adtalem makes use of observable market-based inputs to calculate fair value, in which case the measurements are classified within Level 2. If quoted or observable market prices are not available, fair value is based upon internally developed models that use, where possible, current market-based parameters such as interest rates and yield curves. These measurements are classified within Level 3. Fair value measurements are classified according to the lowest level input or value-driver that is significant to the valuation. A measurement may therefore be classified within Level 3 even though there may be significant inputs that are readily observable. The carrying value of our cash, cash equivalents, and restricted cash approximates fair value because of their short-term nature and is classified as Level 1. Adtalem maintains a rabbi trust with investments in stock and bond mutual funds to fu The carrying value of the credit extension programs, which approximates its fair value, is included in accounts and financing receivables, net and other assets, net on the Consolidated Balance Sheets as of June 30, 2024 and 2023 of $28.9 million and $29.7 million, respectively, and is classified as Level 2. See Note 10 “Accounts and Financing Receivables” for additional information on these credit extension programs. Adtalem has a nonqualified deferred compensation plan for highly compensated employees and its Board members. The participant’s “investments” are in a hypothetical portfolio of investments which are tracked by an administrator. Changes in the fair value of the nonqualified deferred compensation obligation are derived using quoted prices in active markets based on the market price per unit multiplied by the number of units. Total liabilities under the plan included in accrued liabilities on the Consolidated Balance Sheets as of June 30, 2024 and 2023 were $12.2 million and $12.6 million, respectively. The fair value of the nonqualified deferred compensation obligation is classified as Level 2 because their inputs are derived principally from observable market data by correlation to the hypothetical investments. As of June 30, 2024 and 2023, borrowings under our long-term debt agreements were $658.3 million and $708.3 million, respectively. The fair value of the Notes was $389.5 million as of June 30, 2024, which is based upon quoted market prices and is classified as Level 1. The fair value of the Term Loan B was $254.9 million as of June 30, 2024, which is based upon quoted market prices in a non-active market and is classified as Level 2. See Note 14 “Debt” for additional information on our long-term debt agreements. As of June 30, 2024 and 2023, there were no assets or liabilities measured at fair value using Level 3 inputs. We recorded an impairment of $5.0 million on an equity investment with no readily determinable fair value within other income, net in the Consolidated Statements of Income for the year ended June 30, 2023 as the carrying value was no longer recoverable. Since initial recognition of the investment, there had been no upward or downward adjustments as a result of observable price changes. Following the impairment, the carrying amount of $5.0 million was reduced to zero . Adtalem has elected not to measure any assets or liabilities at fair value other than those required to be measured at fair value on a recurring basis. Assets measured at fair value on a nonrecurring basis include goodwill, intangible assets, and assets of businesses where the long-term value of the operations have been impaired. Goodwill and indefinite-lived intangible assets are not amortized, instead must be reviewed annually for impairment or more frequently if circumstances arise indicating potential impairment. This impairment review was most recently completed as of May 31, 2024. See Note 13 “Goodwill and Intangible Assets” for additional information on the impairment review, including valuation techniques and assumptions.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2024
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	21. Commitments and Contingencies Adtalem is subject to lawsuits, administrative proceedings, regulatory reviews and investigations associated with financial assistance programs and other matters arising in the conduct of its business and certain of these matters are discussed below. Descriptions of certain matters from prior SEC filings may not be carried forward in this report to the extent we believe such matters no longer are required to be disclosed or there has not been, to our knowledge, significant activity relating to them. As of June 30, 2024, we have adequately reserved for matters that management has determined a loss is probable and that loss can be reasonably estimated. For those matters for which we have not recorded an accrual, their possible impact on Adtalem’s business, financial condition, or results of operations, cannot be predicted at this time. The continued defense, resolution, or settlement of any of the following matters could require us to expend significant resources and could have a material adverse effect on our business, financial condition, results of operations, and cash flows, and result in the imposition of significant restrictions on us and our ability to operate. On January 12, 2022, Walden was served with a complaint filed in the United States District Court for the District of Maryland by Aljanal Carroll, Claudia Provost Charles, and Tiffany Fair against Walden for damages, injunctive relief, and declaratory relief on behalf of themselves and all other similarly-situated individuals alleging violations of Title VI of the Civil Rights Act of 1964, the Equal Credit Opportunity Act, the Minnesota Prevention of Consumer Fraud Act, the Minnesota Uniform Deceptive Trade Practices Act, Minnesota statutes prohibiting false statements in advertising, and for common law fraudulent misrepresentation. Plaintiffs allege that Walden has targeted, deceived, and exploited Black and female Doctor of Business Administration (“DBA”) students by knowingly misrepresenting and understating the number of “capstone” credits required to complete the DBA program and obtain a degree. On March 23, 2022, Walden filed a Motion to Dismiss the Plaintiffs’ claims for failure to state a claim upon which relief can be granted. On November 27, 2022, the Court denied Walden’s motion to dismiss the complaint. Plaintiffs filed an amended complaint to add an additional plaintiff, Tareion Fluker. Walden answered the amended complaint on February 2, 2023. The parties participated in a non-binding mediation on May 4, 2023 and settlement discussions continued. At a second non-binding mediation held on September 21, 2023, the parties agreed on a $28.5 million payment to resolve the issues in the case, subject to agreement on non-financial terms. The parties subsequently agreed to the non-financial terms including an agreement by Walden to implement certain website disclosures and verifications and to make certain programmatic changes. A settlement agreement has been executed by the parties. The settlement agreement in no way constitutes an admission of wrongdoing or liability by Walden. Plaintiffs filed a motion for preliminary approval of the settlement agreement on March 28, 2024. On April 17, 2024, the District Court preliminarily approved the settlement, which includes the provisional certification of the settlement class (the “Class”). The Class opt-out deadline was June 19, 2024. On June 17, 2024, 25 former Walden students claimed that they should be included as members of the Class. Walden is investigating their claims. The opt-out deadline will be extended in relation to any additional former Walden students who are added to the Class. The Court had scheduled a fairness hearing on October 17, 2024 to determine, among other things, whether the requirements for certification of the Class have been met, whether the settlement should be approved as fair and reasonable, and whether the order and final judgment approving the settlement should be entered. The fairness hearing will be rescheduled to a later date. Regardless of whether any additional members are added to the class, the amount of the $28.5 million payment will be unaffected. We recorded a $28.5 million loss contingency accrual for this matter within accrued liabilities on the Consolidated Balance Sheets as of June 30, 2024. In January 2024, Adtalem made a claim for indemnification under the Membership Interest Purchase Agreement with Laureate Education, Inc. (“Laureate”), dated September 11, 2020, pursuant to which Adtalem purchased Walden. If a settlement is approved by the Court, Adtalem expects to receive $5.5 million from Laureate in connection with such indemnification claim. On June 6, 2022, plaintiff Rajesh Verma filed a lawsuit on behalf of himself and a class of similarly situated individuals in the Circuit Court of the Fourth Judicial Circuit, Duval County Florida, against Walden alleging that Walden was placing telephonic sales calls to persons on the National Do-Not-Call Registry, in violation of the Telephone Consumer Protection Act, 47 U.S.C. § 227, et seq. Although originally filed in state court, Walden removed the case to federal court and filed a motion to dismiss plaintiff’s complaint. On August 26, 2022, plaintiff filed a motion to remand Count I of the complaint to state court. On March 2, 2023, plaintiff filed an amended complaint to add a Florida state law claim against Walden under the Florida Telephone Solicitation Act (“FTSA”). On March 16, 2023, Walden filed its answer to the amended complaint. On March 29, 2023, Walden’s motion to dismiss plaintiff’s complaint and plaintiff’s motion to remand Count I of the complaint were denied. A non-binding mediation was held on September 18, 2023. The parties reached a settlement for an immaterial amount subject to Court approval. On November 27, 2023, the parties filed a motion for preliminary approval of the settlement agreement. On May 20, 2024, the Court granted preliminary approval to the settlement. The final settlement approval hearing is scheduled for October 29, 2024. As previously disclosed, pursuant to the terms of the Stock Purchase Agreement (“SPA”) by and between Adtalem and Cogswell, dated as of December 4, 2017, as amended, Adtalem sold DeVry University to Cogswell and Adtalem agreed to indemnify DeVry University for certain losses up to $340.0 million (the “Liability Cap”). Adtalem has previously disclosed DeVry University related matters that have consumed a portion of the Liability Cap. In late January 2024 and early February 2024, ED sent notice to Chamberlain, RUSM, RUSVM, and Walden that it had received approximately 3,225, 1,700, 1,900, and 7,740 borrower defense to repayment applications filed by students at Chamberlain, RUSM, RUSVM, and Walden respectively between June 23, 2022 and November 15, 2022. Each application seeks forgiveness of federal student loans made to these students. In the notices received, ED indicated that: (1) the notification was occurring prior to any substantive review of the application as well as its adjudication; (2) it would send the applications to each institution in batches of 500 per week; (3) it is optional for institutions to respond to the applications; and (4) not responding will result in no negative inference by ED. ED has also explained that it will separately decide whether to seek recoupment on any approved claim and that any recoupment actions ED chooses to initiate will have their own notification and response processes, which include an opportunity to provide additional evidence to the institutions. ED has indicated that an institution will learn of ED’s determination to forgive student loans only if it approves a borrower defense to repayment application and ED seeks recoupment. Chamberlain, RUSM, RUSVM, and Walden have responded to all of the applications received and they believe that none properly stated a claim for loan forgiveness.

Segment Information

Segment Information	12 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
Segment Information	22. Segment Information We present three reportable segments as follows: Chamberlain Walden Medical and Veterinary Certain expenses previously allocated to ACAMS, Becker, OCL, and EduPristine within our former Financial Services segment during the first quarter of fiscal year 2022 have been reclassified to Home Office based on discontinued operations reporting guidance regarding allocation of corporate overhead. Beginning in the second quarter of fiscal year 2022, these costs are being allocated to the Chamberlain, Walden, and Medical and Veterinary segments. These segments are consistent with the method by which the Chief Operating Decision Maker (Adtalem’s President and Chief Executive Officer) evaluates performance and allocates resources. Performance evaluations are based on each segment’s adjusted operating income. Adjusted operating income excludes special items, which consists of deferred revenue adjustment, CEO transition costs, restructuring expense, business acquisition and integration expense, amortization of acquired intangible assets, litigation reserve, loss on assets held for sale, debt modification costs, and gain on sale of assets. Adtalem’s management excludes these items from its review of the results of the operating segments for purposes of measuring segment profitability and allocating resources. “Home Office” includes activities not allocated to a reportable segment and is included to reconcile segment results to the Consolidated Financial Statements. Total assets by segment is not presented as our CODM does not review or allocate resources based on segment assets. The accounting policies of the segments are the same as those described in Note 2 “Summary of Significant Accounting Policies.” Summary financial information by reportable segment is as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Revenue: ​ ​ ​ ​ ​ ​ ​ ​ Chamberlain ​ $ 633,522 ​ $ 571,034 ​ $ 557,536 Walden ​ ​ 595,332 ​ ​ 533,725 ​ ​ 485,393 Medical and Veterinary ​ ​ 355,798 ​ ​ 346,067 ​ ​ 338,913 Total consolidated revenue ​ $ 1,584,652 ​ $ 1,450,826 ​ $ 1,381,842 Adjusted operating income: ​ ​ ​ ​ ​ ​ ​ ​ ​ Chamberlain ​ $ 137,800 ​ $ 135,503 ​ $ 127,252 Walden ​ ​ 130,547 ​ ​ 110,364 ​ ​ 104,582 Medical and Veterinary ​ ​ 71,507 ​ ​ 67,336 ​ ​ 69,148 Home Office ​ (31,076) ​ (25,633) ​ (33,380) Total consolidated adjusted operating income ​ ​ 308,778 ​ ​ 287,570 ​ ​ 267,602 Reconciliation to Consolidated Financial Statements: ​ ​ ​ ​ ​ ​ ​ ​ ​ Deferred revenue adjustment ​ ​ — ​ ​ — ​ ​ (8,561) CEO transition costs ​ ​ — ​ ​ — ​ ​ (6,195) Restructuring expense ​ (1,870) ​ (18,817) ​ (25,628) Business acquisition and integration expense ​ ​ (34,215) ​ (42,661) ​ (53,198) Amortization of acquired intangible assets: ​ ​ (35,644) ​ (61,239) ​ (97,274) Litigation reserve ​ ​ (18,500) ​ (10,000) ​ — Loss on assets held for sale ​ ​ (647) ​ — ​ — Debt modification costs ​ ​ (848) ​ — ​ — Gain on sale of assets ​ ​ — ​ 13,317 ​ — Total consolidated operating income ​ ​ 217,054 ​ ​ 168,170 ​ ​ 76,746 Interest expense ​ (63,659) ​ (63,100) ​ (129,348) Other income, net ​ 10,542 ​ 6,965 ​ 1,108 Total consolidated income (loss) from continuing operations before income taxes ​ $ 163,937 ​ $ 112,035 ​ $ (51,494) Capital expenditures: ​ ​ ​ ​ ​ ​ ​ ​ ​ Chamberlain ​ $ 26,293 ​ $ 13,934 ​ $ 15,235 Walden ​ ​ 5,889 ​ ​ 1,084 ​ ​ 5,393 Medical and Veterinary ​ ​ 5,708 ​ ​ 3,358 ​ ​ 3,277 Home Office ​ 11,003 ​ 7,638 ​ 7,149 Total consolidated capital expenditures ​ $ 48,893 ​ $ 26,014 ​ $ 31,054 Depreciation: ​ ​ ​ ​ ​ ​ ​ ​ ​ Chamberlain ​ $ 18,752 ​ $ 17,175 ​ $ 18,547 Walden ​ ​ 7,389 ​ ​ 9,419 ​ ​ 9,255 Medical and Veterinary ​ ​ 11,983 ​ ​ 12,438 ​ ​ 13,890 Home Office ​ 1,552 ​ 2,344 ​ 2,882 Total consolidated depreciation ​ $ 39,676 ​ $ 41,376 ​ $ 44,574 Amortization of acquired intangible assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Walden ​ $ 35,644 ​ $ 61,239 ​ $ 97,274 Total consolidated amortization of acquired intangible assets ​ $ 35,644 ​ $ 61,239 ​ $ 97,274 ​ Adtalem conducts its educational operations in the U.S., Barbados, St. Kitts, and St. Maarten. Revenue and long-lived assets by geographic area are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Revenue by geographic area: ​ ​ ​ ​ ​ ​ ​ ​ Domestic operations ​ $ 1,228,854 ​ $ 1,104,759 ​ $ 1,042,929 Barbados, St. Kitts, and St. Maarten ​ 355,798 ​ 346,067 ​ 338,913 Total consolidated revenue ​ $ 1,584,652 ​ $ 1,450,826 ​ $ 1,381,842 Long-lived assets by geographic area: ​ ​ ​ ​ ​ ​ ​ ​ ​ Domestic operations ​ $ 283,597 ​ $ 256,268 ​ $ 289,129 Barbados, St. Kitts, and St. Maarten ​ 149,507 ​ 163,058 ​ 178,792 Total consolidated long-lived assets ​ $ 433,104 ​ $ 419,326 ​ $ 467,921 ​ No one customer accounted for more than 10% of Adtalem’s consolidated revenue for all periods presented.

Revision of Previously Issued C

Revision of Previously Issued Consolidated Financial Statements (Unaudited)	12 Months Ended
	Jun. 30, 2024
Accounting Changes and Error Corrections [Abstract]
Revision of Previously Issued Consolidated Financial Statements (Unaudited)	23. Revision of Previously Issued Consolidated Financial Statements (Unaudited) As described in Note 2 “Summary of Significant Accounting Policies,” Adtalem identified an error in the presentation of capitalized cloud computing implementation costs in its previously issued financial statements. Adtalem assessed the materiality of this error individually and in the aggregate with other previously identified errors to prior periods’ Consolidated Financial Statements and concluded the errors were not material to prior periods and therefore, amendments of previously filed reports are not required. The errors impacted the unaudited Consolidated Balance Sheets and unaudited Consolidated Statements of Cash Flows as of and for the nine months ended March 31, 2024 and 2023, as of and for the six months ended December 31, 2023 and 2022, and as of and for the three months ended September 30, 2023 and 2022. In each of Adtalem’s fiscal year 2025 interim Form 10-Qs, the impact of this revision will be incorporated into the prior periods, as applicable. In connection with this revision, Adtalem also corrected other immaterial errors in the prior periods, including certain errors that had previously been adjusted for in the period identified. The following tables summarize the effect of the revision on the affected line items within the Consolidated Balance Sheets (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2024 ​ ​ As Reported ​ Adjustment ​ As Revised Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Prepaid expenses and other current assets ​ $ 59,401 ​ $ 4,183 ​ $ 63,584 Total current assets ​ ​ 387,634 ​ ​ 4,183 ​ ​ 391,817 Noncurrent assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Property and equipment, net ​ ​ 272,792 ​ ​ (33,135) ​ ​ 239,657 Other assets, net ​ ​ 67,768 ​ ​ 28,952 ​ ​ 96,720 Total noncurrent assets ​ ​ 2,327,400 ​ ​ (4,183) ​ ​ 2,323,217 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 ​ ​ As Reported ​ Adjustment ​ As Revised Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Prepaid expenses and other current assets ​ $ 58,356 ​ $ 3,010 ​ $ 61,366 Total current assets ​ ​ 378,099 ​ ​ 3,010 ​ ​ 381,109 Noncurrent assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Property and equipment, net ​ ​ 260,484 ​ ​ (25,187) ​ ​ 235,297 Other assets, net ​ ​ 65,852 ​ ​ 22,177 ​ ​ 88,029 Total noncurrent assets ​ ​ 2,322,826 ​ ​ (3,010) ​ ​ 2,319,816 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2023 ​ ​ As Reported ​ Adjustment ​ As Revised Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 262,438 ​ $ (1,612) ​ $ 260,826 Restricted cash ​ ​ 1,988 ​ ​ 1,612 ​ ​ 3,600 Prepaid expenses and other current assets ​ ​ 60,750 ​ ​ 2,103 ​ ​ 62,853 Total current assets ​ ​ 472,928 ​ ​ 2,103 ​ ​ 475,031 Noncurrent assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Property and equipment, net ​ ​ 264,766 ​ ​ (18,097) ​ ​ 246,669 Other assets, net ​ ​ 67,634 ​ ​ 15,994 ​ ​ 83,628 Total noncurrent assets ​ ​ 2,321,233 ​ ​ (2,103) ​ ​ 2,319,130 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2023 ​ ​ As Reported ​ Adjustment ​ As Revised Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 315,373 ​ $ (1,613) ​ $ 313,760 Restricted cash ​ ​ 1,804 ​ ​ 1,613 ​ ​ 3,417 Prepaid expenses and other current assets ​ ​ 102,573 ​ ​ 514 ​ ​ 103,087 Total current assets ​ ​ 533,034 ​ ​ 514 ​ ​ 533,548 Noncurrent assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Property and equipment, net ​ ​ 252,797 ​ ​ (6,234) ​ ​ 246,563 Other assets, net ​ ​ 67,618 ​ ​ 5,720 ​ ​ 73,338 Total noncurrent assets ​ ​ 2,334,083 ​ ​ (514) ​ ​ 2,333,569 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2022 ​ ​ As Reported ​ Adjustment ​ As Revised Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 207,776 ​ $ (1,492) ​ $ 206,284 Restricted cash ​ ​ 2,234 ​ ​ 1,492 ​ ​ 3,726 Prepaid expenses and other current assets ​ ​ 113,564 ​ ​ 1,081 ​ ​ 114,645 Total current assets ​ ​ 423,116 ​ ​ 1,081 ​ ​ 424,197 Noncurrent assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Property and equipment, net ​ ​ 275,617 ​ ​ (3,275) ​ ​ 272,342 Other assets, net ​ ​ 116,613 ​ ​ 3,043 ​ ​ 119,656 Total noncurrent assets ​ ​ 2,419,922 ​ ​ (232) ​ ​ 2,419,690 Total assets ​ ​ 2,843,038 ​ ​ 849 ​ ​ 2,843,887 Liabilities and shareholders' equity: ​ ​ ​ ​ ​ ​ ​ ​ ​ Current liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Deferred revenue ​ ​ 115,658 ​ ​ 5,177 ​ ​ 120,835 Total current liabilities ​ ​ 371,462 ​ ​ 5,177 ​ ​ 376,639 Noncurrent liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Other liabilities ​ ​ 61,901 ​ ​ 9,177 ​ ​ 71,078 Total noncurrent liabilities ​ ​ 948,854 ​ ​ 9,177 ​ ​ 958,031 Total liabilities ​ ​ 1,320,316 ​ ​ 14,354 ​ ​ 1,334,670 Shareholders' equity: ​ ​ ​ ​ ​ ​ ​ ​ ​ Retained earnings ​ ​ 2,349,146 ​ ​ (13,505) ​ ​ 2,335,641 Total shareholders' equity ​ ​ 1,522,722 ​ ​ (13,505) ​ ​ 1,509,217 Total liabilities and shareholders' equity ​ ​ 2,843,038 ​ ​ 849 ​ ​ 2,843,887 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2022 ​ ​ As Reported ​ Adjustment ​ As Revised Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 327,515 ​ $ (1,681) ​ $ 325,834 Restricted cash ​ ​ 2,480 ​ ​ 1,681 ​ ​ 4,161 Noncurrent assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Property and equipment, net ​ ​ 281,581 ​ ​ (416) ​ ​ 281,165 Other assets, net ​ ​ 120,630 ​ ​ 416 ​ ​ 121,046 ​ The following tables summarize the effect of the revision on the affected line items within the Consolidated Statements of Cash Flows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended March 31, 2024 ​ ​ As Reported ​ Adjustment ​ As Revised Operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustments to reconcile net income to net cash provided by operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation ​ $ 32,106 ​ $ (2,227) ​ $ 29,879 Changes in assets and liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cloud computing implementation assets ​ ​ — ​ ​ (19,262) ​ ​ (19,262) Accounts payable ​ ​ 10,841 ​ ​ 1,791 ​ ​ 12,632 Net cash provided by operating activities-continuing operations ​ ​ 246,809 ​ ​ (19,698) ​ ​ 227,111 Net cash provided by operating activities ​ ​ 255,205 ​ ​ (19,698) ​ ​ 235,507 Investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures ​ ​ (52,014) ​ ​ 19,698 ​ ​ (32,316) Net cash used in investing activities-continuing operations ​ ​ (51,886) ​ ​ 19,698 ​ ​ (32,188) Net cash used in investing activities ​ ​ (51,886) ​ ​ 19,698 ​ ​ (32,188) Non-cash investing and financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued capital expenditures ​ ​ 11,086 ​ ​ (4,869) ​ ​ 6,217 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended December 31, 2023 ​ ​ As Reported ​ Adjustment ​ As Revised Operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustments to reconcile net income to net cash provided by operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation ​ $ 20,714 ​ $ (1,333) ​ $ 19,381 Changes in assets and liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cloud computing implementation assets ​ ​ — ​ ​ (11,314) ​ ​ (11,314) Accounts payable ​ ​ 7,824 ​ ​ 1,931 ​ ​ 9,755 Net cash provided by operating activities-continuing operations ​ ​ 83,069 ​ ​ (10,716) ​ ​ 72,353 Net cash provided by operating activities ​ ​ 92,584 ​ ​ (10,716) ​ ​ 81,868 Investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures ​ ​ (30,328) ​ ​ 10,716 ​ ​ (19,612) Net cash used in investing activities-continuing operations ​ ​ (30,200) ​ ​ 10,716 ​ ​ (19,484) Net cash used in investing activities ​ ​ (30,200) ​ ​ 10,716 ​ ​ (19,484) Non-cash investing and financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued capital expenditures ​ ​ 9,062 ​ ​ (5,009) ​ ​ 4,053 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, 2023 ​ ​ As Reported ​ Adjustment ​ As Revised Operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustments to reconcile net income to net cash provided by operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation ​ $ 9,778 ​ $ (440) ​ $ 9,338 Changes in assets and liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cloud computing implementation assets ​ ​ — ​ ​ (4,224) ​ ​ (4,224) Accounts payable ​ ​ (2,870) ​ ​ 52 ​ ​ (2,818) Net cash provided by operating activities-continuing operations ​ ​ 90,726 ​ ​ (4,612) ​ ​ 86,114 Net cash provided by operating activities ​ ​ 99,685 ​ ​ (4,612) ​ ​ 95,073 Investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures ​ ​ (15,046) ​ ​ 4,612 ​ ​ (10,434) Net cash used in investing activities-continuing operations ​ ​ (14,946) ​ ​ 4,612 ​ ​ (10,334) Net cash used in investing activities ​ ​ (14,946) ​ ​ 4,612 ​ ​ (10,334) Non-cash investing and financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued capital expenditures ​ ​ 9,217 ​ ​ (3,130) ​ ​ 6,087 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended March 31, 2023 ​ ​ As Reported ​ Adjustment ​ As Revised Operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustments to reconcile net income to net cash provided by operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation ​ $ 31,618 ​ $ (112) ​ $ 31,506 Changes in assets and liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cloud computing implementation assets ​ ​ — ​ ​ (6,234) ​ ​ (6,234) Accounts payable ​ ​ 12,286 ​ ​ 1,483 ​ ​ 13,769 Net cash provided by operating activities-continuing operations ​ ​ 149,821 ​ ​ (4,863) ​ ​ 144,958 Net cash provided by operating activities ​ ​ 149,417 ​ ​ (4,863) ​ ​ 144,554 Investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures ​ ​ (19,056) ​ ​ 4,863 ​ ​ (14,193) Net cash provided by investing activities-continuing operations ​ ​ 33,871 ​ ​ 4,863 ​ ​ 38,734 Net cash provided by investing activities ​ ​ 30,697 ​ ​ 4,863 ​ ​ 35,560 Non-cash investing and financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued capital expenditures ​ ​ 10,474 ​ ​ (1,483) ​ ​ 8,991 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended December 31, 2022 ​ ​ As Reported ​ Adjustment ​ As Revised Operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustments to reconcile net income to net cash provided by operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation ​ $ 21,461 ​ $ (34) ​ $ 21,427 Changes in assets and liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cloud computing implementation assets ​ ​ — ​ ​ (3,275) ​ ​ (3,275) Accounts payable ​ ​ 13,233 ​ ​ 475 ​ ​ 13,708 Net cash provided by operating activities-continuing operations ​ ​ 42,277 ​ ​ (2,834) ​ ​ 39,443 Net cash provided by operating activities ​ ​ 41,415 ​ ​ (2,834) ​ ​ 38,581 Investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures ​ ​ (9,747) ​ ​ 2,834 ​ ​ (6,913) Net cash used in investing activities-continuing operations ​ ​ (9,748) ​ ​ 2,834 ​ ​ (6,914) Net cash used in investing activities ​ ​ (12,922) ​ ​ 2,834 ​ ​ (10,088) Non-cash investing and financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued capital expenditures ​ ​ 5,209 ​ ​ (475) ​ ​ 4,734 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, 2022 ​ ​ As Reported ​ Adjustment ​ As Revised Operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Changes in assets and liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cloud computing implementation assets ​ $ — ​ $ (416) ​ $ (416) Accounts payable ​ ​ 8,711 ​ ​ 243 ​ ​ 8,954 Net cash provided by operating activities-continuing operations ​ ​ 91,476 ​ ​ (173) ​ ​ 91,303 Net cash provided by operating activities ​ ​ 91,346 ​ ​ (173) ​ ​ 91,173 Investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures ​ ​ (5,551) ​ ​ 173 ​ ​ (5,378) Net cash used in investing activities-continuing operations ​ ​ (5,503) ​ ​ 173 ​ ​ (5,330) Net cash used in investing activities ​ ​ (6,314) ​ ​ 173 ​ ​ (6,141) Non-cash investing and financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued capital expenditures ​ ​ 4,713 ​ ​ (243) ​ ​ 4,470 ​

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ 136,777	$ 93,358	$ 310,991

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Modified	false
Rule 10b5-1 Arrangement Modified	false

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The Consolidated Financial Statements include the accounts of Adtalem and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. We have prepared the Consolidated Financial Statements in accordance with GAAP. Unless otherwise noted, amounts presented within the Notes to Consolidated Financial Statements refer to our continuing operations. Unless indicated, or the context requires otherwise, references to years refer to Adtalem’s fiscal years. Certain items presented in tables may not sum due to rounding. Business acquisition and integration expense was $34.2 million, $42.7 million, and $53.2 million in fiscal year 2024, 2023, and 2022, respectively. These are transaction costs associated with acquiring Walden and costs associated with integrating Walden into Adtalem. In addition, during fiscal year 2023, we initiated transformation initiatives to accelerate growth and organizational agility. Certain costs relating to this transformation are included in business acquisition and integration expense in the Consolidated Statements of Income.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of highly liquid investments with original maturities of three months or less. The carrying value of cash and cash equivalents approximate fair value. We maintain cash and cash equivalent balances that exceed federally insured limits. We have not experienced any losses on our cash and cash equivalents.
Restricted Cash	Restricted Cash Restricted cash represents amounts received from federal and state governments under various student aid grant and loan programs and such restricted funds are held in separate bank accounts. Once the financial aid authorization and disbursement process for the student has been completed, the funds are transferred to unrestricted accounts, and these funds then become available for use in Adtalem’s operations. This authorization and disbursement process that precedes the transfer of funds generally occurs within the period of the academic term for which such funds were authorized. Restricted cash also includes an imprest cash balance used for Adtalem’s self-insured employee medical benefits program.
Property and Equipment	Property and Equipment Property and equipment is recorded at cost less accumulated depreciation. Cost includes additions and those improvements that enhance performance, increase the capacity, or lengthen the useful lives of the assets. Purchases of computer software, including external costs and certain internal costs (including payroll and payroll-related costs of employees) directly associated with developing computer software applications for internal use, are capitalized. Assets under construction are reflected in construction in progress until they are placed into service for their intended use. Depreciation is recognized on a straight-line basis over the estimated useful lives of the related assets. Leasehold improvements are amortized on a straight-line basis over the shorter of the useful life of the asset or lease term. Repairs and maintenance costs are expensed as incurred. Upon sale or retirement of an asset, the accounts are relieved of the cost and the related accumulated depreciation, with any resulting gain or loss included in income. See Note 11 “Property and Equipment, Net” for additional information, including useful lives by asset category.
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill and indefinite-lived intangible assets are not amortized, but are tested for impairment annually and when an event occurs or circumstances change such that it is more likely than not that an impairment may exist. Our annual testing date is May 31. We have the option to assess goodwill for impairment by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If it is determined that the reporting unit fair value is more likely than not less than its carrying value, or if we do not elect the option to perform an initial qualitative assessment, we perform a quantitative assessment of the reporting unit’s fair value. If the carrying value of a reporting unit containing the goodwill exceeds the fair value of that reporting unit, an impairment loss is recognized equal to the difference between the carrying value of the reporting unit and its fair value, not to exceed the carrying value of goodwill. We also have the option to perform a qualitative assessment to test indefinite-lived intangible assets for impairment by determining whether it is more likely than not that the indefinite-lived intangible assets are impaired. If it is determined that the indefinite-lived intangible asset is more likely than not impaired, or if we do not elect the option to perform an initial qualitative assessment, we perform a quantitative assessment of the indefinite-lived intangible assets. If the carrying value of the indefinite-lived intangible assets exceeds its fair value, an impairment loss is recognized to the extent the carrying value exceeds fair value. For intangible assets with finite lives, we evaluate for potential impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If the carrying value is no longer recoverable based upon the undiscounted future cash flows of the asset or asset group, the amount of the impairment is the difference between the carrying amount and the fair value of the asset or asset group. Intangible assets with finite lives are amortized over their expected economic lives, ranging from three All intangible assets and certain goodwill are being amortized for tax reporting purposes over statutory lives. Determining the fair value of a reporting unit or an intangible asset involves the use of significant estimates and assumptions. Management bases its fair value estimates on assumptions it believes to be reasonable at the time, but such assumptions are subject to inherent uncertainty. Actual results may differ from those estimates, which could lead to future impairments of goodwill or intangible assets. See Note 13 “Goodwill and Intangible Assets” for additional information on our goodwill and intangible assets impairment analysis.
Capitalized Curriculum Development	Capitalized Curriculum Development Certain costs incurred to create course and educational material for a program offering are capitalized as curriculum development assets within other assets, net on the Consolidated Balance Sheets. Costs are capitalized for new programs or products, or the content being developed enhances, updates, or improves current programs, curriculum, or products, so long as the cost incurred extends the useful life of the existing curriculum and course content. Costs that are capitalized include payroll and payroll-related costs for employees who spend time producing content and external vendor costs related to the project. Adtalem begins capitalizing costs during the content development phase, which includes time to develop course materials based on the requirements defined in the planning phase. Curriculum development assets are amortized on a straight-line basis over the estimated useful life, which is generally three
Cloud Computing Arrangements	Cloud Computing Arrangements For cloud computing arrangements that are a service contract, we capitalize certain implementation costs incurred, including external costs and certain internal costs (including payroll and payroll-related costs of employees), during the development stage of implementing the cloud computing hosting arrangement. Capitalized costs related to cloud computing arrangements are included within prepaid expenses and other current assets and other assets, net on the Consolidated Balance Sheets. We expense costs as incurred during the preliminary planning and post-implementation stages. Capitalized implementation costs are amortized on a straight-line basis over the contractual term of the cloud computing arrangement, which includes renewal options that are reasonably certain to be exercised, which is generally five years.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If the carrying value is no longer recoverable based upon the undiscounted future cash flows of the asset or asset group, the amount of the impairment is the difference between the carrying amount and the fair value of the asset or asset group. Events that may trigger an impairment analysis could include a decision by management to exit a market or a line of business or to consolidate operating locations.
Treasury Stock	Treasury Stock Shares that are repurchased by Adtalem under its share repurchase programs are recorded as treasury stock at cost and result in a reduction in shareholders’ equity. See Note 16 “Share Repurchases” for additional information. From time to time, shares of our common stock are delivered back to Adtalem under a swap arrangement resulting from employees’ exercise of stock options pursuant to the terms of the Adtalem’s stock-based incentive plans (see Note 18 “Stock-Based Compensation”). In addition, shares of our common stock are delivered back to Adtalem for payment of withholding taxes from employees for vesting of stock-based compensation awards. These shares are recorded as treasury stock at cost and result in a reduction in shareholders’ equity. Treasury shares are reissued at market value, less a 10% discount, to the Adtalem Colleague Stock Purchase Plan in exchange for employee payroll deductions. The 10% discount is considered compensatory and recorded as an expense in the Consolidated Statements of Income. When treasury shares are reissued, Adtalem uses an average cost method to reduce the treasury stock balance. Gains on the difference between the average cost and the reissuance price, less the amount recorded as expense, are credited to additional paid-in capital. Losses on the difference are charged to additional paid-in capital to the extent that previous net gains from reissuance are included therein, otherwise such losses are charged to retained earnings.
Earnings per Share	Earnings per Share Basic earnings per share (“EPS”) is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted EPS is computed by dividing net income by diluted weighted-average number of shares outstanding during the period. Diluted EPS considers the impact of potentially dilutive shares, except in periods in which there is a loss from continuing operations, because the inclusion of the potential common shares would have an antidilutive effect. Dilutive shares are computed using the treasury stock method and reflect the additional shares that would be outstanding if dilutive stock-based grants were exercised or vested during the period.
Income Taxes	Income Taxes Adtalem accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences of temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Adtalem also recognizes future tax benefits associated with tax loss and credit carryforwards as deferred tax assets. Adtalem’s deferred tax assets are reduced by a valuation allowance, when in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Adtalem measures deferred tax assets and liabilities using enacted tax rates in effect for the year in which Adtalem expects to recover or settle the temporary differences. The effect of a change in tax rates on deferred taxes is recognized in the period that the change is enacted. Adtalem reduces its net tax assets for the estimated additional tax and interest that may result from tax authorities disputing uncertain tax positions Adtalem has taken.
Restructuring Charges	Restructuring Charges Restructuring charges include costs for severance and related benefits for workforce reductions, impairments on operating lease assets, losses on disposals of property and equipment related to campus and administrative office consolidations, and contract termination costs (see Note 6 “Restructuring Expense”). When estimating the costs of exiting lease space, estimates are made which could differ materially from actual results and result in additional restructuring charges or reversals in future periods.
Advertising Costs	Advertising Costs Advertising costs are expensed when incurred and totaled $227.9 million, $219.4 million, and $190.7 million for the years ended June 30, 2024, 2023, and 2022, respectively. Advertising costs are included in student services and administrative expense in the Consolidated Statements of Income.
Foreign Currency Translation	Foreign Currency Translation The financial position and results of operations of the AUC, RUSM, and RUSVM Caribbean operations are measured using the U.S. dollar as the functional currency. As such, there is no translation gain or loss associated with these operations. EduPristine’s operations and Becker’s and ACAMS’s international operations were measured using the local currency as the functional currency. Assets and liabilities of these entities are translated to U.S. dollars using exchange rates in effect at the balance sheet dates. Income and expense items are translated at monthly average exchange rates. The resulting translation adjustments are recorded as foreign currency translation adjustments in the Consolidated Statements of Comprehensive Income. Translation adjustments for foreign subsidiaries whose functional currencies were previously their respective currencies are suspended in accumulated other comprehensive loss on the Consolidated Balance Sheets. Transaction gains or losses during each of the fiscal years presented were not material.
Recent Accounting Standards	Recent Accounting Standards In March 2022, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2022-02: “Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures.” The guidance was issued as improvements to Accounting Standards Codification (“ASC”) 326. The vintage disclosure changes are relevant to Adtalem and require an entity to disclose current-period gross write-offs by year of origination for financing receivables. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The amendments should be applied prospectively. We adopted this guidance on July 1, 2023. The amendments impacted our disclosures and did not otherwise impact Adtalem’s Consolidated Financial Statements. In November 2023, the FASB issued ASU No. 2023-07: “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” The guidance was issued to improve disclosures about reportable segments and addresses requests from investors for additional, more detailed information about a reportable segment’s expenses by requiring entities to provide disclosures of significant segment expenses and other segment items. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The amendments should be applied retrospectively. Early adoption of the amendments is permitted, including adoption in an interim period. The amendments will impact our segment disclosures but will not otherwise impact Adtalem’s Consolidated Financial Statements. In December 2023, the FASB issued ASU No. 2023-09: “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” The guidance was issued to enhance the transparency and decision usefulness of income tax disclosures by requiring entities to provide additional information in the rate reconciliation and additional disclosures about income taxes paid. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2024. The amendments should be applied prospectively and retrospective application is permitted. Early adoption of the amendments is permitted. The amendments will impact our income tax disclosures but will not otherwise impact Adtalem’s Consolidated Financial Statements. We reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on our Consolidated Financial Statements.
Revision of Previously Issued Financial Statements	Revision to Previously Issued Financial Statements During the fourth quarter of fiscal year 2024, Adtalem identified an error in the presentation of capitalized cloud computing implementation costs in its previously issued financial statements. In accordance with Accounting Standards Codification (“ASC”) 350-40 “Intangibles, Goodwill and Other, Internal-Use Software,” capitalized cloud computing implementation costs should be presented in the same line item in the Consolidated Balance Sheets as a prepayment of the fees for the associated hosting arrangement, and the cash flows from capitalized implementation costs should be presented in the same manner as cash flows for the fees associated with the hosting arrangement. Adtalem previously presented capitalized cloud implementation costs in property and equipment, net rather than as prepaid expenses and other current assets and other assets, net on the Consolidated Balance Sheets. Adtalem previously presented the cash flows from capitalized implementation costs as capital expenditures within investing activities rather than within cash flows from operating activities in the Consolidated Statements of Cash Flows. Adtalem assessed the materiality of this error individually and in the aggregate with other previously identified errors to prior periods’ Consolidated Financial Statements in accordance with SEC Staff Accounting Bulletin (“SAB”) No. 99 “Materiality” and SAB 108 “Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements” codified in ASC 250 “Accounting Changes and Error Corrections.” Adtalem concluded that the errors were not material to prior periods and therefore, amendments of previously filed reports are not required. However, Adtalem determined it was appropriate to revise its previously issued financial statements. In accordance with ASC 250, Adtalem corrected prior periods presented herein by revising the financial statement line item amounts previously disclosed in SEC filings in order to achieve comparability in the Consolidated Financial Statements. The Consolidated Balance Sheets as of June 30, 2023 and the Consolidated Statements of Cash Flows for the year ended June 30, 2023 have been revised in this Annual Report on Form 10-K, and the impact of this revision of Adtalem’s previously reported annual Consolidated Financial Statements are detailed below. In connection with this revision, Adtalem also corrected other immaterial errors in the prior periods, including certain errors that had previously been adjusted for in the period identified. We have also revised impacted amounts within the accompanying Notes to Consolidated Financial Statements. The following table summarizes the effect of the revision on the affected line items within the Consolidated Balance Sheets (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2023 ​ ​ As Reported ​ Adjustment ​ As Revised Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 273,689 ​ $ (1,495) ​ $ 272,194 Restricted cash ​ ​ 1,386 ​ ​ 1,495 ​ ​ 2,881 Prepaid expenses and other current assets ​ ​ 100,715 ​ ​ 1,758 ​ ​ 102,473 Total current assets ​ ​ 478,539 ​ ​ 1,758 ​ ​ 480,297 Noncurrent assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Property and equipment, net ​ ​ 258,522 ​ ​ (13,873) ​ ​ 244,649 Other assets, net ​ ​ 68,509 ​ ​ 12,115 ​ ​ 80,624 Total noncurrent assets ​ ​ 2,332,002 ​ ​ (1,758) ​ ​ 2,330,244 The following table summarizes the effect of the revision on the affected line items within the Consolidated Statements of Cash Flows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2023 ​ ​ As Reported ​ Adjustment ​ As Revised Operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustments to reconcile net income to net cash provided by operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation ​ $ 41,575 ​ $ (199) ​ $ 41,376 Changes in assets and liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cloud computing implementation assets ​ ​ — ​ ​ (13,873) ​ ​ (13,873) Accounts payable ​ ​ 21,666 ​ ​ 3,078 ​ ​ 24,744 Net cash provided by operating activities-continuing operations ​ ​ 205,684 ​ ​ (10,994) ​ ​ 194,690 Net cash provided by operating activities ​ ​ 202,908 ​ ​ (10,994) ​ ​ 191,914 Investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures ​ ​ (37,008) ​ ​ 10,994 ​ ​ (26,014) Net cash provided by investing activities-continuing operations ​ ​ 15,919 ​ ​ 10,994 ​ ​ 26,913 Net cash provided by investing activities ​ ​ 12,745 ​ ​ 10,994 ​ ​ 23,739 Non-cash investing and financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued capital expenditures ​ ​ 8,203 ​ ​ (3,078) ​ ​ 5,125 ​

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Effect of revision on affected line items within financial statements	The following table summarizes the effect of the revision on the affected line items within the Consolidated Balance Sheets (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2023 ​ ​ As Reported ​ Adjustment ​ As Revised Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 273,689 ​ $ (1,495) ​ $ 272,194 Restricted cash ​ ​ 1,386 ​ ​ 1,495 ​ ​ 2,881 Prepaid expenses and other current assets ​ ​ 100,715 ​ ​ 1,758 ​ ​ 102,473 Total current assets ​ ​ 478,539 ​ ​ 1,758 ​ ​ 480,297 Noncurrent assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Property and equipment, net ​ ​ 258,522 ​ ​ (13,873) ​ ​ 244,649 Other assets, net ​ ​ 68,509 ​ ​ 12,115 ​ ​ 80,624 Total noncurrent assets ​ ​ 2,332,002 ​ ​ (1,758) ​ ​ 2,330,244 The following table summarizes the effect of the revision on the affected line items within the Consolidated Statements of Cash Flows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2023 ​ ​ As Reported ​ Adjustment ​ As Revised Operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustments to reconcile net income to net cash provided by operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation ​ $ 41,575 ​ $ (199) ​ $ 41,376 Changes in assets and liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cloud computing implementation assets ​ ​ — ​ ​ (13,873) ​ ​ (13,873) Accounts payable ​ ​ 21,666 ​ ​ 3,078 ​ ​ 24,744 Net cash provided by operating activities-continuing operations ​ ​ 205,684 ​ ​ (10,994) ​ ​ 194,690 Net cash provided by operating activities ​ ​ 202,908 ​ ​ (10,994) ​ ​ 191,914 Investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures ​ ​ (37,008) ​ ​ 10,994 ​ ​ (26,014) Net cash provided by investing activities-continuing operations ​ ​ 15,919 ​ ​ 10,994 ​ ​ 26,913 Net cash provided by investing activities ​ ​ 12,745 ​ ​ 10,994 ​ ​ 23,739 Non-cash investing and financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued capital expenditures ​ ​ 8,203 ​ ​ (3,078) ​ ​ 5,125 ​ The following tables summarize the effect of the revision on the affected line items within the Consolidated Balance Sheets (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2024 ​ ​ As Reported ​ Adjustment ​ As Revised Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Prepaid expenses and other current assets ​ $ 59,401 ​ $ 4,183 ​ $ 63,584 Total current assets ​ ​ 387,634 ​ ​ 4,183 ​ ​ 391,817 Noncurrent assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Property and equipment, net ​ ​ 272,792 ​ ​ (33,135) ​ ​ 239,657 Other assets, net ​ ​ 67,768 ​ ​ 28,952 ​ ​ 96,720 Total noncurrent assets ​ ​ 2,327,400 ​ ​ (4,183) ​ ​ 2,323,217 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 ​ ​ As Reported ​ Adjustment ​ As Revised Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Prepaid expenses and other current assets ​ $ 58,356 ​ $ 3,010 ​ $ 61,366 Total current assets ​ ​ 378,099 ​ ​ 3,010 ​ ​ 381,109 Noncurrent assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Property and equipment, net ​ ​ 260,484 ​ ​ (25,187) ​ ​ 235,297 Other assets, net ​ ​ 65,852 ​ ​ 22,177 ​ ​ 88,029 Total noncurrent assets ​ ​ 2,322,826 ​ ​ (3,010) ​ ​ 2,319,816 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2023 ​ ​ As Reported ​ Adjustment ​ As Revised Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 262,438 ​ $ (1,612) ​ $ 260,826 Restricted cash ​ ​ 1,988 ​ ​ 1,612 ​ ​ 3,600 Prepaid expenses and other current assets ​ ​ 60,750 ​ ​ 2,103 ​ ​ 62,853 Total current assets ​ ​ 472,928 ​ ​ 2,103 ​ ​ 475,031 Noncurrent assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Property and equipment, net ​ ​ 264,766 ​ ​ (18,097) ​ ​ 246,669 Other assets, net ​ ​ 67,634 ​ ​ 15,994 ​ ​ 83,628 Total noncurrent assets ​ ​ 2,321,233 ​ ​ (2,103) ​ ​ 2,319,130 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2023 ​ ​ As Reported ​ Adjustment ​ As Revised Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 315,373 ​ $ (1,613) ​ $ 313,760 Restricted cash ​ ​ 1,804 ​ ​ 1,613 ​ ​ 3,417 Prepaid expenses and other current assets ​ ​ 102,573 ​ ​ 514 ​ ​ 103,087 Total current assets ​ ​ 533,034 ​ ​ 514 ​ ​ 533,548 Noncurrent assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Property and equipment, net ​ ​ 252,797 ​ ​ (6,234) ​ ​ 246,563 Other assets, net ​ ​ 67,618 ​ ​ 5,720 ​ ​ 73,338 Total noncurrent assets ​ ​ 2,334,083 ​ ​ (514) ​ ​ 2,333,569 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2022 ​ ​ As Reported ​ Adjustment ​ As Revised Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 207,776 ​ $ (1,492) ​ $ 206,284 Restricted cash ​ ​ 2,234 ​ ​ 1,492 ​ ​ 3,726 Prepaid expenses and other current assets ​ ​ 113,564 ​ ​ 1,081 ​ ​ 114,645 Total current assets ​ ​ 423,116 ​ ​ 1,081 ​ ​ 424,197 Noncurrent assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Property and equipment, net ​ ​ 275,617 ​ ​ (3,275) ​ ​ 272,342 Other assets, net ​ ​ 116,613 ​ ​ 3,043 ​ ​ 119,656 Total noncurrent assets ​ ​ 2,419,922 ​ ​ (232) ​ ​ 2,419,690 Total assets ​ ​ 2,843,038 ​ ​ 849 ​ ​ 2,843,887 Liabilities and shareholders' equity: ​ ​ ​ ​ ​ ​ ​ ​ ​ Current liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Deferred revenue ​ ​ 115,658 ​ ​ 5,177 ​ ​ 120,835 Total current liabilities ​ ​ 371,462 ​ ​ 5,177 ​ ​ 376,639 Noncurrent liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Other liabilities ​ ​ 61,901 ​ ​ 9,177 ​ ​ 71,078 Total noncurrent liabilities ​ ​ 948,854 ​ ​ 9,177 ​ ​ 958,031 Total liabilities ​ ​ 1,320,316 ​ ​ 14,354 ​ ​ 1,334,670 Shareholders' equity: ​ ​ ​ ​ ​ ​ ​ ​ ​ Retained earnings ​ ​ 2,349,146 ​ ​ (13,505) ​ ​ 2,335,641 Total shareholders' equity ​ ​ 1,522,722 ​ ​ (13,505) ​ ​ 1,509,217 Total liabilities and shareholders' equity ​ ​ 2,843,038 ​ ​ 849 ​ ​ 2,843,887 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2022 ​ ​ As Reported ​ Adjustment ​ As Revised Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 327,515 ​ $ (1,681) ​ $ 325,834 Restricted cash ​ ​ 2,480 ​ ​ 1,681 ​ ​ 4,161 Noncurrent assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Property and equipment, net ​ ​ 281,581 ​ ​ (416) ​ ​ 281,165 Other assets, net ​ ​ 120,630 ​ ​ 416 ​ ​ 121,046 ​ The following tables summarize the effect of the revision on the affected line items within the Consolidated Statements of Cash Flows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended March 31, 2024 ​ ​ As Reported ​ Adjustment ​ As Revised Operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustments to reconcile net income to net cash provided by operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation ​ $ 32,106 ​ $ (2,227) ​ $ 29,879 Changes in assets and liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cloud computing implementation assets ​ ​ — ​ ​ (19,262) ​ ​ (19,262) Accounts payable ​ ​ 10,841 ​ ​ 1,791 ​ ​ 12,632 Net cash provided by operating activities-continuing operations ​ ​ 246,809 ​ ​ (19,698) ​ ​ 227,111 Net cash provided by operating activities ​ ​ 255,205 ​ ​ (19,698) ​ ​ 235,507 Investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures ​ ​ (52,014) ​ ​ 19,698 ​ ​ (32,316) Net cash used in investing activities-continuing operations ​ ​ (51,886) ​ ​ 19,698 ​ ​ (32,188) Net cash used in investing activities ​ ​ (51,886) ​ ​ 19,698 ​ ​ (32,188) Non-cash investing and financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued capital expenditures ​ ​ 11,086 ​ ​ (4,869) ​ ​ 6,217 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended December 31, 2023 ​ ​ As Reported ​ Adjustment ​ As Revised Operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustments to reconcile net income to net cash provided by operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation ​ $ 20,714 ​ $ (1,333) ​ $ 19,381 Changes in assets and liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cloud computing implementation assets ​ ​ — ​ ​ (11,314) ​ ​ (11,314) Accounts payable ​ ​ 7,824 ​ ​ 1,931 ​ ​ 9,755 Net cash provided by operating activities-continuing operations ​ ​ 83,069 ​ ​ (10,716) ​ ​ 72,353 Net cash provided by operating activities ​ ​ 92,584 ​ ​ (10,716) ​ ​ 81,868 Investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures ​ ​ (30,328) ​ ​ 10,716 ​ ​ (19,612) Net cash used in investing activities-continuing operations ​ ​ (30,200) ​ ​ 10,716 ​ ​ (19,484) Net cash used in investing activities ​ ​ (30,200) ​ ​ 10,716 ​ ​ (19,484) Non-cash investing and financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued capital expenditures ​ ​ 9,062 ​ ​ (5,009) ​ ​ 4,053 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, 2023 ​ ​ As Reported ​ Adjustment ​ As Revised Operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustments to reconcile net income to net cash provided by operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation ​ $ 9,778 ​ $ (440) ​ $ 9,338 Changes in assets and liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cloud computing implementation assets ​ ​ — ​ ​ (4,224) ​ ​ (4,224) Accounts payable ​ ​ (2,870) ​ ​ 52 ​ ​ (2,818) Net cash provided by operating activities-continuing operations ​ ​ 90,726 ​ ​ (4,612) ​ ​ 86,114 Net cash provided by operating activities ​ ​ 99,685 ​ ​ (4,612) ​ ​ 95,073 Investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures ​ ​ (15,046) ​ ​ 4,612 ​ ​ (10,434) Net cash used in investing activities-continuing operations ​ ​ (14,946) ​ ​ 4,612 ​ ​ (10,334) Net cash used in investing activities ​ ​ (14,946) ​ ​ 4,612 ​ ​ (10,334) Non-cash investing and financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued capital expenditures ​ ​ 9,217 ​ ​ (3,130) ​ ​ 6,087 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended March 31, 2023 ​ ​ As Reported ​ Adjustment ​ As Revised Operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustments to reconcile net income to net cash provided by operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation ​ $ 31,618 ​ $ (112) ​ $ 31,506 Changes in assets and liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cloud computing implementation assets ​ ​ — ​ ​ (6,234) ​ ​ (6,234) Accounts payable ​ ​ 12,286 ​ ​ 1,483 ​ ​ 13,769 Net cash provided by operating activities-continuing operations ​ ​ 149,821 ​ ​ (4,863) ​ ​ 144,958 Net cash provided by operating activities ​ ​ 149,417 ​ ​ (4,863) ​ ​ 144,554 Investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures ​ ​ (19,056) ​ ​ 4,863 ​ ​ (14,193) Net cash provided by investing activities-continuing operations ​ ​ 33,871 ​ ​ 4,863 ​ ​ 38,734 Net cash provided by investing activities ​ ​ 30,697 ​ ​ 4,863 ​ ​ 35,560 Non-cash investing and financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued capital expenditures ​ ​ 10,474 ​ ​ (1,483) ​ ​ 8,991 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended December 31, 2022 ​ ​ As Reported ​ Adjustment ​ As Revised Operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustments to reconcile net income to net cash provided by operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation ​ $ 21,461 ​ $ (34) ​ $ 21,427 Changes in assets and liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cloud computing implementation assets ​ ​ — ​ ​ (3,275) ​ ​ (3,275) Accounts payable ​ ​ 13,233 ​ ​ 475 ​ ​ 13,708 Net cash provided by operating activities-continuing operations ​ ​ 42,277 ​ ​ (2,834) ​ ​ 39,443 Net cash provided by operating activities ​ ​ 41,415 ​ ​ (2,834) ​ ​ 38,581 Investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures ​ ​ (9,747) ​ ​ 2,834 ​ ​ (6,913) Net cash used in investing activities-continuing operations ​ ​ (9,748) ​ ​ 2,834 ​ ​ (6,914) Net cash used in investing activities ​ ​ (12,922) ​ ​ 2,834 ​ ​ (10,088) Non-cash investing and financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued capital expenditures ​ ​ 5,209 ​ ​ (475) ​ ​ 4,734 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, 2022 ​ ​ As Reported ​ Adjustment ​ As Revised Operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Changes in assets and liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cloud computing implementation assets ​ $ — ​ $ (416) ​ $ (416) Accounts payable ​ ​ 8,711 ​ ​ 243 ​ ​ 8,954 Net cash provided by operating activities-continuing operations ​ ​ 91,476 ​ ​ (173) ​ ​ 91,303 Net cash provided by operating activities ​ ​ 91,346 ​ ​ (173) ​ ​ 91,173 Investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures ​ ​ (5,551) ​ ​ 173 ​ ​ (5,378) Net cash used in investing activities-continuing operations ​ ​ (5,503) ​ ​ 173 ​ ​ (5,330) Net cash used in investing activities ​ ​ (6,314) ​ ​ 173 ​ ​ (6,141) Non-cash investing and financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued capital expenditures ​ ​ 4,713 ​ ​ (243) ​ ​ 4,470 ​

Acquisitions (Tables)

Acquisitions (Tables) - Walden University, LLC	12 Months Ended
	Jun. 30, 2024
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes the fair values of the assets acquired and liabilities assumed at the date of acquisition (in thousands): ​ ​ ​ ​ ​ ​ ​ August 12, ​ ​ 2021 Assets acquired: ​ ​ ​ Cash and cash equivalents ​ $ 65,010 Restricted cash ​ ​ 18,389 Accounts and financing receivables ​ ​ 22,091 Prepaid expenses and other current assets ​ ​ 8,819 Property and equipment ​ 25,882 Operating lease assets ​ ​ 6,096 Deferred income taxes ​ ​ 59 Intangible assets ​ 833,351 Goodwill ​ 651,052 Other assets, net ​ 21,316 Total assets acquired ​ 1,652,065 Liabilities assumed: ​ ​ Accounts payable ​ 31,971 Accrued payroll and benefits ​ 25,639 Accrued liabilities ​ 1,620 Deferred revenue ​ ​ 10,958 Current operating lease liabilities ​ ​ 1,983 Long-term operating lease liabilities ​ ​ 4,343 Other liabilities ​ ​ 4,098 Total liabilities assumed ​ 80,612 Net assets acquired ​ $ 1,571,453
Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination	The values and estimated useful lives of other intangible assets acquired were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ August 12, 2021 ​ ​ Value ​ Estimated ​ ​ Assigned ​ Useful Life Student relationships ​ $ 161,900 ​ 3 years Curriculum $ 56,091 5 years
Schedule of pro forma financial information	The following unaudited pro forma financial information summarizes our results of operations as though the acquisition occurred on July 1, 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2022 Revenue ​ $ 1,451,081 Net income ​ $ 385,110 ​

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Jun. 30, 2024
Discontinued Operations And Disposal Groups [Abstract]
Income Statement Information of Discontinued Operations	The following is a summary of income statement information reported as discontinued operations, which includes expense from ongoing litigation costs and settlements related to the DeVry University and Carrington College divestitures, ACAMS, Becker, OCL, and EduPristine operations through the date of each respective sale, the gain on disposal of these entities, a loss from post-closing working capital adjustments to the initial sales prices and a tax return to provision adjustment, and the earn-outs we received (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Revenue ​ $ — ​ $ — ​ $ 153,762 Operating cost and expense: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cost of educational services ​ — ​ — ​ 26,996 Student services and administrative expense ​ 762 ​ 8,464 ​ 126,252 Restructuring expense ​ — ​ — ​ 1,500 Total operating cost and expense ​ 762 ​ 8,464 ​ 154,748 Loss from discontinued operations before income taxes ​ (762) ​ (8,464) ​ (986) (Loss) gain on disposal of discontinued operations before income taxes ​ ​ — ​ ​ (3,576) ​ ​ 473,483 (Provision for) benefit from income taxes ​ (174) ​ 3,646 ​ (125,551) (Loss) income from discontinued operations ​ $ (936) ​ $ (8,394) ​ $ 346,946 ​

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Jun. 30, 2024
Revenue from Contract with Customer [Abstract]
Disaggregate revenue	The following tables disaggregate revenue by source (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2024 ​ ​ Chamberlain ​ Walden Medical and Veterinary ​ Consolidated Tuition and fees $ 633,522 $ 595,332 $ 342,389 $ 1,571,243 Other ​ ​ — ​ ​ — ​ ​ 13,409 ​ ​ 13,409 Total $ 633,522 $ 595,332 $ 355,798 $ 1,584,652 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2023 ​ ​ Chamberlain ​ Walden Medical and Veterinary ​ Consolidated Tuition and fees ​ $ 571,034 $ 533,725 $ 334,323 $ 1,439,082 Other ​ ​ — ​ ​ — ​ ​ 11,744 ​ ​ 11,744 Total $ 571,034 $ 533,725 $ 346,067 $ 1,450,826 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2022 ​ ​ Chamberlain ​ Walden Medical and Veterinary ​ Consolidated Tuition and fees ​ $ 557,536 $ 485,393 $ 328,382 $ 1,371,311 Other ​ ​ — ​ ​ — ​ ​ 10,531 ​ ​ 10,531 Total $ 557,536 $ 485,393 $ 338,913 $ 1,381,842

Restructuring Expense (Tables)

Restructuring Expense (Tables)	12 Months Ended
	Jun. 30, 2024
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs	Restructuring expense by segment were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2024 ​ ​ Real Estate and Other ​ Termination Benefits ​ Total Walden ​ $ (776) $ — $ (776) Medical and Veterinary ​ ​ 402 ​ 40 ​ 442 Home Office ​ ​ 2,204 ​ — ​ 2,204 Total ​ $ 1,830 ​ $ 40 ​ $ 1,870 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2023 ​ ​ Real Estate and Other ​ Termination Benefits ​ Total Chamberlain ​ $ 818 $ — $ 818 Walden ​ ​ 3,191 ​ 54 ​ 3,245 Medical and Veterinary ​ ​ 7,071 ​ 616 ​ 7,687 Home Office ​ ​ 6,117 ​ 950 ​ 7,067 Total ​ $ 17,197 ​ $ 1,620 ​ $ 18,817 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2022 ​ ​ Real Estate and Other ​ Termination Benefits ​ Total Chamberlain ​ $ 835 $ 2,003 $ 2,838 Walden ​ ​ — ​ 4,053 ​ 4,053 Medical and Veterinary ​ ​ 7,675 ​ 2,116 ​ 9,791 Home Office ​ ​ 5,977 ​ 2,969 ​ 8,946 Total ​ $ 14,487 ​ $ 11,141 ​ $ 25,628
Separation and Restructuring Plan Activity	The following table summarizes the separation and restructuring plan activity for fiscal years 2023 and 2024, for which cash payments are required (in thousands): ​ ​ ​ ​ ​ Liability balance as of June 30, 2022 ​ $ 813 Increase in liability (separation and other charges) ​ 1,620 Reduction in liability (payments and adjustments) ​ (1,692) Liability balance as of June 30, 2023 ​ 741 Increase in liability (separation and other charges) ​ 40 Reduction in liability (payments and adjustments) ​ (781) Liability balance as of June 30, 2024 ​ $ —

Other Income, Net (Tables)

Other Income, Net (Tables)	12 Months Ended
	Jun. 30, 2024
Other Income and Expenses [Abstract]
Schedule of other income, net	Other income, net consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Interest and dividend income ​ $ 9,177 ​ $ 10,654 ​ $ 4,379 Investment gain (loss) ​ 1,365 ​ (3,689) ​ (3,271) Other income, net ​ $ 10,542 ​ $ 6,965 ​ $ 1,108

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Income before Income Tax	Income from continuing operations before income taxes, classified by source of income, was as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Domestic ​ $ 89,752 ​ $ 51,422 ​ $ (112,151) Foreign ​ 74,185 ​ 60,613 ​ 60,657 Total ​ $ 163,937 ​ $ 112,035 ​ $ (51,494)
Income Tax Provisions (Benefits)	The components of the provision for (benefit from) income taxes were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ 2024 ​ 2023 ​ 2022 Current tax provision (benefit): ​ ​ ​ ​ ​ ​ ​ ​ U.S. federal ​ $ 11,243 ​ $ 13,761 ​ $ (6,767) State and local ​ 3,489 ​ 824 ​ 4,154 Foreign ​ 419 ​ 614 ​ 725 Total current ​ 15,151 ​ 15,199 ​ (1,888) Deferred tax provision (benefit): ​ ​ ​ ​ ​ ​ ​ ​ ​ U.S. federal ​ 4,870 ​ (1,099) ​ (6,425) State and local ​ 2,745 ​ (4,347) ​ (6,597) Foreign ​ 3,458 ​ 530 ​ (629) Total deferred ​ 11,073 ​ (4,916) ​ (13,651) Provision for (benefit from) income taxes ​ $ 26,224 ​ $ 10,283 ​ $ (15,539)
Income Tax Provisions Computed using Statutory U.S. Federal Rate	The effective tax rate differs from the statutory tax rates as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ ​ 2023 ​ ​ 2022 Income tax at statutory rate ​ $ 34,427 ​ 21.0 % ​ $ 23,527 ​ 21.0 % ​ $ (10,814) ​ 21.0 % Lower rates on foreign operations ​ (11,419) (7.0) % ​ (11,668) (10.4) % ​ (12,879) 25.0 % State income taxes ​ 4,557 2.8 % ​ 2,719 2.4 % ​ (661) 1.3 % Loss on investment in subsidiary ​ — — % ​ — — % ​ (1,669) 3.2 % Deferred tax benefit from acquisitions and divestitures ​ — — % ​ — — % ​ (1,153) 2.2 % Research and development tax credits ​ ​ (1,589) ​ (1.0) % ​ ​ (1,862) ​ (1.7) % ​ ​ — — % Change in valuation allowance ​ ​ (621) ​ (0.4) % ​ ​ (9,769) ​ (8.7) % ​ ​ 5,406 (10.5) % Reduction in state loss carryforwards ​ ​ — ​ — % ​ ​ 2,340 ​ 2.1 % ​ ​ (5,882) 11.4 % Permanent non-deductible items ​ 2,293 1.4 % ​ 1,630 1.5 % ​ 2,788 (5.4) % Foreign tax provisions under GILTI ​ ​ 4,908 ​ 3.0 % ​ 3,569 ​ 3.2 % ​ 8,581 ​ (16.7) % Change in unrecognized tax benefits ​ ​ (6,849) ​ (4.2) % ​ 791 ​ 0.7 % ​ 56 ​ (0.1) % Other ​ 517 0.3 % ​ (994) (0.9) % ​ 688 (1.3) % Provision for (benefit from) income taxes ​ $ 26,224 16.0 % ​ $ 10,283 9.2 % ​ $ (15,539) 30.2 %
Deferred Tax Assets (Liabilities)	The components of the deferred income tax assets and liabilities were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2024 ​ 2023 Employee benefits ​ $ 15,866 ​ $ 11,719 Stock-based compensation ​ 7,664 ​ 7,310 Receivable reserve ​ 9,028 ​ 6,246 Capitalized research and experimental costs ​ 9,322 ​ 8,075 Operating lease liabilities ​ ​ 42,526 ​ ​ 41,235 Other reserves ​ 12,439 ​ 6,246 Loss and credit carryforwards, net ​ 15,426 ​ 19,259 Less: valuation allowance ​ — ​ (621) Gross deferred tax assets ​ 112,271 ​ 99,469 Depreciation ​ (8,298) ​ (5,643) Deferred taxes on unremitted foreign earnings ​ ​ (210) ​ ​ (428) Amortization of intangible assets ​ (50,035) ​ (31,294) Operating lease assets ​ ​ (34,166) ​ ​ (31,478) Gross deferred tax liability ​ (92,709) ​ (68,843) Net deferred tax asset ​ $ 19,562 ​ $ 30,626
Net Operating Loss and Credit Carryforwards	Adtalem has the following tax net operating loss (tax effected), interest (tax effected), and credit carryforwards as of June 30, 2024 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ Years of Expiration ​ ​ 2024 ​ Beginning ​ Ending U.S. interest expense carryforwards ​ $ 506 no expiration U.S. credit carryforwards ​ ​ 672 ​ 2027 ​ 2030 State net operating loss carryforwards ​ 9,053 2025 2043 State interest expense carryforwards ​ ​ 592 ​ no expiration State credit carryforwards ​ ​ 130 ​ no expiration Foreign net operating loss carryforwards ​ 4,473 2030 2033 Total loss and credit carryforwards, net ​ $ 15,426 ​ ​ ​
Changes in Valuation Allowance	The changes in our valuation allowances were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Balance at beginning of period ​ $ 621 ​ $ 10,390 ​ $ 4,985 Charged to costs and expenses ​ — ​ (2,677) ​ 5,522 Deductions ​ (621) ​ (7,092) ​ (117) Balance at end of period ​ $ — ​ $ 621 ​ $ 10,390
Changes in Unrecognized Tax Benefits	The changes in our unrecognized tax benefits were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Balance at beginning of period ​ $ 13,128 ​ $ 11,645 ​ $ 9,836 Increases from positions taken during prior periods ​ 953 ​ 1,299 ​ 1,074 Decreases from positions taken during prior periods ​ (1,248) ​ — ​ (1,737) Increases from positions taken during the current period ​ 554 ​ 665 ​ 2,845 Reductions due to lapse of statute ​ (6,664) ​ (481) ​ (373) Balance at end of period ​ $ 6,723 ​ $ 13,128 ​ $ 11,645

Earnings per Share (Tables)

Earnings per Share (Tables)	12 Months Ended
	Jun. 30, 2024
Earnings per Share
Schedule of earnings per share	The following table sets forth the computations of basic and diluted earnings per share and antidilutive shares (in thousands, except per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Numerator: ​ ​ ​ ​ ​ ​ ​ ​ ​ Net income (loss): ​ ​ ​ ​ ​ ​ Continuing operations ​ $ 137,713 ​ $ 101,752 ​ $ (35,955) Discontinued operations ​ ​ (936) ​ ​ (8,394) ​ ​ 346,946 Net income ​ $ 136,777 ​ $ 93,358 ​ $ 310,991 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Denominator: ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-average basic shares outstanding ​ ​ 39,413 ​ 44,781 ​ 48,388 Effect of dilutive stock awards ​ ​ 894 ​ 743 ​ — Effect of ASR ​ ​ — ​ 76 ​ — Weighted-average diluted shares outstanding ​ ​ 40,307 ​ 45,600 ​ 48,388 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Earnings (loss) per share: ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic: ​ ​ ​ ​ ​ ​ ​ ​ ​ Continuing operations ​ $ 3.49 ​ $ 2.27 ​ $ (0.74) Discontinued operations ​ $ (0.02) ​ $ (0.19) ​ $ 7.17 Total basic earnings per share ​ $ 3.47 ​ $ 2.08 ​ $ 6.43 Diluted: ​ ​ ​ ​ ​ ​ ​ ​ ​ Continuing operations ​ $ 3.42 ​ $ 2.23 ​ $ (0.74) Discontinued operations ​ $ (0.02) ​ $ (0.18) ​ $ 7.17 Total diluted earnings per share ​ $ 3.39 ​ $ 2.05 ​ $ 6.43 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-average antidilutive shares ​ ​ 115 ​ ​ 403 ​ ​ 1,869

Accounts and Financing Receiv_2

Accounts and Financing Receivables (Tables)	12 Months Ended
	Jun. 30, 2024
Receivables [Abstract]
Schedule of classification of accounts and financing receivable	The classification of our accounts and financing receivable balances was as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2024 ​ ​ ​ Gross ​ ​ Allowance ​ ​ Net Accounts receivables, current ​ $ 159,406 ​ $ (35,336) ​ $ 124,070 Financing receivables, current ​ ​ 5,239 ​ ​ (2,476) ​ ​ 2,763 Accounts and financing receivables, current ​ $ 164,645 ​ $ (37,812) ​ $ 126,833 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Financing receivables, current ​ $ 5,239 ​ $ (2,476) ​ $ 2,763 Financing receivables, noncurrent ​ ​ 36,214 ​ ​ (10,082) ​ ​ 26,132 Total financing receivables ​ $ 41,453 ​ $ (12,558) ​ $ 28,895 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2023 ​ ​ ​ Gross ​ ​ Allowance ​ ​ Net Accounts receivables, current ​ $ 129,318 ​ $ (29,190) ​ $ 100,128 Financing receivables, current ​ ​ 4,757 ​ ​ (2,136) ​ ​ 2,621 Accounts and financing receivables, current ​ $ 134,075 ​ $ (31,326) ​ $ 102,749 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Financing receivables, current ​ $ 4,757 ​ $ (2,136) ​ $ 2,621 Financing receivables, noncurrent ​ ​ 36,368 ​ ​ (9,332) ​ ​ 27,036 Total financing receivables ​ $ 41,125 ​ $ (11,468) ​ $ 29,657
Schedule of credit quality analysis of financing receivable	The credit quality analysis of financing receivables as of June 30, 2024 was as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortized Cost Basis by Origination Year ​ ​ ​ ​ ​ Prior ​ 2020 ​ 2021 ​ 2022 ​ 2023 ​ 2024 ​ Total 1-30 days past due $ 552 ​ $ — $ 214 $ 111 $ 1,188 $ 1,146 $ 3,211 31-60 days past due ​ ​ 213 ​ ​ 90 ​ ​ 65 ​ ​ 37 ​ ​ 567 ​ ​ 1,488 ​ ​ 2,460 61-90 days past due ​ ​ 174 ​ ​ — ​ ​ 5 ​ ​ 110 ​ ​ 370 ​ ​ 257 ​ ​ 916 91-120 days past due ​ ​ — ​ ​ 11 ​ ​ 434 ​ ​ 20 ​ ​ 206 ​ ​ 791 ​ ​ 1,462 121-150 days past due ​ ​ 51 ​ ​ 88 ​ ​ 63 ​ ​ 314 ​ ​ 268 ​ ​ 91 ​ ​ 875 Greater than 150 days past due ​ ​ 2,556 ​ ​ 466 ​ ​ 1,366 ​ ​ 1,300 ​ ​ 1,920 ​ ​ 987 ​ ​ 8,595 Total past due ​ ​ 3,546 ​ ​ 655 ​ ​ 2,147 ​ ​ 1,892 ​ ​ 4,519 ​ ​ 4,760 ​ ​ 17,519 Current ​ ​ 6,014 ​ ​ 748 ​ ​ 3,944 ​ ​ 1,897 ​ ​ 4,549 ​ ​ 6,782 ​ ​ 23,934 Financing receivables, gross ​ $ 9,560 ​ $ 1,403 ​ $ 6,091 ​ $ 3,789 ​ $ 9,068 ​ $ 11,542 ​ $ 41,453 Gross write-offs ​ $ 1,145 ​ $ 279 ​ $ 509 ​ $ 597 ​ $ 729 ​ $ 2 ​ $ 3,261 The credit quality analysis of financing receivables as of June 30, 2023 was as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortized Cost Basis by Origination Year ​ ​ ​ ​ ​ Prior ​ 2019 ​ 2020 ​ 2021 ​ 2022 ​ 2023 ​ Total 1-30 days past due $ 186 ​ $ 79 $ 115 $ 137 $ 735 $ 1,944 $ 3,196 31-60 days past due ​ ​ 61 ​ ​ 34 ​ ​ — ​ ​ 359 ​ ​ 573 ​ ​ 1,103 ​ ​ 2,130 61-90 days past due ​ ​ 97 ​ ​ 39 ​ ​ 110 ​ ​ 65 ​ ​ 559 ​ ​ 368 ​ ​ 1,238 91-120 days past due ​ ​ 2 ​ ​ 17 ​ ​ 2 ​ ​ 13 ​ ​ 77 ​ ​ 200 ​ ​ 311 121-150 days past due ​ ​ 62 ​ ​ 37 ​ ​ 26 ​ ​ 45 ​ ​ 147 ​ ​ 129 ​ ​ 446 Greater than 150 days past due ​ ​ 2,641 ​ ​ 734 ​ ​ 708 ​ ​ 2,071 ​ ​ 1,457 ​ ​ 381 ​ ​ 7,992 Total past due ​ ​ 3,049 ​ ​ 940 ​ ​ 961 ​ ​ 2,690 ​ ​ 3,548 ​ ​ 4,125 ​ ​ 15,313 Current ​ ​ 6,199 ​ ​ 1,112 ​ ​ 820 ​ ​ 5,350 ​ ​ 2,608 ​ ​ 9,723 ​ ​ 25,812 Financing receivables, gross ​ $ 9,248 ​ $ 2,052 ​ $ 1,781 ​ $ 8,040 ​ $ 6,156 ​ $ 13,848 ​ $ 41,125
Schedule of the allowance for credit losses roll-forward	The following tables provide a roll-forward of the allowance for credit losses (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accounts ​ Financing ​ Total June 30, 2021 $ 11,559 ​ $ 16,832 $ 28,391 Write-offs ​ ​ (15,980) ​ ​ (5,287) ​ ​ (21,267) Recoveries ​ ​ 11,488 ​ ​ 35 ​ ​ 11,523 Provision for credit losses ​ ​ 23,830 ​ ​ 3,311 ​ ​ 27,141 June 30, 2022 ​ ​ 30,897 ​ ​ 14,891 ​ ​ 45,788 Write-offs ​ ​ (43,273) ​ ​ (7,653) ​ ​ (50,926) Recoveries ​ ​ 12,207 ​ ​ 590 ​ ​ 12,797 Provision for credit losses ​ ​ 29,359 ​ ​ 3,640 ​ ​ 32,999 June 30, 2023 ​ ​ 29,190 ​ ​ 11,468 ​ ​ 40,658 Write-offs ​ ​ (54,897) ​ ​ (3,261) ​ ​ (58,158) Recoveries ​ ​ 10,806 ​ ​ 1,413 ​ ​ 12,219 Provision for credit losses ​ ​ 50,237 ​ ​ 2,938 ​ ​ 53,175 June 30, 2024 ​ $ 35,336 ​ $ 12,558 ​ $ 47,894

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Jun. 30, 2024
Property, Plant And Equipment [Abstract]
Schedule of Property and equipment, net	Property and equipment, net consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ Useful Life ​ 2024 ​ 2023 Land - $ 31,776 ​ $ 35,956 Buildings and improvements ​ 10 - 31 years ​ ​ 200,274 ​ ​ 206,349 Leasehold improvements ​ Shorter of asset useful life or lease term ​ ​ 114,019 ​ ​ 99,777 Furniture and equipment ​ 3 - 8 years ​ ​ 103,961 ​ ​ 125,594 Software ​ 3 - 5 years ​ ​ 113,219 ​ ​ 92,212 Construction in progress ​ - ​ ​ 11,554 ​ ​ 23,390 Property and equipment, gross ​ ​ ​ ​ 574,803 ​ ​ 583,278 Accumulated depreciation ​ ​ ​ (326,279) ​ (338,629) Property and equipment, net ​ ​ ​ $ 248,524 ​ $ 244,649

Leases (Tables)

Leases (Tables)	12 Months Ended
	Jun. 30, 2024
Lessee Disclosure [Abstract]
Summary of components of lease cost	The components of lease cost were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Operating lease cost ​ $ 44,365 ​ $ 48,181 ​ $ 55,257 Sublease income ​ (9,107) ​ (13,329) ​ (13,920) Total lease cost ​ $ 35,258 ​ $ 34,852 ​ $ 41,337
Summary of maturities of lease liabilities	Maturities of lease liabilities as of June 30, 2024 were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ Operating Fiscal Year ​ Leases 2025 ​ $ 44,419 2026 ​ ​ 44,406 2027 ​ ​ 43,012 2028 ​ ​ 36,054 2029 ​ ​ 26,313 Thereafter ​ ​ 89,337 Total lease payments ​ 283,541 Less: tenant improvement allowance not yet received ​ ​ (8,631) Less: imputed interest ​ ​ (75,769) Present value of lease liabilities ​ $ 199,141
Summary of lease term and discount rate	Lease term and discount rate were as follows: ​ ​ ​ ​ ​ ​ ​ June 30, 2024 Weighted-average remaining operating lease term (years) ​ ​ 6.8 Weighted-average operating lease discount rate ​ ​ 7.4%
Summary of supplemental disclosures of cash flow information related to leases	Supplemental of cash flow information related to leases were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Cash paid for amounts in the measurement of operating lease liabilities (net of sublease receipts) ​ $ 41,063 ​ $ 58,198 ​ $ 52,540 Operating lease assets obtained in exchange for operating lease liabilities ​ $ 34,719 ​ $ 32,476 ​ $ 49,136
Schedule of Future minimum lease and sublease rental income	Future minimum sublease income under these agreements as of June 30, 2024, were as follows (in thousands): ​ ​ ​ ​ ​ Fiscal Year ​ Amount 2025 ​ $ 5,255 2026 ​ 2,038 Total sublease rental income ​ $ 7,293 ​

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Goodwill	Goodwill balances by reporting unit were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2024 ​ 2023 Chamberlain ​ $ 4,716 ​ $ 4,716 Walden ​ ​ 651,052 ​ ​ 651,052 AUC ​ 68,321 ​ 68,321 RUSM ​ 180,089 ​ 180,089 RUSVM ​ 57,084 ​ 57,084 Total ​ $ 961,262 ​ $ 961,262 ​ Goodwill balances by reportable segment were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2024 ​ 2023 Chamberlain ​ $ 4,716 ​ $ 4,716 Walden ​ ​ 651,052 ​ ​ 651,052 Medical and Veterinary ​ ​ 305,494 ​ ​ 305,494 Total ​ $ 961,262 ​ $ 961,262 ​
Summary of Amortizable Intangible Assets	Amortizable intangible assets consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2024 ​ June 30, 2023 ​ ​ ​ ​ Gross Carrying ​ Accumulated ​ Gross Carrying ​ Accumulated ​ Weighted-Average ​ ​ Amount ​ Amortization ​ Amount ​ Amortization ​ Amortization Period Student relationships ​ $ 161,900 ​ $ (161,900) $ 161,900 ​ $ (137,476) 3 Years Curriculum ​ 56,091 ​ (32,257) 56,091 ​ (21,037) 5 Years Total ​ $ 217,991 ​ $ (194,157) $ 217,991 ​ $ (158,513) ​
Summary of Indefinite-Lived Intangible Assets	Indefinite-lived intangible assets consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2024 ​ 2023 Walden trade name ​ $ 119,560 ​ $ 119,560 AUC trade name ​ ​ 17,100 ​ ​ 17,100 RUSM trade name ​ ​ 3,500 ​ ​ 3,500 RUSVM trade name ​ ​ 1,600 ​ ​ 1,600 Chamberlain Title IV eligibility and accreditations ​ 1,200 ​ 1,200 Walden Title IV eligibility and accreditations ​ ​ 495,800 ​ ​ 495,800 AUC Title IV eligibility and accreditations ​ 100,000 ​ 100,000 RUSM Title IV eligibility and accreditations ​ 11,600 ​ 11,600 RUSVM Title IV eligibility and accreditations ​ 2,500 ​ 2,500 Total ​ $ 752,860 ​ $ 752,860 ​ Indefinite-lived intangible asset balances by reportable segment were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2024 ​ 2023 Chamberlain ​ $ 1,200 ​ $ 1,200 Walden ​ ​ 615,360 ​ ​ 615,360 Medical and Veterinary ​ ​ 136,300 ​ ​ 136,300 Total ​ $ 752,860 ​ $ 752,860 ​
Estimated Amortization Expense for Amortized Intangible Assets	Future intangible asset amortization expense, by reporting unit, is expected to be as follows (in thousands): ​ ​ ​ ​ ​ Fiscal Year ​ Walden 2025 ​ $ 11,220 2026 ​ 11,220 2027 ​ 1,394 Total ​ $ 23,834

Debt (Tables)

Debt (Tables)	12 Months Ended
	Jun. 30, 2024
Debt Instruments [Abstract]
Schedule of Long-term Debt Instruments	Long-term debt consisted of the following senior secured credit facilities (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2024 ​ 2023 Senior Secured Notes due 2028 ​ $ 404,950 ​ $ 404,950 Term Loan B ​ 253,333 ​ 303,333 Total principal ​ 658,283 ​ 708,283 Unamortized debt discount and issuance costs ​ (9,571) ​ (13,206) Long-term debt ​ $ 648,712 ​ $ 695,077
Schedule of Maturities of Long-term Debt	Scheduled future maturities of long-term debt were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ Maturity Fiscal Year ​ Payments 2025 ​ $ — 2026 ​ — 2027 ​ — 2028 ​ 404,950 2029 ​ 253,333 Total ​ $ 658,283
Schedule Of Debt Issuance Costs	The following table summarizes the unamortized debt discount and issuance costs activity for fiscal year 2024 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Notes ​ Term Loan B ​ Revolver ​ Total Unamortized debt discount and issuance costs as of June 30, 2023 ​ $ 5,592 ​ $ 7,614 ​ $ 6,355 ​ $ 19,561 Amortization of debt discount and issuance costs ​ (1,146) ​ (1,376) ​ (2,028) ​ (4,550) Debt discount and issuance costs write-off ​ ​ — ​ ​ (1,113) ​ ​ — ​ ​ (1,113) Unamortized debt discount and issuance costs as of June 30, 2024 ​ $ 4,446 ​ $ 5,125 ​ $ 4,327 ​ $ 13,898
Schedule of components of interest expense	Interest expense consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Notes interest expense ​ $ 22,272 ​ $ 22,301 ​ $ 39,371 Term Loan B interest expense ​ ​ 26,324 ​ ​ 26,831 ​ ​ 33,413 Term Loan B ticking fees ​ ​ — ​ ​ — ​ ​ 5,330 Prior Term Loan B interest expense ​ ​ — ​ ​ — ​ ​ 1,272 Term Loan B debt discount and issuance costs write-off ​ ​ 1,113 ​ ​ 4,282 ​ ​ 12,471 Notes issuance costs write-off ​ ​ — ​ ​ 15 ​ ​ 6,771 Gain on extinguishment of debt ​ ​ — ​ ​ (71) ​ ​ (2,072) Unused bridge fee ​ ​ — ​ ​ — ​ ​ 10,329 Prior Credit Facility issuance costs write-off ​ ​ — ​ ​ — ​ ​ 6,000 Swap settlement ​ ​ — ​ ​ — ​ ​ 4,525 Amortization of debt discount and issuance costs ​ ​ 4,550 ​ ​ 4,832 ​ ​ 7,083 Letters of credit fees ​ ​ 8,639 ​ ​ 3,847 ​ ​ 3,968 Other ​ ​ 761 ​ ​ 1,063 ​ ​ 887 Total ​ $ 63,659 ​ $ 63,100 ​ $ 129,348

Share Repurchases (Tables)

Share Repurchases (Tables)	12 Months Ended
	Jun. 30, 2024
Treasury Stock, Number of Shares and Restriction Disclosures [Abstract]
Shares repurchased under programs	Adtalem made share repurchases under its share repurchase programs as follows, which includes the market price of the shares, commissions, and excise tax (in thousands, except shares and per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Total number of share repurchases ​ ​ 5,446,113 ​ ​ 3,207,036 ​ ​ — Total cost of share repurchases ​ $ 261,183 ​ $ 127,254 ​ $ — Average price paid per share ​ $ 47.96 ​ $ 39.68 ​ $ —

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	12 Months Ended
	Jun. 30, 2024
Comprehensive Income, Net Of Tax [Abstract]
Schedule of accumulated other comprehensive income loss	The following table shows the changes in accumulated other comprehensive loss by component (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Foreign currency translation adjustments ​ ​ ​ ​ ​ ​ ​ ​ ​ Beginning balance ​ $ (2,227) ​ $ (2,227) ​ $ (2,523) Reclassification from other comprehensive income ​ ​ — ​ ​ — ​ ​ 296 Ending balance ​ $ (2,227) ​ $ (2,227) ​ $ (2,227) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest rate swap ​ ​ ​ ​ ​ ​ ​ ​ ​ Beginning balance, gross ​ $ — ​ $ — ​ $ (8,926) Beginning balance, tax effect ​ ​ — ​ ​ — ​ ​ 2,231 Beginning balance, net of tax ​ ​ — ​ ​ — ​ ​ (6,695) Reclassification from other comprehensive income ​ ​ — ​ ​ — ​ ​ 6,695 Ending balance ​ $ — ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total ending balance ​ $ (2,227) ​ $ (2,227) ​ $ (2,227) ​

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Jun. 30, 2024
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Stock-based compensation expense	Stock-based compensation expense, which is included in student services and administrative expense, and the related income tax benefit were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Stock-based compensation ​ $ 25,947 ​ $ 14,299 ​ $ 22,611 Income tax benefit ​ (8,594) ​ (3,938) ​ (3,658) Stock-based compensation, net of tax ​ $ 17,353 ​ $ 10,361 ​ $ 18,953
Summary of Options Activity	The following table summarizes stock option activity for the year ended June 30, 2024: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ ​ ​ Number of ​ ​ ​ Remaining ​ Aggregate ​ ​ Stock ​ Weighted-Average ​ Contractual Life ​ Intrinsic Value ​ ​ Options ​ Exercise Price ​ (in years) ​ (in thousands) Outstanding as of June 30, 2023 1,045,801 ​ $ 36.02 ​ ​ ​ ​ Exercised (494,314) ​ ​ 34.57 ​ ​ ​ ​ Expired (1,144) ​ ​ 28.32 ​ ​ ​ ​ Outstanding as of June 30, 2024 550,343 ​ 37.34 6.0 ​ $ 16,989 Exercisable as of June 30, 2024 410,668 ​ $ 38.07 5.7 ​ $ 12,376
Fair Values of Stock Option Awards Estimated Weighted Average Assumptions	The fair value of Adtalem’s stock option grants was estimated assuming the following weighted-average assumptions: ​ ​ ​ ​ ​ ​ ​ Fiscal Year ​ ​ ​ 2022 ​ Expected life (in years) 6.56 Expected volatility 39.99 % Risk-free interest rate 0.94 % Dividend yield 0.00 %
Summary of Restricted Stock Units Activity	The following table summarizes RSU activity for the year ended June 30, 2024: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ Number of ​ Grant Date ​ ​ RSUs ​ Fair Value Unvested as of June 30, 2023 737,733 ​ $ 37.22 Granted 399,220 ​ 44.24 Vested (340,923) ​ 38.00 Forfeited (40,189) ​ 38.53 Unvested as of June 30, 2024 755,841 ​ $ 40.51
Summary of Performance Shares Unit Activity	The following table summarizes PSU activity for the year ended June 30, 2024: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ Number of ​ Grant Date ​ ​ PSUs ​ Fair Value Unvested as of June 30, 2023 490,300 ​ $ 35.17 Granted (1) 336,900 ​ 50.02 Vested (126,918) ​ 29.92 Forfeited (70,512) ​ 35.60 Unvested as of June 30, 2024 629,770 ​ $ 43.77 (1)

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
Tabulation of Business Segment Information Based on Current Segmentation	Summary financial information by reportable segment is as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Revenue: ​ ​ ​ ​ ​ ​ ​ ​ Chamberlain ​ $ 633,522 ​ $ 571,034 ​ $ 557,536 Walden ​ ​ 595,332 ​ ​ 533,725 ​ ​ 485,393 Medical and Veterinary ​ ​ 355,798 ​ ​ 346,067 ​ ​ 338,913 Total consolidated revenue ​ $ 1,584,652 ​ $ 1,450,826 ​ $ 1,381,842 Adjusted operating income: ​ ​ ​ ​ ​ ​ ​ ​ ​ Chamberlain ​ $ 137,800 ​ $ 135,503 ​ $ 127,252 Walden ​ ​ 130,547 ​ ​ 110,364 ​ ​ 104,582 Medical and Veterinary ​ ​ 71,507 ​ ​ 67,336 ​ ​ 69,148 Home Office ​ (31,076) ​ (25,633) ​ (33,380) Total consolidated adjusted operating income ​ ​ 308,778 ​ ​ 287,570 ​ ​ 267,602 Reconciliation to Consolidated Financial Statements: ​ ​ ​ ​ ​ ​ ​ ​ ​ Deferred revenue adjustment ​ ​ — ​ ​ — ​ ​ (8,561) CEO transition costs ​ ​ — ​ ​ — ​ ​ (6,195) Restructuring expense ​ (1,870) ​ (18,817) ​ (25,628) Business acquisition and integration expense ​ ​ (34,215) ​ (42,661) ​ (53,198) Amortization of acquired intangible assets: ​ ​ (35,644) ​ (61,239) ​ (97,274) Litigation reserve ​ ​ (18,500) ​ (10,000) ​ — Loss on assets held for sale ​ ​ (647) ​ — ​ — Debt modification costs ​ ​ (848) ​ — ​ — Gain on sale of assets ​ ​ — ​ 13,317 ​ — Total consolidated operating income ​ ​ 217,054 ​ ​ 168,170 ​ ​ 76,746 Interest expense ​ (63,659) ​ (63,100) ​ (129,348) Other income, net ​ 10,542 ​ 6,965 ​ 1,108 Total consolidated income (loss) from continuing operations before income taxes ​ $ 163,937 ​ $ 112,035 ​ $ (51,494) Capital expenditures: ​ ​ ​ ​ ​ ​ ​ ​ ​ Chamberlain ​ $ 26,293 ​ $ 13,934 ​ $ 15,235 Walden ​ ​ 5,889 ​ ​ 1,084 ​ ​ 5,393 Medical and Veterinary ​ ​ 5,708 ​ ​ 3,358 ​ ​ 3,277 Home Office ​ 11,003 ​ 7,638 ​ 7,149 Total consolidated capital expenditures ​ $ 48,893 ​ $ 26,014 ​ $ 31,054 Depreciation: ​ ​ ​ ​ ​ ​ ​ ​ ​ Chamberlain ​ $ 18,752 ​ $ 17,175 ​ $ 18,547 Walden ​ ​ 7,389 ​ ​ 9,419 ​ ​ 9,255 Medical and Veterinary ​ ​ 11,983 ​ ​ 12,438 ​ ​ 13,890 Home Office ​ 1,552 ​ 2,344 ​ 2,882 Total consolidated depreciation ​ $ 39,676 ​ $ 41,376 ​ $ 44,574 Amortization of acquired intangible assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Walden ​ $ 35,644 ​ $ 61,239 ​ $ 97,274 Total consolidated amortization of acquired intangible assets ​ $ 35,644 ​ $ 61,239 ​ $ 97,274 ​
Revenues and long-lived assets by geographic area	Revenue and long-lived assets by geographic area are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2024 ​ 2023 ​ 2022 Revenue by geographic area: ​ ​ ​ ​ ​ ​ ​ ​ Domestic operations ​ $ 1,228,854 ​ $ 1,104,759 ​ $ 1,042,929 Barbados, St. Kitts, and St. Maarten ​ 355,798 ​ 346,067 ​ 338,913 Total consolidated revenue ​ $ 1,584,652 ​ $ 1,450,826 ​ $ 1,381,842 Long-lived assets by geographic area: ​ ​ ​ ​ ​ ​ ​ ​ ​ Domestic operations ​ $ 283,597 ​ $ 256,268 ​ $ 289,129 Barbados, St. Kitts, and St. Maarten ​ 149,507 ​ 163,058 ​ 178,792 Total consolidated long-lived assets ​ $ 433,104 ​ $ 419,326 ​ $ 467,921

Revision of Previously Issued_2

Revision of Previously Issued Consolidated Financial Statements (Unaudited) (Tables)	12 Months Ended
	Jun. 30, 2024
Accounting Changes and Error Corrections [Abstract]
Effect of revision on affected line items within financial statements	The following table summarizes the effect of the revision on the affected line items within the Consolidated Balance Sheets (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2023 ​ ​ As Reported ​ Adjustment ​ As Revised Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 273,689 ​ $ (1,495) ​ $ 272,194 Restricted cash ​ ​ 1,386 ​ ​ 1,495 ​ ​ 2,881 Prepaid expenses and other current assets ​ ​ 100,715 ​ ​ 1,758 ​ ​ 102,473 Total current assets ​ ​ 478,539 ​ ​ 1,758 ​ ​ 480,297 Noncurrent assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Property and equipment, net ​ ​ 258,522 ​ ​ (13,873) ​ ​ 244,649 Other assets, net ​ ​ 68,509 ​ ​ 12,115 ​ ​ 80,624 Total noncurrent assets ​ ​ 2,332,002 ​ ​ (1,758) ​ ​ 2,330,244 The following table summarizes the effect of the revision on the affected line items within the Consolidated Statements of Cash Flows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2023 ​ ​ As Reported ​ Adjustment ​ As Revised Operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustments to reconcile net income to net cash provided by operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation ​ $ 41,575 ​ $ (199) ​ $ 41,376 Changes in assets and liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cloud computing implementation assets ​ ​ — ​ ​ (13,873) ​ ​ (13,873) Accounts payable ​ ​ 21,666 ​ ​ 3,078 ​ ​ 24,744 Net cash provided by operating activities-continuing operations ​ ​ 205,684 ​ ​ (10,994) ​ ​ 194,690 Net cash provided by operating activities ​ ​ 202,908 ​ ​ (10,994) ​ ​ 191,914 Investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures ​ ​ (37,008) ​ ​ 10,994 ​ ​ (26,014) Net cash provided by investing activities-continuing operations ​ ​ 15,919 ​ ​ 10,994 ​ ​ 26,913 Net cash provided by investing activities ​ ​ 12,745 ​ ​ 10,994 ​ ​ 23,739 Non-cash investing and financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued capital expenditures ​ ​ 8,203 ​ ​ (3,078) ​ ​ 5,125 ​ The following tables summarize the effect of the revision on the affected line items within the Consolidated Balance Sheets (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2024 ​ ​ As Reported ​ Adjustment ​ As Revised Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Prepaid expenses and other current assets ​ $ 59,401 ​ $ 4,183 ​ $ 63,584 Total current assets ​ ​ 387,634 ​ ​ 4,183 ​ ​ 391,817 Noncurrent assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Property and equipment, net ​ ​ 272,792 ​ ​ (33,135) ​ ​ 239,657 Other assets, net ​ ​ 67,768 ​ ​ 28,952 ​ ​ 96,720 Total noncurrent assets ​ ​ 2,327,400 ​ ​ (4,183) ​ ​ 2,323,217 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 ​ ​ As Reported ​ Adjustment ​ As Revised Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Prepaid expenses and other current assets ​ $ 58,356 ​ $ 3,010 ​ $ 61,366 Total current assets ​ ​ 378,099 ​ ​ 3,010 ​ ​ 381,109 Noncurrent assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Property and equipment, net ​ ​ 260,484 ​ ​ (25,187) ​ ​ 235,297 Other assets, net ​ ​ 65,852 ​ ​ 22,177 ​ ​ 88,029 Total noncurrent assets ​ ​ 2,322,826 ​ ​ (3,010) ​ ​ 2,319,816 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2023 ​ ​ As Reported ​ Adjustment ​ As Revised Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 262,438 ​ $ (1,612) ​ $ 260,826 Restricted cash ​ ​ 1,988 ​ ​ 1,612 ​ ​ 3,600 Prepaid expenses and other current assets ​ ​ 60,750 ​ ​ 2,103 ​ ​ 62,853 Total current assets ​ ​ 472,928 ​ ​ 2,103 ​ ​ 475,031 Noncurrent assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Property and equipment, net ​ ​ 264,766 ​ ​ (18,097) ​ ​ 246,669 Other assets, net ​ ​ 67,634 ​ ​ 15,994 ​ ​ 83,628 Total noncurrent assets ​ ​ 2,321,233 ​ ​ (2,103) ​ ​ 2,319,130 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2023 ​ ​ As Reported ​ Adjustment ​ As Revised Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 315,373 ​ $ (1,613) ​ $ 313,760 Restricted cash ​ ​ 1,804 ​ ​ 1,613 ​ ​ 3,417 Prepaid expenses and other current assets ​ ​ 102,573 ​ ​ 514 ​ ​ 103,087 Total current assets ​ ​ 533,034 ​ ​ 514 ​ ​ 533,548 Noncurrent assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Property and equipment, net ​ ​ 252,797 ​ ​ (6,234) ​ ​ 246,563 Other assets, net ​ ​ 67,618 ​ ​ 5,720 ​ ​ 73,338 Total noncurrent assets ​ ​ 2,334,083 ​ ​ (514) ​ ​ 2,333,569 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2022 ​ ​ As Reported ​ Adjustment ​ As Revised Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 207,776 ​ $ (1,492) ​ $ 206,284 Restricted cash ​ ​ 2,234 ​ ​ 1,492 ​ ​ 3,726 Prepaid expenses and other current assets ​ ​ 113,564 ​ ​ 1,081 ​ ​ 114,645 Total current assets ​ ​ 423,116 ​ ​ 1,081 ​ ​ 424,197 Noncurrent assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Property and equipment, net ​ ​ 275,617 ​ ​ (3,275) ​ ​ 272,342 Other assets, net ​ ​ 116,613 ​ ​ 3,043 ​ ​ 119,656 Total noncurrent assets ​ ​ 2,419,922 ​ ​ (232) ​ ​ 2,419,690 Total assets ​ ​ 2,843,038 ​ ​ 849 ​ ​ 2,843,887 Liabilities and shareholders' equity: ​ ​ ​ ​ ​ ​ ​ ​ ​ Current liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Deferred revenue ​ ​ 115,658 ​ ​ 5,177 ​ ​ 120,835 Total current liabilities ​ ​ 371,462 ​ ​ 5,177 ​ ​ 376,639 Noncurrent liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Other liabilities ​ ​ 61,901 ​ ​ 9,177 ​ ​ 71,078 Total noncurrent liabilities ​ ​ 948,854 ​ ​ 9,177 ​ ​ 958,031 Total liabilities ​ ​ 1,320,316 ​ ​ 14,354 ​ ​ 1,334,670 Shareholders' equity: ​ ​ ​ ​ ​ ​ ​ ​ ​ Retained earnings ​ ​ 2,349,146 ​ ​ (13,505) ​ ​ 2,335,641 Total shareholders' equity ​ ​ 1,522,722 ​ ​ (13,505) ​ ​ 1,509,217 Total liabilities and shareholders' equity ​ ​ 2,843,038 ​ ​ 849 ​ ​ 2,843,887 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2022 ​ ​ As Reported ​ Adjustment ​ As Revised Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 327,515 ​ $ (1,681) ​ $ 325,834 Restricted cash ​ ​ 2,480 ​ ​ 1,681 ​ ​ 4,161 Noncurrent assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Property and equipment, net ​ ​ 281,581 ​ ​ (416) ​ ​ 281,165 Other assets, net ​ ​ 120,630 ​ ​ 416 ​ ​ 121,046 ​ The following tables summarize the effect of the revision on the affected line items within the Consolidated Statements of Cash Flows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended March 31, 2024 ​ ​ As Reported ​ Adjustment ​ As Revised Operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustments to reconcile net income to net cash provided by operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation ​ $ 32,106 ​ $ (2,227) ​ $ 29,879 Changes in assets and liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cloud computing implementation assets ​ ​ — ​ ​ (19,262) ​ ​ (19,262) Accounts payable ​ ​ 10,841 ​ ​ 1,791 ​ ​ 12,632 Net cash provided by operating activities-continuing operations ​ ​ 246,809 ​ ​ (19,698) ​ ​ 227,111 Net cash provided by operating activities ​ ​ 255,205 ​ ​ (19,698) ​ ​ 235,507 Investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures ​ ​ (52,014) ​ ​ 19,698 ​ ​ (32,316) Net cash used in investing activities-continuing operations ​ ​ (51,886) ​ ​ 19,698 ​ ​ (32,188) Net cash used in investing activities ​ ​ (51,886) ​ ​ 19,698 ​ ​ (32,188) Non-cash investing and financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued capital expenditures ​ ​ 11,086 ​ ​ (4,869) ​ ​ 6,217 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended December 31, 2023 ​ ​ As Reported ​ Adjustment ​ As Revised Operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustments to reconcile net income to net cash provided by operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation ​ $ 20,714 ​ $ (1,333) ​ $ 19,381 Changes in assets and liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cloud computing implementation assets ​ ​ — ​ ​ (11,314) ​ ​ (11,314) Accounts payable ​ ​ 7,824 ​ ​ 1,931 ​ ​ 9,755 Net cash provided by operating activities-continuing operations ​ ​ 83,069 ​ ​ (10,716) ​ ​ 72,353 Net cash provided by operating activities ​ ​ 92,584 ​ ​ (10,716) ​ ​ 81,868 Investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures ​ ​ (30,328) ​ ​ 10,716 ​ ​ (19,612) Net cash used in investing activities-continuing operations ​ ​ (30,200) ​ ​ 10,716 ​ ​ (19,484) Net cash used in investing activities ​ ​ (30,200) ​ ​ 10,716 ​ ​ (19,484) Non-cash investing and financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued capital expenditures ​ ​ 9,062 ​ ​ (5,009) ​ ​ 4,053 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, 2023 ​ ​ As Reported ​ Adjustment ​ As Revised Operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustments to reconcile net income to net cash provided by operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation ​ $ 9,778 ​ $ (440) ​ $ 9,338 Changes in assets and liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cloud computing implementation assets ​ ​ — ​ ​ (4,224) ​ ​ (4,224) Accounts payable ​ ​ (2,870) ​ ​ 52 ​ ​ (2,818) Net cash provided by operating activities-continuing operations ​ ​ 90,726 ​ ​ (4,612) ​ ​ 86,114 Net cash provided by operating activities ​ ​ 99,685 ​ ​ (4,612) ​ ​ 95,073 Investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures ​ ​ (15,046) ​ ​ 4,612 ​ ​ (10,434) Net cash used in investing activities-continuing operations ​ ​ (14,946) ​ ​ 4,612 ​ ​ (10,334) Net cash used in investing activities ​ ​ (14,946) ​ ​ 4,612 ​ ​ (10,334) Non-cash investing and financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued capital expenditures ​ ​ 9,217 ​ ​ (3,130) ​ ​ 6,087 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended March 31, 2023 ​ ​ As Reported ​ Adjustment ​ As Revised Operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustments to reconcile net income to net cash provided by operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation ​ $ 31,618 ​ $ (112) ​ $ 31,506 Changes in assets and liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cloud computing implementation assets ​ ​ — ​ ​ (6,234) ​ ​ (6,234) Accounts payable ​ ​ 12,286 ​ ​ 1,483 ​ ​ 13,769 Net cash provided by operating activities-continuing operations ​ ​ 149,821 ​ ​ (4,863) ​ ​ 144,958 Net cash provided by operating activities ​ ​ 149,417 ​ ​ (4,863) ​ ​ 144,554 Investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures ​ ​ (19,056) ​ ​ 4,863 ​ ​ (14,193) Net cash provided by investing activities-continuing operations ​ ​ 33,871 ​ ​ 4,863 ​ ​ 38,734 Net cash provided by investing activities ​ ​ 30,697 ​ ​ 4,863 ​ ​ 35,560 Non-cash investing and financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued capital expenditures ​ ​ 10,474 ​ ​ (1,483) ​ ​ 8,991 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended December 31, 2022 ​ ​ As Reported ​ Adjustment ​ As Revised Operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustments to reconcile net income to net cash provided by operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation ​ $ 21,461 ​ $ (34) ​ $ 21,427 Changes in assets and liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cloud computing implementation assets ​ ​ — ​ ​ (3,275) ​ ​ (3,275) Accounts payable ​ ​ 13,233 ​ ​ 475 ​ ​ 13,708 Net cash provided by operating activities-continuing operations ​ ​ 42,277 ​ ​ (2,834) ​ ​ 39,443 Net cash provided by operating activities ​ ​ 41,415 ​ ​ (2,834) ​ ​ 38,581 Investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures ​ ​ (9,747) ​ ​ 2,834 ​ ​ (6,913) Net cash used in investing activities-continuing operations ​ ​ (9,748) ​ ​ 2,834 ​ ​ (6,914) Net cash used in investing activities ​ ​ (12,922) ​ ​ 2,834 ​ ​ (10,088) Non-cash investing and financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued capital expenditures ​ ​ 5,209 ​ ​ (475) ​ ​ 4,734 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, 2022 ​ ​ As Reported ​ Adjustment ​ As Revised Operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Changes in assets and liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cloud computing implementation assets ​ $ — ​ $ (416) ​ $ (416) Accounts payable ​ ​ 8,711 ​ ​ 243 ​ ​ 8,954 Net cash provided by operating activities-continuing operations ​ ​ 91,476 ​ ​ (173) ​ ​ 91,303 Net cash provided by operating activities ​ ​ 91,346 ​ ​ (173) ​ ​ 91,173 Investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures ​ ​ (5,551) ​ ​ 173 ​ ​ (5,378) Net cash used in investing activities-continuing operations ​ ​ (5,503) ​ ​ 173 ​ ​ (5,330) Net cash used in investing activities ​ ​ (6,314) ​ ​ 173 ​ ​ (6,141) Non-cash investing and financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued capital expenditures ​ ​ 4,713 ​ ​ (243) ​ ​ 4,470 ​

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Business acquisition and integration expense	$ 34,215	$ 42,661	$ 53,198
Brokerage commissions and administrative fees, percentage	10%
Advertising expense	$ 227,900	219,400	190,700
Minimum
Finite live intangible assets amortization period	3 years
Maximum
Finite live intangible assets amortization period	5 years
Curriculum
Finite live intangible assets amortization period	5 years
Curriculum | Minimum
Finite live intangible assets amortization period	3 years
Curriculum | Maximum
Finite live intangible assets amortization period	5 years
Cloud Computing Arrangements
Finite live intangible assets amortization period	5 years
Walden University, LLC
Business acquisition and integration expense	$ 34,200	$ 42,700	$ 53,200

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Effect of Revision on Affected Line Items Within Consolidated Balance Sheets) (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022
Current assets:
Cash and cash equivalents	$ 219,306			$ 260,826	$ 272,194	$ 313,760	$ 206,284	$ 325,834
Restricted cash	1,896			3,600	2,881	3,417	3,726	4,161
Prepaid expenses and other current assets	70,050	$ 63,584	$ 61,366	62,853	102,473	103,087	114,645
Total current assets	418,085	391,817	381,109	475,031	480,297	533,548	424,197
Noncurrent assets:
Property and equipment, net	248,524	239,657	235,297	246,669	244,649	246,563	272,342	281,165
Other assets, net	103,184	96,720	88,029	83,628	80,624	73,338	119,656	121,046
Total noncurrent assets	$ 2,323,332	2,323,217	2,319,816	2,319,130	2,330,244	2,333,569	2,419,690
As Reported
Current assets:
Cash and cash equivalents				262,438	273,689	315,373	207,776	327,515
Restricted cash				1,988	1,386	1,804	2,234	2,480
Prepaid expenses and other current assets		59,401	58,356	60,750	100,715	102,573	113,564
Total current assets		387,634	378,099	472,928	478,539	533,034	423,116
Noncurrent assets:
Property and equipment, net		272,792	260,484	264,766	258,522	252,797	275,617	281,581
Other assets, net		67,768	65,852	67,634	68,509	67,618	116,613	120,630
Total noncurrent assets		2,327,400	2,322,826	2,321,233	2,332,002	2,334,083	2,419,922
Adjustment
Current assets:
Cash and cash equivalents				(1,612)	(1,495)	(1,613)	(1,492)	(1,681)
Restricted cash				1,612	1,495	1,613	1,492	1,681
Prepaid expenses and other current assets		4,183	3,010	2,103	1,758	514	1,081
Total current assets		4,183	3,010	2,103	1,758	514	1,081
Noncurrent assets:
Property and equipment, net		(33,135)	(25,187)	(18,097)	(13,873)	(6,234)	(3,275)	(416)
Other assets, net		28,952	22,177	15,994	12,115	5,720	3,043	$ 416
Total noncurrent assets		$ (4,183)	$ (3,010)	$ (2,103)	$ (1,758)	$ (514)	$ (232)

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Effect of Revision on Affected Line Items Within Consolidated Statements of Cash Flows) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2024	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	$ 9,338		$ 19,381	$ 21,427	$ 29,879	$ 31,506	$ 39,676	$ 41,376	$ 44,574
Changes in assets and liabilities:
Cloud computing implementation assets	(4,224)	$ (416)	(11,314)	(3,275)	(19,262)	(6,234)	(27,154)	(13,873)	0
Accounts payable	(2,818)	8,954	9,755	13,708	12,632	13,769	18,330	24,744	(15,724)
Net cash provided by operating activities-continuing operations	86,114	91,303	72,353	39,443	227,111	144,958	288,367	194,690	164,002
Net cash provided by operating activities	95,073	91,173	81,868	38,581	235,507	144,554	295,775	191,914	10,601
Investing activities:
Capital expenditures	(10,434)	(5,378)	(19,612)	(6,913)	(32,316)	(14,193)	(48,893)	(26,014)	(31,054)
Net cash used in investing activities-continuing operations	(10,334)	(5,330)	(19,484)	(6,914)	(32,188)	38,734	(47,850)	26,913	(1,509,285)
Net cash used in investing activities	(10,334)	(6,141)	(19,484)	(10,088)	(32,188)	35,560	(47,850)	23,739	(551,804)
Non-cash investing and financing activities:
Accrued capital expenditures	6,087	4,470	4,053	4,734	6,217	8,991	$ 8,718	5,125	$ 4,321
As Reported
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	9,778		20,714	21,461	32,106	31,618		41,575
Changes in assets and liabilities:
Cloud computing implementation assets								0
Accounts payable	(2,870)	8,711	7,824	13,233	10,841	12,286		21,666
Net cash provided by operating activities-continuing operations	90,726	91,476	83,069	42,277	246,809	149,821		205,684
Net cash provided by operating activities	99,685	91,346	92,584	41,415	255,205	149,417		202,908
Investing activities:
Capital expenditures	(15,046)	(5,551)	(30,328)	(9,747)	(52,014)	(19,056)		(37,008)
Net cash used in investing activities-continuing operations	(14,946)	(5,503)	(30,200)	(9,748)	(51,886)	33,871		15,919
Net cash used in investing activities	(14,946)	(6,314)	(30,200)	(12,922)	(51,886)	30,697		12,745
Non-cash investing and financing activities:
Accrued capital expenditures	9,217	4,713	9,062	5,209	11,086	10,474		8,203
Adjustment
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	(440)		(1,333)	(34)	(2,227)	(112)		(199)
Changes in assets and liabilities:
Cloud computing implementation assets	(4,224)	(416)	(11,314)	(3,275)	(19,262)	(6,234)		(13,873)
Accounts payable	52	243	1,931	475	1,791	1,483		3,078
Net cash provided by operating activities-continuing operations	(4,612)	(173)	(10,716)	(2,834)	(19,698)	(4,863)		(10,994)
Net cash provided by operating activities	(4,612)	(173)	(10,716)	(2,834)	(19,698)	(4,863)		(10,994)
Investing activities:
Capital expenditures	4,612	173	10,716	2,834	19,698	4,863		10,994
Net cash used in investing activities-continuing operations	4,612	173	10,716	2,834	19,698	4,863		10,994
Net cash used in investing activities	4,612	173	10,716	2,834	19,698	4,863		10,994
Non-cash investing and financing activities:
Accrued capital expenditures	$ (3,130)	$ (243)	$ (5,009)	$ (475)	$ (4,869)	$ (1,483)		$ (3,078)

Acquisitions (Estimated Fair Va

Acquisitions (Estimated Fair Values of Assets Acquired and Liabilities Assumed) (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023	Aug. 12, 2021
Assets acquired:
Goodwill	$ 961,262	$ 961,262
Walden University, LLC
Assets acquired:
Cash and cash equivalents			$ 65,010
Restricted cash			18,389
Accounts and financing receivables			22,091
Prepaid expenses and other current assets			8,819
Property and equipment			25,882
Operating lease assets			6,096
Deferred income taxes			59
Intangible assets			833,351
Goodwill			651,052
Other assets, net			21,316
Total assets acquired			1,652,065
Liabilities assumed:
Accounts payable			31,971
Accrued payroll and benefits			25,639
Accrued liabilities			1,620
Deferred revenue			10,958
Current operating lease liabilities			1,983
Long-term operating lease liabilities			4,343
Other liabilities			4,098
Total liabilities assumed			80,612
Net assets acquired			$ 1,571,453

Acquisitions (Acquired Intangib

Acquisitions (Acquired Intangible Assets Subject to Amortization and Values and Estimated Useful Lives) (Details) - Walden University, LLC $ in Thousands	Aug. 12, 2021 USD ($)
Student Relationships
Business Acquisition [Line Items]
Intangible assets, finite lived	$ 161,900
Amortizable intangible assets, estimated useful lives	3 years
Curriculum
Business Acquisition [Line Items]
Intangible assets, finite lived	$ 56,091
Amortizable intangible assets, estimated useful lives	5 years

Acquisitions (Unaudited Proform

Acquisitions (Unaudited Proforma Financial Information) (Details) $ in Thousands	12 Months Ended
	Jun. 30, 2022 USD ($)
Unaudited pro forma financial information
Revenue	$ 1,451,081
Net income	$ 385,110

Acquisitions (Additional Inform

Acquisitions (Additional Information) (Details) $ in Thousands		12 Months Ended
	Aug. 12, 2021 USD ($) item	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)
Business Acquisition [Line Items]
Payments to acquire business		$ 0	$ 0	$ 1,488,054
Long-term debt, gross		658,283	708,283
Senior Secured Notes Due 2028
Business Acquisition [Line Items]
Long-term debt, gross		404,950	404,950
Term B Loan
Business Acquisition [Line Items]
Long-term debt, gross		$ 253,333	$ 303,333
Walden University, LLC
Business Acquisition [Line Items]
Percentage of voting interests acquired	100%
Payments to acquire business	$ 1,488,100
Cash acquired from acquisition	$ 83,400
Minimum number of courses offered | item	100
Revenue				485,400
Net loss				(3,900)
Acquisition costs				$ 22,300
Fair value of acquired accounts receivable	$ 22,100
Gross amount due under contracts	37,900
Expected uncollectible	15,800
Intangible assets	833,351
Walden University, LLC | Senior Secured Notes Due 2028
Business Acquisition [Line Items]
Long-term debt, gross	800,000
Walden University, LLC | Term B Loan
Business Acquisition [Line Items]
Long-term debt, gross	850,000
Walden University, LLC | Walden Title IV eligibility and accreditations
Business Acquisition [Line Items]
Intangible assets, indefinite lived	495,800
Walden University, LLC | Trade Name
Business Acquisition [Line Items]
Intangible assets	$ 119,600

Discontinued Operations (Additi

Discontinued Operations (Additional Information) (Details) - USD ($) $ in Thousands			3 Months Ended	12 Months Ended			36 Months Ended
	Mar. 10, 2022	Dec. 11, 2018	Mar. 31, 2022	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2024	Jun. 17, 2022
Earn Out Received				$ 5,500	$ 4,100	$ 2,900	$ 12,500
Loan payment received				0	46,800	0
(Loss) gain on disposal of discontinued operations before income taxes				$ 0	(3,576)	$ 473,483
Wendel Group and Colibri Group | Equity Purchase Agreement
Sale of stock	$ 962,700
Cash balance	$ 21,500
DeVry University
Earn Out Maximum		$ 20,000
Earn Out Term		10 years
Receivable with Imputed Interest, Face Amount		$ 10,000
Receivable with Imputed Interest, Effective Yield (Interest Rate)		4%
Receivable with Imputed Interest, Due Date		Jan. 01, 2022
Loan payment received			$ 10,000
EduPristine | Wendel Group and Colibri Group | Equity Purchase Agreement
Cash Transferred Out From Divestitures Of Discontinued Operation								$ 1,900
Association of Certified Anti-Money Laundering Specialists | Wendel Group and Colibri Group | Equity Purchase Agreement
(Loss) gain on disposal of discontinued operations before income taxes					$ (3,600)

Discontinued Operations (Summar

Discontinued Operations (Summary of Income Statement Information of Operations) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Discontinued Operations And Disposal Groups [Abstract]
Revenue	$ 0	$ 0	$ 153,762
Operating cost and expense:
Cost of educational services	0	0	26,996
Student services and administrative expense	762	8,464	126,252
Restructuring expense	0	0	1,500
Total operating cost and expense	762	8,464	154,748
Loss from discontinued operations before income taxes	(762)	(8,464)	(986)
(Loss) gain on disposal of discontinued operations before income taxes	0	(3,576)	473,483
(Provision for) benefit from income taxes	(174)	3,646	(125,551)
(Loss) income from discontinued operations	$ (936)	$ (8,394)	$ 346,946

Revenue (Disaggregate revenue)

Revenue (Disaggregate revenue) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Disaggregation of Revenue [Line Items]
Revenue	$ 1,584,652	$ 1,450,826	$ 1,381,842
Tuition and fees
Disaggregation of Revenue [Line Items]
Revenue	1,571,243	1,439,082	1,371,311
Other
Disaggregation of Revenue [Line Items]
Revenue	13,409	11,744	10,531
Chamberlain
Disaggregation of Revenue [Line Items]
Revenue	633,522	571,034	557,536
Chamberlain | Tuition and fees
Disaggregation of Revenue [Line Items]
Revenue	633,522	571,034	557,536
Chamberlain | Other
Disaggregation of Revenue [Line Items]
Revenue	0	0	0
Walden
Disaggregation of Revenue [Line Items]
Revenue	595,332	533,725	485,393
Walden | Tuition and fees
Disaggregation of Revenue [Line Items]
Revenue	595,332	533,725	485,393
Walden | Other
Disaggregation of Revenue [Line Items]
Revenue	0	0	0
Medical and Veterinary
Disaggregation of Revenue [Line Items]
Revenue	355,798	346,067	338,913
Medical and Veterinary | Tuition and fees
Disaggregation of Revenue [Line Items]
Revenue	342,389	334,323	328,382
Medical and Veterinary | Other
Disaggregation of Revenue [Line Items]
Revenue	$ 13,409	$ 11,744	$ 10,531

Revenue (Additional Information

Revenue (Additional Information) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Deferred revenue, current	$ 185,272	$ 153,871	$ 120,835
Deferred revenue, non-current	19,600	10,400
Revenue recognized included in the deferred revenue	153,900	149,800
Deferred revenue, current
Disaggregation of Revenue [Line Items]
Contract liability, current	24,100	10,600
Other Liabilities
Disaggregation of Revenue [Line Items]
Contract liability, non-current	$ 19,600	$ 10,400

Restructuring Expense (Restruct

Restructuring Expense (Restructuring and Related Costs) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring expense	$ 1,870	$ 18,817	$ 25,628
Home Office
Restructuring Cost and Reserve [Line Items]
Restructuring expense	2,204	7,067	8,946
Operating Segments [Member] | Chamberlain.
Restructuring Cost and Reserve [Line Items]
Restructuring expense		818	2,838
Operating Segments [Member] | Walden
Restructuring Cost and Reserve [Line Items]
Restructuring expense	(776)	3,245	4,053
Operating Segments [Member] | Medical and Veterinary
Restructuring Cost and Reserve [Line Items]
Restructuring expense	442	7,687	9,791
Real Estate and Other
Restructuring Cost and Reserve [Line Items]
Restructuring expense	1,830	17,197	14,487
Real Estate and Other | Home Office
Restructuring Cost and Reserve [Line Items]
Restructuring expense	2,204	6,117	5,977
Real Estate and Other | Operating Segments [Member] | Chamberlain.
Restructuring Cost and Reserve [Line Items]
Restructuring expense		818	835
Real Estate and Other | Operating Segments [Member] | Walden
Restructuring Cost and Reserve [Line Items]
Restructuring expense	(776)	3,191
Real Estate and Other | Operating Segments [Member] | Medical and Veterinary
Restructuring Cost and Reserve [Line Items]
Restructuring expense	402	7,071	7,675
Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring expense	40	1,620	11,141
Termination Benefits | Home Office
Restructuring Cost and Reserve [Line Items]
Restructuring expense	0	950	2,969
Termination Benefits | Operating Segments [Member] | Chamberlain.
Restructuring Cost and Reserve [Line Items]
Restructuring expense			2,003
Termination Benefits | Operating Segments [Member] | Walden
Restructuring Cost and Reserve [Line Items]
Restructuring expense	0	54	4,053
Termination Benefits | Operating Segments [Member] | Medical and Veterinary
Restructuring Cost and Reserve [Line Items]
Restructuring expense	$ 40	$ 616	$ 2,116

Restructuring Expense (Separati

Restructuring Expense (Separation and Restructuring Plan Activity) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Restructuring and Related Activities [Abstract]
Liability beginning balance	$ 741	$ 813
Increase in liability (separation and other charges)	40	1,620
Reduction in liability (payments and adjustments)	$ (781)	(1,692)
Liability ending balance		$ 741

Other Income, Net (Additional I

Other Income, Net (Additional Information) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Other Income and Expenses [Abstract]
Interest and dividend income	$ 9,177	$ 10,654	$ 4,379
Investment gain (loss)	1,365	(3,689)	(3,271)
Other income, net	$ 10,542	$ 6,965	$ 1,108

Other Income, Net - Impairment

Other Income, Net - Impairment (Details) $ in Millions	12 Months Ended
	Jun. 30, 2023 USD ($)
Other Income
Other Income (Expense), Net
Impairment on equity investment	$ 5

Income Taxes (Components of Inc

Income Taxes (Components of Income Before Income Taxes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Domestic	$ 89,752	$ 51,422	$ (112,151)
Foreign	74,185	60,613	60,657
Income (loss) from continuing operations before income taxes	$ 163,937	$ 112,035	$ (51,494)

Income Taxes (Income Tax Provis

Income Taxes (Income Tax Provisions (Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Current tax provision (benefit):
U.S. federal	$ 11,243	$ 13,761	$ (6,767)
State and local	3,489	824	4,154
Foreign	419	614	725
Total current	15,151	15,199	(1,888)
Deferred tax provision (benefit):
U.S. federal	4,870	(1,099)	(6,425)
State and local	2,745	(4,347)	(6,597)
Foreign	3,458	530	(629)
Total deferred	11,073	(4,916)	(13,651)
Provision for (benefit from) income taxes	$ 26,224	$ 10,283	$ (15,539)

Income Taxes (Income Tax Prov_2

Income Taxes (Income Tax Provisions Computed using Statutory U.S. Federal Rate) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income tax at statutory rate	$ 34,427	$ 23,527	$ (10,814)
Lower rates on foreign operations	(11,419)	(11,668)	(12,879)
State income taxes	4,557	2,719	(661)
Loss on investment in subsidiary	0	0	(1,669)
Deferred tax benefit from acquisitions and divestitures	0	0	(1,153)
Research and development tax credits	(1,589)	(1,862)	0
Change in valuation allowance	(621)	(9,769)	5,406
Reduction in state loss carryforwards	0	2,340	(5,882)
Permanent non-deductible items	2,293	1,630	2,788
Foreign tax provisions under GILTI	4,908	3,569	8,581
Change in unrecognized tax benefits	(6,849)	791	56
Other	517	(994)	688
Provision for (benefit from) income taxes	$ 26,224	$ 10,283	$ (15,539)
Income tax at statutory rate	21%	21%	21%
Lower rates on foreign operations	(7.00%)	(10.40%)	25%
State income taxes	2.80%	2.40%	1.30%
Loss on investment in subsidiary	0%	0%	3.20%
Deferred tax benefit from acquisitions and divestitures	0%	0%	2.20%
Research and development tax credits	(1.00%)	(1.70%)	0%
Change in valuation allowance	(0.40%)	(8.70%)	(10.50%)
Reduction in state loss carryforwards	0%	2.10%	11.40%
Permanent non-deductible items	1.40%	1.50%	(5.40%)
Foreign tax provisions under GILTI	3%	3.20%	16.70%
Change in unrecognized tax benefits	(4.20%)	0.70%	(0.10%)
Other	0.30%	(0.90%)	(1.30%)
Provision for (benefit from) income taxes	16%	9.20%	30.20%

Income Taxes (Deferred Income T

Income Taxes (Deferred Income Tax Asset (Liabilities) (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Employee benefits	$ 15,866	$ 11,719
Stock-based compensation	7,664	7,310
Receivable reserve	9,028	6,246
Capitalized research and experimental costs	9,322	8,075
Operating lease liabilities	42,526	41,235
Other reserves	12,439	6,246
Loss and credit carryforwards, net	15,426	19,259
Less: valuation allowance	0	(621)	$ (10,390)	$ (4,985)
Gross deferred tax assets	112,271	99,469
Depreciation	(8,298)	(5,643)
Deferred taxes on unremitted foreign earnings	(210)	(428)
Amortization of intangible assets	(50,035)	(31,294)
Operating lease assets	(34,166)	(31,478)
Gross deferred tax liability	(92,709)	(68,843)
Net deferred tax asset	$ 19,562	$ 30,626

Income Taxes (Tax Net Operating

Income Taxes (Tax Net Operating Loss (Tax Effected) and Credit Carryforwards) (Details) $ in Thousands	12 Months Ended
	Jun. 30, 2024 USD ($)
Gross Deferred Tax Assets	$ 15,426
Domestic Tax Authority [Member]
Tax credit carryforwards	$ 672
Tax Credit Carryforward Expiration Period Start	2027
Tax Credit Carryforward Expiration Period End	2030
U.S. Interest Expense Carryforwards	$ 506
State [Member]
Tax credit carryforwards	130
U.S. Net Operating Loss Carryforwards	$ 9,053
U.S. Net Operating Loss Carryforwards Expiration Period Start	2025
U.S. Net Operating Loss Carryforwards Expiration Period End	2043
U.S. Interest Expense Carryforwards	$ 592
Foreign [Member]
U.S. Net Operating Loss Carryforwards	$ 4,473
U.S. Net Operating Loss Carryforwards Expiration Period Start	2030
U.S. Net Operating Loss Carryforwards Expiration Period End	2033

Income Taxes (Changes in Valuat

Income Taxes (Changes in Valuation Allowances) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Balance at beginning of period	$ 621	$ 10,390	$ 4,985
Charged to costs and expenses		(2,677)	5,522
Deductions	(621)	(7,092)	(117)
Balance at end of period	$ 0	$ 621	$ 10,390

Income Taxes (Changes in Unreco

Income Taxes (Changes in Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Balance at beginning of period	$ 13,128	$ 11,645	$ 9,836
Increases from positions taken during prior periods	953	1,299	1,074
Decreases from positions taken during prior periods	(1,248)		(1,737)
Increases from positions taken during the current period	554	665	2,845
Reductions due to lapse of statute	(6,664)	(481)	(373)
Balance at end of period	$ 6,723	$ 13,128	$ 11,645

Income Taxes (Additional Inform

Income Taxes (Additional Information) (Details) $ in Thousands	12 Months Ended
	Jun. 30, 2024 USD ($) item	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)
Income Tax Disclosure [Abstract]
Deferred tax assets, operating loss carryforwards, state and local	$ 164,400	$ 190,800
Deferred tax assets, operating loss carryforwards, foreign	$ 13,000	17,300
Number of operating units local tax incentives | item	2
Valuation Allowance	$ 0	621	$ 10,390	$ 4,985
Valuation allowance decreased amount	$ 600	$ 9,800
Effective tax rates from continuing operations	16%	9.20%	30.20%
U.S. federal corporate tax rate	21%	21%	21%
Unrecognized tax benefits that would impact effective tax rate	$ 6,700	$ 13,100
Unrecognized tax benefits, income tax penalties and interest accrued	1,200	1,600
Income tax examination, increase (decrease) in liability	$ (400)	$ 700	$ 300

Earnings per Share (Details)

Earnings per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022	Mar. 14, 2022
Numerator:
Continuing operations	$ 137,713	$ 101,752	$ (35,955)
Discontinued operations	(936)	(8,394)	346,946
Net income	$ 136,777	$ 93,358	$ 310,991
Denominator:
Weighted-average basic shares outstanding	39,413	44,781	48,388
Effect of dilutive stock awards	894	743	0
Effect of ASR		76
Weighted-average diluted shares outstanding	40,307	45,600	48,388
Basic:
Continuing operations (In dollars per share)	$ 3.49	$ 2.27	$ (0.74)
Discontinued operations (In dollars per share)	(0.02)	(0.19)	7.17
Total basic earnings per share (In dollar per share)	3.47	2.08	6.43
Diluted:
Continuing operations (In dollars per share)	3.42	2.23	(0.74)
Discontinued operations (In dollars per share)	(0.02)	(0.18)	7.17
Total diluted earnings per share (In dollars per share)	$ 3.39	$ 2.05	$ 6.43
Weighted-average anti-dilutive shares			416
Authorized amount for repurchase				$ 150,000
Weighted Average
Diluted:
Weighted-average anti-dilutive shares	115	403	1,869

Accounts and Financing Receiv_3

Accounts and Financing Receivables (Classification of Accounts and Financing Receivable) (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]
Accounts receivables, current - Gross	$ 159,406	$ 129,318
Accounts receivables, current - Allowance	(35,336)	(29,190)
Accounts receivables, current - Net	124,070	100,128
Financing Receivable, after Allowance for Credit Loss, Current [Abstract]
Financing receivables, current - Gross	5,239	4,757
Financing receivables, current - Allowance	(2,476)	(2,136)
Financing receivables, current - Net	2,763	2,621
Accounts Receivable, after Allowance for Credit Loss [Abstract]
Accounts and financing receivables, current - Gross	164,645	134,075
Accounts and financing receivables, current - Allowance	(37,812)	(31,326)
Accounts and financing receivables, current - Net	126,833	102,749
Financing Receivable, after Allowance for Credit Loss, Noncurrent [Abstract]
Financing receivables, noncurrent - Gross	36,214	36,368
Financing receivables, noncurrent - Allowance	(10,082)	(9,332)
Financing receivables, noncurrent - Net	26,132	27,036
Financing Receivable, after Allowance for Credit Loss [Abstract]
Total financing receivables	41,453	41,125
Total financing receivables - Allowance	(12,558)	(11,468)	$ (14,891)	$ (16,832)
Total financing receivables - Net	$ 28,895	$ 29,657

Accounts and Financing Receiv_4

Accounts and Financing Receivables (Credit Quality Analysis of Financing Receivable) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Financing Receivable, Credit Quality Indicator [Line Items]
Total financing receivables	$ 41,453	$ 41,125
Gross write-offs Prior	1,145
Gross write-offs Four Years Before	279
Gross write-offs Three Years Before	509
Gross write-offs Two Years Before	597
Gross write-offs Year Before	729
Gross write-offs Origination Year	2
Gross write-offs	3,261	7,653	$ 5,287
Financing Receivables 1 To 30 Days Past Due
Financing Receivable, Credit Quality Indicator [Line Items]
Prior	552	186
Four Years Before		79
Three Years Before	214	115
Two Years Before	111	137
Year Before	1,188	735
Origination Year	1,146	1,944
Total financing receivables	3,211	3,196
Financing Receivables 31 To 60 Days Past Due
Financing Receivable, Credit Quality Indicator [Line Items]
Prior	213	61
Four Years Before	90	34
Three Years Before	65
Two Years Before	37	359
Year Before	567	573
Origination Year	1,488	1,103
Total financing receivables	2,460	2,130
Financing Receivables 61 To 90 Days Past Due
Financing Receivable, Credit Quality Indicator [Line Items]
Prior	174	97
Four Years Before		39
Three Years Before	5	110
Two Years Before	110	65
Year Before	370	559
Origination Year	257	368
Total financing receivables	916	1,238
Financing Receivables 91 To 120 Days Past Due
Financing Receivable, Credit Quality Indicator [Line Items]
Prior		2
Four Years Before	11	17
Three Years Before	434	2
Two Years Before	20	13
Year Before	206	77
Origination Year	791	200
Total financing receivables	1,462	311
Financing Receivables 121 To 150 Days Past Due
Financing Receivable, Credit Quality Indicator [Line Items]
Prior	51	62
Four Years Before	88	37
Three Years Before	63	26
Two Years Before	314	45
Year Before	268	147
Origination Year	91	129
Total financing receivables	875	446
Financing Receivables Greater Than 150 Days Past Due
Financing Receivable, Credit Quality Indicator [Line Items]
Prior	2,556	2,641
Four Years Before	466	734
Three Years Before	1,366	708
Two Years Before	1,300	2,071
Year Before	1,920	1,457
Origination Year	987	381
Total financing receivables	8,595	7,992
Financial Asset, Past Due
Financing Receivable, Credit Quality Indicator [Line Items]
Prior	3,546	3,049
Four Years Before	655	940
Three Years Before	2,147	961
Two Years Before	1,892	2,690
Year Before	4,519	3,548
Origination Year	4,760	4,125
Total financing receivables	17,519	15,313
Financing Receivable Current
Financing Receivable, Credit Quality Indicator [Line Items]
Prior	6,014	6,199
Four Years Before	748	1,112
Three Years Before	3,944	820
Two Years Before	1,897	5,350
Year Before	4,549	2,608
Origination Year	6,782	9,723
Total financing receivables	23,934	25,812
Financing Receivable Gross
Financing Receivable, Credit Quality Indicator [Line Items]
Prior	9,560	9,248
Four Years Before	1,403	2,052
Three Years Before	6,091	1,781
Two Years Before	3,789	8,040
Year Before	9,068	6,156
Origination Year	11,542	13,848
Total financing receivables	$ 41,453	$ 41,125

Accounts and Financing Receiv_5

Accounts and Financing Receivables (Roll-forward of Allowances for Credit Losses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Accounts
Beginning balance	$ 29,190	$ 30,897	$ 11,559
Write-offs	(54,897)	(43,273)	(15,980)
Recoveries	10,806	12,207	11,488
Provision for credit losses	50,237	29,359	23,830
Ending balance	35,336	29,190	30,897
Financing
Beginning balance	11,468	14,891	16,832
Write-offs	(3,261)	(7,653)	(5,287)
Recoveries	1,413	590	35
Provision for credit losses	2,938	3,640	3,311
Ending balance	12,558	11,468	14,891
Allowance for credit losses
Beginning balance	40,658	45,788	28,391
Write-offs	(58,158)	(50,926)	(21,267)
Recoveries	12,219	12,797	11,523
Provision for credit losses	53,175	32,999	27,141
Ending balance	$ 47,894	$ 40,658	$ 45,788

Accounts and Financing Receiv_6

Accounts and Financing Receivables (Additional Information) (Details) - USD ($) $ in Thousands			3 Months Ended	12 Months Ended
	Jul. 31, 2019	Dec. 11, 2018	Mar. 31, 2022	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Financing Receivables [Line Items]
Loan payment received				$ 0	$ 46,800	$ 0
Minimum
Financing Receivables [Line Items]
Receivable with Imputed Interest, Effective Yield (Interest Rate)				3%
Maximum
Financing Receivables [Line Items]
Receivable with Imputed Interest, Effective Yield (Interest Rate)				12%
DeVry University
Financing Receivables [Line Items]
Receivable with Imputed Interest, Face Amount		$ 10,000
Receivable with Imputed Interest, Effective Yield (Interest Rate)		4%
Receivable with Imputed Interest, Due Date		Jan. 01, 2022
Loan payment received			$ 10,000
Chicago, Illinois Campus | Discontinued Operations, Disposed of by Sale
Financing Receivables [Line Items]
Receivable with Imputed Interest, Face Amount	$ 46,800
Receivable with Imputed Interest, Effective Yield (Interest Rate)	4%
Receivable with Imputed Interest, Due Date	Jul. 31, 2024
Future Cash Flows Discounting Rate	7%
Loan payment received					$ 46,800

Property and Equipment, Net (Sc

Property and Equipment, Net (Schedule of Property and equipment, net) (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022
Property and Equipment, Net
Property and equipment, gross	$ 574,803				$ 583,278
Accumulated depreciation	(326,279)				(338,629)
Property and equipment, net	248,524	$ 239,657	$ 235,297	$ 246,669	244,649	$ 246,563	$ 272,342	$ 281,165
Land
Property and Equipment, Net
Property and equipment, gross	31,776				35,956
Buildings and improvements
Property and Equipment, Net
Property and equipment, gross	$ 200,274				$ 206,349
Buildings and improvements | Minimum
Property and Equipment, Net
Useful life of assets	10 years				10 years
Buildings and improvements | Maximum
Property and Equipment, Net
Useful life of assets	31 years				31 years
Leasehold improvements
Property and Equipment, Net
Property and equipment, gross	$ 114,019				$ 99,777
Furniture and equipment
Property and Equipment, Net
Property and equipment, gross	$ 103,961				$ 125,594
Furniture and equipment | Minimum
Property and Equipment, Net
Useful life of assets	3 years				3 years
Furniture and equipment | Maximum
Property and Equipment, Net
Useful life of assets	8 years				8 years
Software
Property and Equipment, Net
Property and equipment, gross	$ 113,219				$ 92,212
Software | Minimum
Property and Equipment, Net
Useful life of assets	3 years				3 years
Software | Maximum
Property and Equipment, Net
Useful life of assets	5 years				5 years
Construction in progress
Property and Equipment, Net
Property and equipment, gross	$ 11,554				$ 23,390

Property and Equipment, Net (Ad

Property and Equipment, Net (Additional Information) (Details) - USD ($) $ in Thousands		3 Months Ended	6 Months Ended		9 Months Ended		12 Months Ended
	Jul. 31, 2019	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2024	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Real Estate [Line Items]
Depreciation expense		$ 9,338	$ 19,381	$ 21,427	$ 29,879	$ 31,506	$ 39,676	$ 41,376	$ 44,574
Carrying value			8,400
Estimated fair value less cost			$ 7,800				7,825	0
Impairment of Long-Lived Assets to be Disposed of							647	0	0
Proceeds from note receivable related to property sold							0	46,800	0
Realized Gain on Sale of Assets							0	13,317	0
Discontinued Operations, Disposed of by Sale | Chicago, Illinois Campus
Real Estate [Line Items]
Proceeds from disposal	$ 52,000
Proceeds From Down Payment on Seller Loan	5,200
Receivable with Imputed Interest, Face Amount	$ 46,800
Receivable with Imputed Interest, Effective Yield (Interest Rate)	4%
Proceeds from note receivable related to property sold								46,800
Discontinued Operations, Disposed of by Sale | Chicago, Illinois Campus | Other Noncurrent Assets
Real Estate [Line Items]
Notes receivable	$ 40,300
Discontinued Operations, Disposed of by Sale | Chicago, Illinois Campus | Other Liabilities
Real Estate [Line Items]
Financing payables	$ 45,500
Corporate, Non-Segment [Member]
Real Estate [Line Items]
Depreciation expense							$ 1,552	2,344	$ 2,882
Corporate, Non-Segment [Member] | Discontinued Operations, Disposed of by Sale | Chicago, Illinois Campus
Real Estate [Line Items]
Realized Gain on Sale of Assets								$ 13,300

Leases (Components of Lease Cos

Leases (Components of Lease Cost) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Lease, Cost [Abstract]
Operating lease cost	$ 44,365	$ 48,181	$ 55,257
Sublease income	(9,107)	(13,329)	(13,920)
Total lease cost	$ 35,258	$ 34,852	$ 41,337

Leases (Maturities of Lease Lia

Leases (Maturities of Lease Liabilities) (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Maturities of lease liabilities
2025	$ 44,419
2026	44,406
2027	43,012
2028	36,054
2029	26,313
Thereafter	89,337
Total lease payments	283,541
Less: tenant improvement allowance not yet received	(8,631)
Less: imputed interest	(75,769)
Present value of lease liabilities	$ 199,141

Leases (Lease Term, Discount Ra

Leases (Lease Term, Discount Rate and Cash Flow Information ) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Lessee Disclosure [Abstract]
Weighted-average remaining operating lease term (years)	6 years 9 months 18 days
Weighted-average operating lease discount rate	7.40%
Cash paid for amounts in the measurement of operating lease liabilities (net of sublease receipts)	$ 41,063	$ 58,198	$ 52,540
Operating lease assets obtained in exchange for operating lease liabilities	$ 34,719	$ 32,476	$ 49,136

Leases (Future Minimum Rental C

Leases (Future Minimum Rental Commitments for Noncancelable Operating Leases ) (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract]
2025	$ 5,255
2026	2,038
Total sublease rental income	$ 7,293

Leases (Additional Information)

Leases (Additional Information) (Details) $ in Thousands	12 Months Ended
	Jun. 30, 2024 USD ($) location lease	Dec. 31, 2024 USD ($)	Sep. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)
Lessee, Lease, Description [Line Items]
Option to terminate lease	true
Option to extend lease	true
Extension term	5 years
Number of operating lease locations the entity has agreements to sublease either a portion or the full leased space | location	4
Number of leases yet to commence | lease	3
Operating Lease, Right-of-Use Asset	$ 176,755			$ 174,677
Operating lease liabilities	$ 199,141
Operating Lease, Lease Not yet Commenced, Contract One | Forecast
Lessee, Lease, Description [Line Items]
Lease term on property lease that has not yet commenced			10 years
Operating Lease, Right-of-Use Asset			$ 1,300
Operating lease liabilities			$ 1,300
Operating Lease, Lease Not yet Commenced, Contract Two | Forecast
Lessee, Lease, Description [Line Items]
Lease term on property lease that has not yet commenced		15 years
Operating Lease, Right-of-Use Asset		$ 6,300
Operating lease liabilities		$ 6,300
Operating Lease, Lease Not yet Commenced, Contract Three | Forecast
Lessee, Lease, Description [Line Items]
Lease term on property lease that has not yet commenced		15 years
Operating Lease, Right-of-Use Asset		$ 4,000
Operating lease liabilities		$ 4,000

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets (Summary of Goodwill Balances by Reporting Unit) (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Goodwill [Line Items]
Goodwill	$ 961,262	$ 961,262
Chamberlain
Goodwill [Line Items]
Goodwill	4,716	4,716
Walden
Goodwill [Line Items]
Goodwill	651,052	651,052
AUC
Goodwill [Line Items]
Goodwill	68,321	68,321
RUSM
Goodwill [Line Items]
Goodwill	180,089	180,089
RUSVM
Goodwill [Line Items]
Goodwill	$ 57,084	$ 57,084

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets (Summary of Goodwill Balances by Reporting Segment) (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Goodwill [Line Items]
Goodwill	$ 961,262	$ 961,262
Chamberlain
Goodwill [Line Items]
Goodwill	4,716	4,716
Walden
Goodwill [Line Items]
Goodwill	651,052	651,052
Medical and Veterinary
Goodwill [Line Items]
Goodwill	$ 305,494	$ 305,494

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Intangible Assets [Line Items]
Amortizable Intangible Assets, Gross Carrying Amount	$ 217,991	$ 217,991
Amortizable Intangible Assets, Accumulated Amortization	(194,157)	(158,513)
Indefinite-lived Intangible Assets, Gross Carrying Amount	752,860	752,860
Student Relationships
Intangible Assets [Line Items]
Amortizable Intangible Assets, Gross Carrying Amount	161,900	161,900
Amortizable Intangible Assets, Accumulated Amortization	$ (161,900)	(137,476)
Amortizable Intangible Assets, Weighted Average Amortization Period	3 years
Curriculum
Intangible Assets [Line Items]
Amortizable Intangible Assets, Gross Carrying Amount	$ 56,091	56,091
Amortizable Intangible Assets, Accumulated Amortization	$ (32,257)	(21,037)
Amortizable Intangible Assets, Weighted Average Amortization Period	5 years
Walden trade name
Intangible Assets [Line Items]
Indefinite-lived Intangible Assets, Gross Carrying Amount	$ 119,560	119,560
AUC trade name
Intangible Assets [Line Items]
Indefinite-lived Intangible Assets, Gross Carrying Amount	17,100	17,100
RUSM trade name
Intangible Assets [Line Items]
Indefinite-lived Intangible Assets, Gross Carrying Amount	3,500	3,500
RUSVM trade name
Intangible Assets [Line Items]
Indefinite-lived Intangible Assets, Gross Carrying Amount	1,600	1,600
Chamberlain Title IV eligibility and accreditations
Intangible Assets [Line Items]
Indefinite-lived Intangible Assets, Gross Carrying Amount	1,200	1,200
Walden Title IV eligibility and accreditations
Intangible Assets [Line Items]
Indefinite-lived Intangible Assets, Gross Carrying Amount	495,800	495,800
AUC Title IV eligibility and accreditations
Intangible Assets [Line Items]
Indefinite-lived Intangible Assets, Gross Carrying Amount	100,000	100,000
RUSM Title IV eligibility and accreditations
Intangible Assets [Line Items]
Indefinite-lived Intangible Assets, Gross Carrying Amount	11,600	11,600
RUSVM Title IV eligibility and accreditations
Intangible Assets [Line Items]
Indefinite-lived Intangible Assets, Gross Carrying Amount	$ 2,500	$ 2,500

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets (Summary of Indefinite-Lived Intangible Assets Balances by Reporting Segment) (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets balances	$ 752,860	$ 752,860
Chamberlain
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets balances	1,200	1,200
Walden
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets balances	615,360	615,360
Medical and Veterinary
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets balances	$ 136,300	$ 136,300

Goodwill and Intangible Asset_6

Goodwill and Intangible Assets (Estimated Amortization Expense for Amortized Intangible Assets) (Details) - Walden University $ in Thousands	Jun. 30, 2024 USD ($)
Intangible Assets [Line Items]
2025	$ 11,220
2026	11,220
2027	1,394
Total	$ 23,834

Goodwill and Intangible Asset_7

Goodwill and Intangible Assets (Additional Information) (Details) $ in Thousands	11 Months Ended	12 Months Ended
	May 31, 2024 USD ($) segment	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)
Intangible Assets [Line Items]
Number of reporting units | segment	5
Number of reporting units qualitative assessment performed | segment	4
Amortization of Intangible Assets		$ 35,644	$ 61,239	$ 97,274
Walden
Intangible Assets [Line Items]
Indefinite lived intangible assets write-off	$ 0
Goodwill write-off	$ 0
Discount rate | Walden | Fair Value, Inputs, Level 3 [Member]
Intangible Assets [Line Items]
Intangible assets, measurement input	0.125
Measurement Input Terminal Growth Rate [Member] | Walden | Fair Value, Inputs, Level 3 [Member]
Intangible Assets [Line Items]
Intangible assets, measurement input	0.030
Walden trade name | Discount rate | Walden | Fair Value, Inputs, Level 3 [Member]
Intangible Assets [Line Items]
Intangible assets, measurement input	0.125
Walden trade name | Measurement Input Terminal Growth Rate [Member] | Walden | Fair Value, Inputs, Level 3 [Member]
Intangible Assets [Line Items]
Intangible assets, measurement input	0.030
Walden trade name | Measurement Input, Royalty Rate [Member] | Walden | Fair Value, Inputs, Level 3 [Member]
Intangible Assets [Line Items]
Intangible assets, measurement input	0.055
Walden Title IV eligibility and accreditations | Discount rate | Walden | Fair Value, Inputs, Level 3 [Member]
Intangible Assets [Line Items]
Intangible assets, measurement input	0.125

Debt (Long-term debt) (Details)

Debt (Long-term debt) (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Total debt:
Long-term Debt, Gross	$ 658,283	$ 708,283
Unamortized debt discount and issuance costs	(9,571)	(13,206)
Total Amount Outstanding	648,712	695,077
Senior Secured Notes Due 2028
Total debt:
Long-term Debt, Gross	404,950	404,950
Term B Loan
Total debt:
Long-term Debt, Gross	$ 253,333	$ 303,333

Debt (Scheduled maturities of l

Debt (Scheduled maturities of long-term debt) (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Debt Disclosure [Abstract]
2025	$ 0
2026	0
2027	0
2028	404,950
2029	253,333
Long-term Debt	$ 658,283	$ 708,283

Debt (Debt Issuance Costs) (Det

Debt (Debt Issuance Costs) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Unamortized debt discount and issuance costs, beginning	$ 19,561
Amortization of debt discount and issuance costs	(4,550)	$ (4,832)	$ (7,083)
Debt discount and issuance costs write-off	(1,113)
Unamortized debt discount and issuance costs, ending	13,898	19,561
Revolver
Unamortized debt discount and issuance costs, beginning	6,355
Amortization of debt discount and issuance costs	(2,028)
Unamortized debt discount and issuance costs, ending	4,327	6,355
Senior Secured Notes Due 2028
Unamortized debt discount and issuance costs, beginning	5,592
Amortization of debt discount and issuance costs	(1,146)
Debt discount and issuance costs write-off		(15)	(6,771)
Unamortized debt discount and issuance costs, ending	4,446	5,592
Term B Loan
Unamortized debt discount and issuance costs, beginning	7,614
Amortization of debt discount and issuance costs	(1,376)
Debt discount and issuance costs write-off	(1,113)	(4,282)	$ (12,471)
Unamortized debt discount and issuance costs, ending	$ 5,125	$ 7,614

Debt (Interest Expense) (Detail

Debt (Interest Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Interest Expense, Debt [Abstract]
Debt discount and issuance costs write-off	$ 1,113
Gain on extinguishment of debt	0	$ (71)	$ (2,072)
Amortization of debt discount and issuance costs	4,550	4,832	7,083
Other	761	1,063	887
Total	63,659	63,100	129,348
Senior Secured Notes Due 2028
Interest Expense, Debt [Abstract]
Interest expense	22,272	22,301	39,371
Debt discount and issuance costs write-off		15	6,771
Gain on extinguishment of debt		(100)	(2,100)
Amortization of debt discount and issuance costs	1,146
Term B Loan
Interest Expense, Debt [Abstract]
Interest expense	26,324	26,831	33,413
Ticking fees			5,330
Debt discount and issuance costs write-off	1,113	4,282	12,471
Amortization of debt discount and issuance costs	1,376
Prior Term Loan B
Interest Expense, Debt [Abstract]
Interest expense			1,272
Letter of Credit
Interest Expense, Debt [Abstract]
Interest expense	$ 8,639	$ 3,847	3,968
Interest Rate Swap
Interest Expense, Debt [Abstract]
Loss on derivative			(4,525)
Bridge
Interest Expense, Debt [Abstract]
Debt discount and issuance costs write-off			10,329
Prior Revolving Credit Facility
Interest Expense, Debt [Abstract]
Debt discount and issuance costs write-off			$ 6,000

Debt (Additional Information) (

Debt (Additional Information) (Details) - USD ($)

1 Months Ended

3 Months Ended

12 Months Ended

Jan. 26, 2024

Nov. 22, 2022

Sep. 22, 2022

Apr. 11, 2022

Mar. 11, 2022

Aug. 12, 2021

Jul. 29, 2021

Mar. 01, 2021

Mar. 31, 2020

Mar. 24, 2020

Apr. 13, 2018

Jun. 30, 2022

Mar. 31, 2022

Mar. 31, 2024

Sep. 30, 2022

Jun. 30, 2022

Dec. 31, 2021

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2022

Jun. 30, 2021

Jun. 24, 2024

Apr. 26, 2024

Jan. 31, 2024

Line of Credit Facility [Line Items]

Repayment of long-term debt

$ 51,896,000

$ 150,861,000

$ 1,079,713,000

Gain on extinguishment of debt

0

71,000

2,072,000

Long-term debt, gross

658,283,000

708,283,000

Line of Credit facility, initiation date

Apr. 13, 2018

Debt Issuance Costs Write-off

1,113,000

Surety Bond [Member]

Line of Credit Facility [Line Items]

Guarantor Obligations, Current Carrying Value

44,300,000

Interest Rate Swap

Line of Credit Facility [Line Items]

Gain (Loss) on Derivative Instruments, Net, Pretax

(4,525,000)

Interest Rate Swap | Interest Expense.

Line of Credit Facility [Line Items]

Gain (Loss) on Derivative Instruments, Net, Pretax

$ (4,500,000)

Revolver

Line of Credit Facility [Line Items]

Maximum borrowing capacity

$ 400,000,000

Letters Of Credit Outstanding, Increase (Decrease) Amount

(90,800,000)

Letters of credit outstanding

$ 227,300,000

Letters of credit expired

$ 76,200,000

Commitment fee percentage

0.25%

Undrawn amount on letters of credit

$ 242,100,000

Long-term Line of Credit

$ 0

$ 0

$ 0

0

0

Term

5 years

Revolver | Alternate Base Rate | Minimum

Line of Credit Facility [Line Items]

Basic spread rate

2.75%

Revolver | Alternate Base Rate | Maximum

Line of Credit Facility [Line Items]

Basic spread rate

3.25%

Revolver | SOFR

Line of Credit Facility [Line Items]

Basic spread rate

0.75%

Revolver | SOFR | Minimum

Line of Credit Facility [Line Items]

Basic spread rate

3.75%

Revolver | SOFR | Maximum

Line of Credit Facility [Line Items]

Basic spread rate

4.25%

Walden Title IV Letter Of Credit | Surety Bond [Member]

Line of Credit Facility [Line Items]

Letters of credit outstanding

$ 69,400,000

$ 84,000,000

Title IV Letter Of Credit

Line of Credit Facility [Line Items]

Letters of credit outstanding

$ 157,900,000

Prior Revolving Credit Facility

Line of Credit Facility [Line Items]

Maximum borrowing capacity

$ 300,000,000

Debt Issuance Costs Write-off

6,000,000

Prior Revolving Credit Facility | Interest Expense.

Line of Credit Facility [Line Items]

Debt Issuance Costs Write-off

6,000,000

Prior Revolving Credit Facility | Base Rate | Minimum

Line of Credit Facility [Line Items]

Application rate, percentage

0.75%

Prior Revolving Credit Facility | Base Rate | Maximum

Line of Credit Facility [Line Items]

Application rate, percentage

1.75%

Prior Revolving Credit Facility | Eurocurrency Rate | Minimum

Line of Credit Facility [Line Items]

Application rate, percentage

1.75%

Prior Revolving Credit Facility | Eurocurrency Rate | Maximum

Line of Credit Facility [Line Items]

Application rate, percentage

2.75%

Term Loan B

Line of Credit Facility [Line Items]

Repayment of long-term debt

$ 396,700,000

50,000,000

150,000,000

396,700,000

Debt Instrument, Issuance Price, Percent Of Principal Amount

99%

Debt Instrument, Issuance Discount, Percent

1%

Debt Covenant, Mandatory Cash Payment In Excess Of Amount Minimum

$ 20,000,000

Asset sale or disposition period

1 year

Mandatory prepayment terms

$ 0

Term Loan B | Interest Expense.

Line of Credit Facility [Line Items]

Debt Issuance Costs Write-off

$ 1,100,000

4,300,000

12,500,000

Bridge

Line of Credit Facility [Line Items]

Debt Issuance Costs Write-off

10,329,000

Bridge | Interest Expense.

Line of Credit Facility [Line Items]

Debt Issuance Costs Write-off

10,300,000

Senior Secured Notes Due 2028 And Term B Loan

Line of Credit Facility [Line Items]

Total net leverage ratio

4%

Cap percentage

20%

Amortization period

7 years

Senior Secured Notes Due 2028 And Term B Loan | Scenario, Plan

Line of Credit Facility [Line Items]

Total net leverage ratio

3.25%

Senior Secured Notes Due 2028

Line of Credit Facility [Line Items]

Debt instrument, face amount

$ 800,000,000

Fixed interest rate

5.50%

Repayment of long-term debt

$ 373,300,000

$ 20,800,000

$ 900,000

$ 394,100,000

394,100,000

Gain on extinguishment of debt

100,000

2,100,000

Long-term debt, gross

$ 404,950,000

404,950,000

Percentage of notes issued on par value

100%

Redemption price, percentage of principal amount redeemed

100%

100%

90%

92%

Debt covenant, percentage of principal amount of notes outstanding

25%

Debt Issuance Costs Write-off

15,000

6,771,000

Senior Secured Notes Due 2028 | Interest Expense.

Line of Credit Facility [Line Items]

Debt Issuance Costs Write-off

6,800,000

Senior Secured Notes Due 2028 | Accrued Liabilities

Line of Credit Facility [Line Items]

Debt Instrument, Accrued Interest

$ 7,400,000

7,400,000

Senior Secured Notes Due 2028 | 2024

Line of Credit Facility [Line Items]

Redemption price, percentage of principal amount redeemed

102.75%

Senior Secured Notes Due 2028 | 2025

Line of Credit Facility [Line Items]

Redemption price, percentage of principal amount redeemed

101.375%

Senior Secured Notes Due 2028 | 2026

Line of Credit Facility [Line Items]

Redemption price, percentage of principal amount redeemed

100%

Senior Secured Notes Due 2028 | Prior to March 1,2024

Line of Credit Facility [Line Items]

Redemption price percentage

105.50%

Senior Secured Notes Due 2028 | Maximum | Prior to March 1,2024

Line of Credit Facility [Line Items]

Redemption price, percentage of principal amount redeemed

40%

Term B Loan

Line of Credit Facility [Line Items]

Debt instrument, face amount

$ 850,000,000

Fixed interest rate

8.84%

Repayment of long-term debt

$ 50,000,000

$ 50,000,000

$ 100,000,000

$ 396,700,000

Long-term debt, gross

$ 253,333,000

303,333,000

Reduction in margin interest rate

0.50%

Principal payment

$ 2,125,000

Debt Issuance Costs Write-off

$ 1,113,000

$ 4,282,000

$ 12,471,000

Term B Loan | Alternate Base Rate | Minimum

Line of Credit Facility [Line Items]

Basic spread rate

2.50%

3%

Term B Loan | Alternate Base Rate | Maximum

Line of Credit Facility [Line Items]

Basic spread rate

3%

3.50%

Term B Loan | Eurocurrency Rate | Minimum

Line of Credit Facility [Line Items]

Basic spread rate

3.50%

4%

Term B Loan | Eurocurrency Rate | Maximum

Line of Credit Facility [Line Items]

Basic spread rate

4%

4.50%

Term B Loan | SOFR

Line of Credit Facility [Line Items]

Basic spread rate

0.75%

0.75%

Prior Term Loan B

Line of Credit Facility [Line Items]

Debt instrument, face amount

300,000,000

Principal payment

$ 750,000

Prior Term Loan B | Base Rate

Line of Credit Facility [Line Items]

Basic spread rate

2%

Debt instrument, description of variable rate basis

base rate plus 2%

Prior Term Loan B | Eurocurrency Rate

Line of Credit Facility [Line Items]

Basic spread rate

3%

3%

Debt instrument, description of variable rate basis

LIBOR-equivalent rate plus 3%

Prior Term Loan B | Interest Rate Swap

Line of Credit Facility [Line Items]

Derivative, Fixed Interest Rate

0.946%

Derivative, Swaption Interest Rate

3.946%

Prior Term Loan B | Interest Rate Swap | London Interbank Offered Rate L I B O R Extension [Member]

Line of Credit Facility [Line Items]

Debt instrument, description of variable rate basis

one-month LIBOR

Prior Term Loan B | Interest Rate Swap | London Interbank Offered Rate L I B O R Extension [Member] | Minimum

Line of Credit Facility [Line Items]

Derivative, Floor Interest Rate

0%

Prior Term Loan B | Prior Revolving Credit Facility

Line of Credit Facility [Line Items]

Line of credit facility, expiration date

Apr. 13, 2023

Redeemable Noncontrolling Int_2

Redeemable Noncontrolling Interest (Details) - EduPristine - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021	Mar. 26, 2020
Noncontrolling Interest [Line Items]
Ownership interest of parent in subsidiary	100%	69%
Kaizen
Noncontrolling Interest [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		31%
Ownership percentage held by minority available for purchase			33%
Decrease in noncontrolling interest	$ 1.8

Share Repurchases (Shares Repur

Share Repurchases (Shares Repurchased Under Programs) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Equity, Class of Treasury Stock [Line Items]
Total cost of share repurchases	$ 261,183	$ 127,254	$ 120,000
Open Market Share Repurchase Programs
Equity, Class of Treasury Stock [Line Items]
Total number of share repurchases	5,446,113	3,207,036
Total cost of share repurchases	$ 261,183	$ 127,254
Average price paid per share	$ 47.96	$ 39.68

Share Repurchases (Open Market

Share Repurchases (Open Market Share Repurchase Programs) (Details) - USD ($) $ in Millions	Jun. 30, 2024	Jan. 19, 2024	Mar. 14, 2022	Mar. 01, 2022
Equity, Class of Treasury Stock [Line Items]
Authorized amount for repurchase			$ 150
Maximum
Equity, Class of Treasury Stock [Line Items]
Remaining authorized amount for repurchase	$ 211.6
Maximum | Authorized On March One, Two-Thousand Twenty Two
Equity, Class of Treasury Stock [Line Items]
Authorized amount for repurchase				$ 300
Maximum | Authorized On January Nineteen Two Thousand Twenty Four
Equity, Class of Treasury Stock [Line Items]
Authorized amount for repurchase		$ 300

Share Repurchases (ASR Agreemen

Share Repurchases (ASR Agreement) (Details) - USD ($) $ in Millions		3 Months Ended
	Mar. 14, 2022	Dec. 31, 2022	Nov. 02, 2022	Oct. 14, 2022
Equity, Class of Treasury Stock [Line Items]
Authorized amount for repurchase	$ 150
Asr Agreement
Equity, Class of Treasury Stock [Line Items]
Authorized amount for repurchase	$ 150
Number of shares for common stock	4,709,576
Percentage of total shares expected to be delivered	80%
Shares owed to counterparty				332,212
Accelerated Share Repurchases, Settlement (Payment) or Receipt			$ (13.2)
Asr Agreement | Treasury Stock, Common
Equity, Class of Treasury Stock [Line Items]
Authorized amount for repurchase	$ 120
Accelerated Share Repurchases, Settlement (Payment) or Receipt		$ (13.2)
Asr Agreement | Additional Paid-In Capital
Equity, Class of Treasury Stock [Line Items]
Authorized amount for repurchase	$ 30
Additional paid in capital reclassified into treasury stock		$ 30

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance at the beginning of period	$ 1,457,336	$ 1,491,386	$ 1,293,517
Reclassification adjustment for realized (gain) loss on foreign currency translation adjustments	0	0	(296)
Reclassification from other comprehensive income	0	0	6,695
Balance at the end of period	1,369,135	1,457,336	1,491,386
Accumulated Other Comprehensive Loss
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance at the beginning of period	(2,227)	(2,227)	(9,218)
Reclassification adjustment for realized (gain) loss on foreign currency translation adjustments			(296)
Reclassification from other comprehensive income			6,695
Balance at the end of period	(2,227)	(2,227)	(2,227)
Foreign currency translation adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance at the beginning of period	(2,227)	(2,227)	(2,523)
Reclassification adjustment for realized (gain) loss on foreign currency translation adjustments	0	0	296
Balance at the end of period	(2,227)	(2,227)	(2,227)
Interest Rate Swap.
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance at the beginning of period - Gross	0	0	(8,926)
Balance at the beginning of period - Tax	0	0	2,231
Balance at the beginning of period	0	0	(6,695)
Reclassification from other comprehensive income	0	0	6,695
Balance at the end of period	$ 0	$ 0	$ 0

Stock-Based Compensation (Total

Stock-Based Compensation (Total Stock-Based Compensation Expense Included in Consolidated Statement of Income) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based compensation	$ 25,947	$ 14,299	$ 22,611
Income tax benefit	(8,594)	(3,938)	(3,658)
Stock-based compensation, net of tax	$ 17,353	$ 10,361	$ 18,953

Stock-Based Compensation (Summa

Stock-Based Compensation (Summary of Options Activity) (Details) - Stock Option $ / shares in Units, $ in Thousands	12 Months Ended
	Jun. 30, 2024 USD ($) $ / shares shares
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Number of Options, Outstanding at beginning of period | shares	1,045,801
Number of Options, Exercised | shares	(494,314)
Number of Options Expired | shares	(1,144)
Number of Options, Outstanding at end of period | shares	550,343
Number of Options, Exercisable at end of period | shares	410,668
Weighted Average Exercise Price at beginning of period | $ / shares	$ 36.02
Weighted Average Exercise Price, Options Exercised | $ / shares	34.57
Weighted Average Exercise Price, Options Expired | $ / shares	28.32
Weighted Average Exercise Price, Outstanding at end of period | $ / shares	37.34
Weighted Average Exercise Price, Exercisable at end of period | $ / shares	$ 38.07
Weighted Average Remaining Contractual Life, Outstanding at end of period	6 years
Weighted Average Remaining Contractual Life, Exercisable at end of period	5 years 8 months 12 days
Aggregate Intrinsic Value, Outstanding at End of period | $	$ 16,989
Aggregate Intrinsic Value, Exercisable at end of period | $	$ 12,376

Stock-Based Compensation (Fair

Stock-Based Compensation (Fair Values of Stock Option Awards Weighted Average Assumptions) (Details)	12 Months Ended
	Jun. 30, 2022
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Expected life (in years)	6 years 6 months 21 days
Expected volatility	39.99%
Risk-free interest rate	0.94%
Dividend yield	0%

Stock-Based Compensation (Addit

Stock-Based Compensation (Additional Information) (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total intrinsic value of options exercised	$ 10	$ 1.1	$ 6.9
Tax benefit from options exercised	2.5	0.3	1.8
Share-based Payment Arrangement, Amount Capitalized	0	0
Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs related to non-vested awards	$ 0.4
Unrecognized compensation costs related to non-vested awards expected to be recognized, years	1 year 3 months 18 days
Fair value of stock options	$ 1.9	$ 2.1	$ 4.7
Stock Incentive Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of options (in years)			10 years
Vesting Period (in years)			4 years
Weighted average estimated grant date fair values, for options granted at market price, per share			$ 14.72
Number of options granted	0	0
Common stock available for future issuance	2,106,199
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting Period (in years)	3 years		4 years
Unrecognized compensation costs related to non-vested awards	$ 14.5
Unrecognized compensation costs related to non-vested awards expected to be recognized, years	1 year 7 months 6 days
Fair value of units vested	$ 13	$ 9.4	$ 7.9
Weighted-average grant date fair value	$ 44.24	$ 39.90	$ 35.57
Restricted Stock Units | Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting Period (in years)	1 year
Performance Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of options (in years)	3 years
Unrecognized compensation costs related to non-vested awards	$ 15.5
Unrecognized compensation costs related to non-vested awards expected to be recognized, years	1 year 7 months 6 days
Fair value of units vested	$ 4.1	$ 3.4	$ 2.6
Weighted-average grant date fair value	$ 50.02	$ 40.43	$ 33.84

Stock-Based Compensation (Sum_2

Stock-Based Compensation (Summary of Restricted Stock Units Activity and Performance Stock Units) (Details) - $ / shares	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested shares at beginning of period	737,733
Granted	399,220
Vested	(340,923)
Forfeited	(40,189)
Unvested shares at end of period	755,841	737,733
Weighted Average Grant Date Fair Value, Unvested beginning balance	$ 37.22
Weighted-average grant date fair value	44.24	$ 39.90	$ 35.57
Vested	38
Forfeited	38.53
Weighted Average Grant Date Fair Value, Unvested ending balance	$ 40.51	$ 37.22
Performance Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested shares at beginning of period	490,300
Granted	336,900
Vested	(126,918)
Forfeited	(70,512)
Unvested shares at end of period	629,770	490,300
Weighted Average Grant Date Fair Value, Unvested beginning balance	$ 35.17
Weighted-average grant date fair value	50.02	$ 40.43	$ 33.84
Vested	29.92
Forfeited	35.60
Weighted Average Grant Date Fair Value, Unvested ending balance	$ 43.77	$ 35.17

Employee Benefit Plans (Details

Employee Benefit Plans (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022	Nov. 06, 2019
Defined Benefit Plan Disclosure [Line Items]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100%
Contributes percentage	6%
Matching and discretionary contributions expense	$ 19,700,000	$ 17,900,000	$ 18,400,000
Authorized amount	$ 25,000
Number of ESPP issuable				500,000
Market price	90%
Brokerage commissions and administrative fees, percentage	10%
Total share issued	19,666	18,463	18,328
Nonqualified Deferred Compensation Plan
Defined Benefit Plan Disclosure [Line Items]
Contributes percentage	6%
Deferred Compensation Plan, Maximum Percentage of Deferment of Participant's Salary	50%
Deferred Compensation Plan, Maximum percentage of participant's Bonus or Board Fee	100%
Deferred Compensation Plan Assets, Fair Value Disclosure	$ 13,200,000	$ 12,500,000
Investment, Type [Extensible Enumeration]	atge:InvestmentInRabbiTrustMember	atge:InvestmentInRabbiTrustMember
Accrued Liabilities | Nonqualified Deferred Compensation Plan
Defined Benefit Plan Disclosure [Line Items]
Deferred Compensation Liability, Current	$ 12,200,000	$ 12,600,000

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, gross	$ 708,283	$ 658,283
Assets measured at fair value using Level 3	0	0
Liabilities measured at fair value using Level 3	0	0	$ 5,000
Senior Secured Notes Due 2028
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, gross	404,950	404,950
Senior Secured Notes Due 2028 | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, fair value		389,500
Term B Loan
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, gross	303,333	253,333
Term B Loan | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, fair value		254,900
Other income, net
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment impairment	5,000
Accounts Receivable | Credit extension program
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans Receivable, Fair Value Disclosure	29,700	28,900
Nonqualified Deferred Compensation Plan
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred Compensation Plan Assets, Fair Value Disclosure	$ 12,500	$ 13,200
Investment, type extensible enumeration	atge:InvestmentInRabbiTrustMember	atge:InvestmentInRabbiTrustMember
Nonqualified Deferred Compensation Plan | Accrued Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred Compensation Liability, Current, Fair Value Disclosure	$ 12,600	$ 12,200
Nonqualified Deferred Compensation Plan | Prepaid Expenses and Other Current Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred Compensation Plan Assets, Fair Value Disclosure	$ 12,500	$ 13,200

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions		1 Months Ended	5 Months Ended	12 Months Ended
	Sep. 21, 2023 USD ($)	Jan. 31, 2024 USD ($)	Nov. 15, 2022 item	Jun. 30, 2024 USD ($) item	Jun. 17, 2024 plaintiff	Dec. 04, 2017 USD ($)
Loss Contingencies [Line Items]
Borrower Defense To Repayment Application Batch, Amount Per Week				500
Chamberlain
Loss Contingencies [Line Items]
Borrower Defense To Repayment Applications			3,225
RUSM
Loss Contingencies [Line Items]
Borrower Defense To Repayment Applications			1,700
RUSVM
Loss Contingencies [Line Items]
Borrower Defense To Repayment Applications			1,900
Walden
Loss Contingencies [Line Items]
Borrower Defense To Repayment Applications			7,740
Maximum | DeVry University
Loss Contingencies [Line Items]
Indemnification | $						$ 340
Aljanal Carroll, Claudia Provost Charles, Tiffany Fair Case [Member]
Loss Contingencies [Line Items]
Number of plaintiffs, added | plaintiff					25
Loss contingency accrual | $				$ 28.5
Remitted | $	$ 28.5
Scenario, Plan | Laureate
Loss Contingencies [Line Items]
Litigation Settlement, Amount Awarded from Other Party | $		$ 5.5

Segment Information (Tabulation

Segment Information (Tabulation of Business Segment Information Based on Current Segmentation) (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2024	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Segment Reporting Information [Line Items]
Total Consolidated Revenue						$ 1,584,652	$ 1,450,826	$ 1,381,842
Total consolidated adjusted operating income						308,778	287,570	267,602
Deferred revenue adjustment								(8,561)
CEO transition costs								(6,195)
Restructuring expense						(1,870)	(18,817)	(25,628)
Business acquisition and integration expense						(34,215)	(42,661)	(53,198)
Litigation reserve						18,500	10,000
Loss on assets held for sale						(647)	0	0
Debt modification costs						(848)
Gain on sale of assets						0	13,317	0
Total consolidated operating income						217,054	168,170	76,746
Interest expense						(63,659)	(63,100)	(129,348)
Other income, net						10,542	6,965	1,108
Total consolidated income from continuing operations before income taxes						163,937	112,035	(51,494)
Total Consolidated capital expenditures						48,893	26,014	31,054
Total consolidated depreciation expense	$ 9,338	$ 19,381	$ 21,427	$ 29,879	$ 31,506	39,676	41,376	44,574
Total consolidated intangible amortization expense						(35,644)	(61,239)	(97,274)
Chamberlain
Segment Reporting Information [Line Items]
Total Consolidated Revenue						633,522	571,034	557,536
Walden University
Segment Reporting Information [Line Items]
Total Consolidated Revenue						595,332	533,725	485,393
Medical and Veterinary
Segment Reporting Information [Line Items]
Total Consolidated Revenue						355,798	346,067	338,913
Operating Segments [Member] | Chamberlain
Segment Reporting Information [Line Items]
Total Consolidated Revenue						633,522	571,034	557,536
Total consolidated adjusted operating income						137,800	135,503	127,252
Total Consolidated capital expenditures						26,293	13,934	15,235
Total consolidated depreciation expense						18,752	17,175	18,547
Operating Segments [Member] | Walden University
Segment Reporting Information [Line Items]
Total Consolidated Revenue						595,332	533,725	485,393
Total consolidated adjusted operating income						130,547	110,364	104,582
Total Consolidated capital expenditures						5,889	1,084	5,393
Total consolidated depreciation expense						7,389	9,419	9,255
Total consolidated intangible amortization expense						(35,644)	(61,239)	(97,274)
Operating Segments [Member] | Medical and Veterinary
Segment Reporting Information [Line Items]
Total Consolidated Revenue						355,798	346,067	338,913
Total consolidated adjusted operating income						71,507	67,336	69,148
Restructuring expense						(442)	(7,687)	(9,791)
Total Consolidated capital expenditures						5,708	3,358	3,277
Total consolidated depreciation expense						11,983	12,438	13,890
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Total consolidated adjusted operating income						(31,076)	(25,633)	(33,380)
Total Consolidated capital expenditures						11,003	7,638	7,149
Total consolidated depreciation expense						$ 1,552	$ 2,344	$ 2,882

Segment Information (Revenues a

Segment Information (Revenues and Long-Lived Assets by Geographic Area) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Total Consolidated Revenue	$ 1,584,652	$ 1,450,826	$ 1,381,842
Total Consolidated Long-lived Assets	433,104	419,326	467,921
Domestic Operations
Revenues from External Customers and Long-Lived Assets [Line Items]
Total Consolidated Revenue	1,228,854	1,104,759	1,042,929
Total Consolidated Long-lived Assets	283,597	256,268	289,129
Barbados, St. Kitts, and St. Maarten
Revenues from External Customers and Long-Lived Assets [Line Items]
Total Consolidated Revenue	355,798	346,067	338,913
Total Consolidated Long-lived Assets	$ 149,507	$ 163,058	$ 178,792

Segment Information (Additional

Segment Information (Additional Information) (Details)	12 Months Ended
	Jun. 30, 2024 segment
Segment Reporting [Abstract]
Number of reportable segments	3

Revision of Previously Issued_3

Revision of Previously Issued Consolidated Financial Statements (Unaudited) (Effect of Revision on Affected Line Items Within Consolidated Balance Sheets) (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Jun. 30, 2021
Current assets:
Cash and cash equivalents	$ 219,306			$ 260,826	$ 272,194	$ 313,760	$ 206,284	$ 325,834
Restricted cash	1,896			3,600	2,881	3,417	3,726	4,161
Prepaid expenses and other current assets	70,050	$ 63,584	$ 61,366	62,853	102,473	103,087	114,645
Total current assets	418,085	391,817	381,109	475,031	480,297	533,548	424,197
Noncurrent assets:
Property and equipment, net	248,524	239,657	235,297	246,669	244,649	246,563	272,342	281,165
Other assets, net	103,184	96,720	88,029	83,628	80,624	73,338	119,656	121,046
Total noncurrent assets	2,323,332	2,323,217	2,319,816	2,319,130	2,330,244	2,333,569	2,419,690
Total assets	2,741,417				2,810,541		2,843,887
Current liabilities:
Deferred revenue	185,272				153,871		120,835
Total current liabilities	487,657				431,203		376,639
Noncurrent liabilities:
Other liabilities	38,675				37,416		71,078
Total noncurrent liabilities	884,625				922,002		958,031
Total liabilities	1,372,282				1,353,205		1,334,670
Shareholders' equity:
Retained earnings	2,540,509				2,403,750		2,335,641
Total shareholders' equity	1,369,135				1,457,336		1,509,217		$ 1,491,386	$ 1,293,517
Total liabilities and shareholders' equity	$ 2,741,417				2,810,541		2,843,887
As Reported
Current assets:
Cash and cash equivalents				262,438	273,689	315,373	207,776	327,515
Restricted cash				1,988	1,386	1,804	2,234	2,480
Prepaid expenses and other current assets		59,401	58,356	60,750	100,715	102,573	113,564
Total current assets		387,634	378,099	472,928	478,539	533,034	423,116
Noncurrent assets:
Property and equipment, net		272,792	260,484	264,766	258,522	252,797	275,617	281,581
Other assets, net		67,768	65,852	67,634	68,509	67,618	116,613	120,630
Total noncurrent assets		2,327,400	2,322,826	2,321,233	2,332,002	2,334,083	2,419,922
Total assets							2,843,038
Current liabilities:
Deferred revenue							115,658
Total current liabilities							371,462
Noncurrent liabilities:
Other liabilities							61,901
Total noncurrent liabilities							948,854
Total liabilities							1,320,316
Shareholders' equity:
Retained earnings							2,349,146
Total shareholders' equity							1,522,722
Total liabilities and shareholders' equity							2,843,038
Adjustment
Current assets:
Cash and cash equivalents				(1,612)	(1,495)	(1,613)	(1,492)	(1,681)
Restricted cash				1,612	1,495	1,613	1,492	1,681
Prepaid expenses and other current assets		4,183	3,010	2,103	1,758	514	1,081
Total current assets		4,183	3,010	2,103	1,758	514	1,081
Noncurrent assets:
Property and equipment, net		(33,135)	(25,187)	(18,097)	(13,873)	(6,234)	(3,275)	(416)
Other assets, net		28,952	22,177	15,994	12,115	5,720	3,043	$ 416
Total noncurrent assets		$ (4,183)	$ (3,010)	$ (2,103)	$ (1,758)	$ (514)	(232)
Total assets							849
Current liabilities:
Deferred revenue							5,177
Total current liabilities							5,177
Noncurrent liabilities:
Other liabilities							9,177
Total noncurrent liabilities							9,177
Total liabilities							14,354
Shareholders' equity:
Retained earnings							(13,505)
Total shareholders' equity							(13,505)
Total liabilities and shareholders' equity							$ 849

Revision of Previously Issued_4

Revision of Previously Issued Consolidated Financial Statements (Unaudited) (Effect of Revision on Affected Line Items Within Consolidated Statements of Cash Flows) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2024	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	$ 9,338		$ 19,381	$ 21,427	$ 29,879	$ 31,506	$ 39,676	$ 41,376	$ 44,574
Changes in assets and liabilities:
Cloud computing implementation assets	(4,224)	$ (416)	(11,314)	(3,275)	(19,262)	(6,234)	(27,154)	(13,873)	0
Accounts payable	(2,818)	8,954	9,755	13,708	12,632	13,769	18,330	24,744	(15,724)
Net cash provided by operating activities-continuing operations	86,114	91,303	72,353	39,443	227,111	144,958	288,367	194,690	164,002
Net cash provided by operating activities	95,073	91,173	81,868	38,581	235,507	144,554	295,775	191,914	10,601
Investing activities:
Capital expenditures	(10,434)	(5,378)	(19,612)	(6,913)	(32,316)	(14,193)	(48,893)	(26,014)	(31,054)
Net cash used in investing activities-continuing operations	(10,334)	(5,330)	(19,484)	(6,914)	(32,188)	38,734	(47,850)	26,913	(1,509,285)
Net cash used in investing activities	(10,334)	(6,141)	(19,484)	(10,088)	(32,188)	35,560	(47,850)	23,739	(551,804)
Non-cash investing and financing activities:
Accrued capital expenditures	6,087	4,470	4,053	4,734	6,217	8,991	$ 8,718	5,125	$ 4,321
As Reported
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	9,778		20,714	21,461	32,106	31,618		41,575
Changes in assets and liabilities:
Cloud computing implementation assets								0
Accounts payable	(2,870)	8,711	7,824	13,233	10,841	12,286		21,666
Net cash provided by operating activities-continuing operations	90,726	91,476	83,069	42,277	246,809	149,821		205,684
Net cash provided by operating activities	99,685	91,346	92,584	41,415	255,205	149,417		202,908
Investing activities:
Capital expenditures	(15,046)	(5,551)	(30,328)	(9,747)	(52,014)	(19,056)		(37,008)
Net cash used in investing activities-continuing operations	(14,946)	(5,503)	(30,200)	(9,748)	(51,886)	33,871		15,919
Net cash used in investing activities	(14,946)	(6,314)	(30,200)	(12,922)	(51,886)	30,697		12,745
Non-cash investing and financing activities:
Accrued capital expenditures	9,217	4,713	9,062	5,209	11,086	10,474		8,203
Adjustment
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	(440)		(1,333)	(34)	(2,227)	(112)		(199)
Changes in assets and liabilities:
Cloud computing implementation assets	(4,224)	(416)	(11,314)	(3,275)	(19,262)	(6,234)		(13,873)
Accounts payable	52	243	1,931	475	1,791	1,483		3,078
Net cash provided by operating activities-continuing operations	(4,612)	(173)	(10,716)	(2,834)	(19,698)	(4,863)		(10,994)
Net cash provided by operating activities	(4,612)	(173)	(10,716)	(2,834)	(19,698)	(4,863)		(10,994)
Investing activities:
Capital expenditures	4,612	173	10,716	2,834	19,698	4,863		10,994
Net cash used in investing activities-continuing operations	4,612	173	10,716	2,834	19,698	4,863		10,994
Net cash used in investing activities	4,612	173	10,716	2,834	19,698	4,863		10,994
Non-cash investing and financing activities:
Accrued capital expenditures	$ (3,130)	$ (243)	$ (5,009)	$ (475)	$ (4,869)	$ (1,483)		$ (3,078)